var title_f39_1_39952="Tc99m sestamibi rest imaging";
var content_f39_1_39952=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Representative short axis (top row) vertical long axis (middle row) and horizontal long axis (bottom row) tomograms from the resting tc-99m sestamibi scans of two patients referred for assessment of viability in the left anterior descending (LAD) coronary",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Both patients had heart failure and extensive regional akinesis in the LAD territory. Patient A has minimal tracer uptake in the septum, apex and anterior wall (white arrows) indicating predominantly scar tissue. Patient B has significant uptake of tracer in the septum and anterior wall (yellow arrows) indicative of the presence of viable myocardium, and predominantly scar in the apex. The inferior wall that was also dyskinetic shows only modest tracer uptake (extracardiac tracer activity in overlying gut is also seen).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_1_39952=[""].join("\n");
var outline_f39_1_39952=null;
var title_f39_1_39953="Toxic epidermal necrolysis - back";
var content_f39_1_39953=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toxic epidermal necrolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse erythema and large areas of desquamation are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_1_39953=[""].join("\n");
var outline_f39_1_39953=null;
var title_f39_1_39954="Numerous atypical nevi";
var content_f39_1_39954=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple common and atypical nevi",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_1_39954=[""].join("\n");
var outline_f39_1_39954=null;
var title_f39_1_39955="Carpal tunnel PI";
var content_f39_1_39955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F80666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F80666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Carpal tunnel syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 625px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The carpal tunnel is a tunnel in the wrist that is formed by the bones of the wrist and a tough band of tissue called a \"ligament.\" Carpal tunnel syndrome happens when a nerve that goes through that tunnel, called the \"median nerve,\" gets pinched or squeezed. Carpal tunnel syndrome causes pain and numbness most often in the areas shaded here in blue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_1_39955=[""].join("\n");
var outline_f39_1_39955=null;
var title_f39_1_39956="Pulmonary vein velocities";
var content_f39_1_39956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Pulmonary vein velocities",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Sherif F Nagueh.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_1_39956=[""].join("\n");
var outline_f39_1_39956=null;
var title_f39_1_39957="Porokeratosis of Mibelli";
var content_f39_1_39957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Porokeratosis of Mibelli",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large plaque with a slightly atrophic center and a prominent peripheral keratotic ridge is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_1_39957=[""].join("\n");
var outline_f39_1_39957=null;
var title_f39_1_39958="Acitretin: Drug information";
var content_f39_1_39958=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acitretin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/53/42837?source=see_link\">",
"    see \"Acitretin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Soriatane&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F130261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Soriatane&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F130294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Retinoid-Like Compound",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F130264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Psoriasis:",
"     </b>",
"     Oral: Individualization of dosage is required to achieve maximum therapeutic response while minimizing side effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Initial therapy:",
"     </i>",
"     Therapy should be initiated at 25-50 mg/day, given as a single dose with the main meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance:",
"     </i>",
"     Doses of 25-50 mg/day may be given after initial response to treatment; the maintenance dose should be based on clinical efficacy and tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     American Academy of Dermatology recommends: 10-50 mg/day as a single dose; doses &le;25 mg/day are used to decrease side effects (Menter, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F130265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13243849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     There are no dosage adjustments provided in manufacturer's labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hemodialysis: Not removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13243848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F130240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Soriatane&reg;: 10 mg, 17.5 mg, 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F130226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089133.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089133.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9405608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food, preferably with the main meal of the day.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F130241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of severe psoriasis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F130302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Soriatane&reg; may be confused with Loxitane&reg;, sertraline, Sonata&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F130292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Hyperesthesia (10% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Cheilitis (&gt;75%), alopecia (50% to 75%), skin peeling (50% to 75%), dry skin (25% to 50%), nail disorder (25% to 50%), pruritus (25% to 50%), erythematous rash (10% to 25%), paronychia (10% to 25%), skin atrophy (10% to 25%), sticky skin (10% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypertriglyceridemia (50% to 75%), fasting blood sugar increased (25% to 50%), HDL decreased (25% to 50%), hypercholesterolemia (25% to 50%), fasting blood sugar decreased (10% to 25%), magnesium increased/decreased (10% to 25%), phosphorus increased (10% to 25%), potassium increased (10% to 25%), sodium increased (10% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (10% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Reticulocytes increased (25% to 50%), haptoglobin increased (10% to 25%), hematocrit decreased (10% to 25%), hemoglobin decreased (10% to 25%), neutrophils increased (10% to 25%), WBC increased/decreased (10% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver function tests increased (25% to 50%), alkaline phosphatase increased (10% to 25%), direct bilirubin increased (10% to 25%), GGTP increased (10% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased (25% to 50%), arthralgia (10% to 25%), paresthesia (10% to 25%), rigors (10% to 25%), spinal hyperostosis progression (10% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Xerophthalmia (10% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: WBC in urine (25% to 50%), acetonuria (10% to 25%), hematuria (10% to 25%), RBC in urine (10% to 25%), uric acid increased (10% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (25% to 50%), epistaxis (10% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema, flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression, fatigue, headache, insomnia, pain, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Bullous eruption, cold/clammy skin, dermatitis, fissures, hair texture change, psoriasiform rash, purpura, pyogenic granuloma, rash, seborrhea, skin odor, sunburn, ulcers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Calcium increased or decreased, chloride increased or decreased, hot flashes, iron increased/decreased, phosphorus decreased, potassium decreased, sodium decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, appetite increased, diarrhea, gingival bleeding, gingivitis, nausea, saliva increased, stomatitis, taste disturbance, thirst, tongue disorder, ulcerative stomatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Haptoglobin decreased, hematocrit increased, hemoglobin increased, neutrophils decreased, RBC increased/decreased, reticulocytes decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Total bilirubin increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthritis, arthrosis, back pain, Bell's palsy, hypertonia, myalgia, osteodynia, peripheral joint hyperostosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blepharitis, blurred vision, cataract, conjunctivitis, corneal epithelial abnormality, diplopia, eye pain, eyebrow or eyelash loss, night blindness, photophobia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Earache, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Albumin decreased/increased, BUN increased, creatinine increased, glycosuria, proteinuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal gait, acne, aggression, anal disorder, anxiety, bleeding time increased, bone disorder, breast pain, chalazion, chest pain, ceruminosis, cirrhosis, conjunctival hemorrhage, constipation, corneal lesions, corneal ulceration, cough, cyanosis, cyst, deafness, diplopia, dizziness, dyspepsia, dysphonia, dysuria, ectropion, eczema, esophagitis, ethanol intolerance, fever, flu-like syndrome, fungal infection, furunculosis, gastritis, gastroenteritis, glossitis, gum hyperplasia, hair discoloration, healing impaired, hemorrhage, hemorrhoids, hepatic dysfunction, hepatitis, herpes simplex, hyperkeratosis, hypertrichosis, hypoesthesia, intermittent claudication, itchy eyes, jaundice, lacrimation abnormal, laryngitis, leukorrhea, libido decreased, malaise, melena, MI, migraine, moniliasis, muscle weakness, myopathy with peripheral neuropathy, nail fragility, nervousness, neuritis, olecranon bursitis, otitis media, pancreatitis, papilledema, peripheral ischemia, pharyngitis, photosensitivity, pseudotumor cerebri, recurrent sties, scaling of skin, scleroderma, skin fragility or thinning, skin hypertrophy, skin nodule, spinal hyperostosis (new lesion), sputum increased, suicidal thoughts, taste loss, tendonitis, tenesmus, thromboembolism, tongue ulceration, urticaria, vaginitis, vulvovaginitis, wart, weight gain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F130244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acitretin, other retinoids, or any component of the formulation; patients who are pregnant or intend on becoming pregnant; severe hepatic or renal dysfunction; chronically-elevated blood lipid levels; concomitant use with methotrexate or tetracyclines",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Acitretin is contraindicated in females of childbearing potential unless all of the following conditions apply.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1) Patient has severe psoriasis unresponsive to other therapy or if clinical condition contraindicates other treatments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2) Patient must have two negative urine or serum pregnancy tests prior to therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3) Patient must have pregnancy test repeated monthly during therapy. After discontinuation of therapy, a pregnancy test must be repeated every 3 months for at least 3 years.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4) Patient must commit to using two effective forms of birth control starting 1 month prior to acitretin treatment and for 3 years after discontinuation. Prescriber must counsel patient about contraception every month during therapy and every 3 months following discontinuation for at least 3 years.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5) Patient is reliable in understanding and carrying out instructions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6) Patient has received, and acknowledged, understanding of a careful oral and printed explanation of the hazards of fetal exposure to acitretin and the risk of possible contraception failure. Patient must sign an agreement/informed consent document stating that she understands these risks and that she should not consume ethanol during therapy or for 2 months after discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F130229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Depression, including thoughts of self-harm have been reported; use with caution in patients with a history of mental illness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Changes in transaminases occur in up to",
"     </b>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     <b>",
"      of patients.",
"     </b>",
"     Monitor for hepatotoxicity; discontinue if significant elevations of liver enzymes occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperostosis: Patients receiving long-term treatment should be periodically examined for bony abnormalities; risk vs benefit of therapy should be considered if abnormalities occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Lipid changes including, increased triglycerides, increased cholesterol, and decreased HDL are common (up to 66%); increased triglycerides may lead to pancreatitis. Use with caution in patients at risk of hypertriglyceridemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: May be photosensitizing; minimize sun or other UV exposure to treated areas. The risk of burning is increased with phototherapy; decreased doses are required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pseudotumor cerebri: Rarely associated with pseudotumor cerebri.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Visual disturbances: May cause adverse effects to the eyes and vision, including a decrease in night vision or decreased tolerance to contact lenses. Use caution when operating vehicles at night; discontinue if visual changes occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use:",
"     <b>",
"      [U.S. Boxed Warning]: Female patients should abstain from ethanol or ethanol-containing products during therapy and for 2 months after discontinuation.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tetracyclines: Pseudotumor cerebri (benign intracranial hypertension) has been reported with use of tetracyclines and acitretin independently; concomitant use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Growth potential may be affected. Long-term use of high-dose oral retinoids within this population has been associated with decreased bone mineral density, skeletal hyperostosis, and ossification of interosseous tendons and ligaments of the extremities (Menter, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Not for use by women who are pregnant or want to become pregnant; patient should not get pregnant for at least 3 years after discontinuation.",
"     </b>",
"     The Do Your P.A.R.T. (Pregnancy Prevention Actively Required During and After Treatment) program explains teratogenic risks and requirements expected of females of childbearing potential to prevent pregnancies from occurring during use and 3 years following discontinuation; this should be used to educate patients and healthcare providers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not for the treatment of acne",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood donation:",
"     <b>",
"      [U.S. Boxed Warning]: All patients should be advised not to donate blood during therapy or for 3 years following completion of therapy.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Medication guide:",
"     <b>",
"      [U.S. Boxed Warning]: All patients must be provided with a medication guide each time acitretin is dispensed. Female patients must also sign an informed consent prior to therapy.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Worsening of disease: Transient worsening of psoriasis may initially occur; patients should be advised that it may take 2-3 months to achieve the full benefits of treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F130233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the teratogenic effect of Acitretin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Retinoic Acid Derivatives may diminish the therapeutic effect of Contraceptives (Estrogens). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Acitretin may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Given the potential for progestin-only preparations to fail to prevent pregnancy during acitretin therapy, such products should not be relied upon. Alternative, nonhormonal forms of contraception must be employed during acitretin therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Retinoic Acid Derivatives may diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins).  Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Acitretin may enhance the hepatotoxic effect of Methotrexate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoid-like Compounds.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin A: Retinoic Acid Derivatives may enhance the adverse/toxic effect of Vitamin A.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin A: May enhance the adverse/toxic effect of Retinoid-like Compounds.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F130258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Use leads to formation of etretinate, a teratogenic metabolite with a prolonged half-life. Management: Female patients must avoid ethanol or ethanol-containing products concomitantly or within 2 months after discontinuing acitretin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Absorption increased when administered with food. Management: Take with food; avoid ingestion of additional sources of vitamin A (in excess of RDA).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F130235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F130247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Not for use by women who are pregnant or intend to become pregnant.",
"     </b>",
"     Acitretin is teratogenic in humans. Severe birth defects have been reported when conception occurred during treatment or after therapy was complete. Patients should not get pregnant for at least 3 years after discontinuation. In addition, because ethanol forms a teratogenic metabolite and would increase the duration of teratogenic potential, ethanol should not be consumed during treatment or for 2 months after discontinuation. The Do Your P.A.R.T. (Pregnancy Prevention Actively Required During and After Treatment) program explains teratogenic risks and requirements expected of females of childbearing potential. Limited amounts of acitretin are found in seminal fluid; although it appears this poses little risk to a fetus, the actual risk of teratogenicity is not known. Any pregnancy which occurs during treatment, or within 3 years after treatment is discontinued, should be reported to the manufacturer at 1-888-784-3335 or to the FDA at 1-800-FDA-1088.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F130267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F130248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acitretin should not be given prior to or during nursing due to the potential for adverse effects in the nursing infant.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F130249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food. Avoid ingestion of additional sources of exogenous vitamin A (in excess of RDA); use of ethanol and ethanol-containing products is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Soriatane Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $945.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     17.5 mg (30): $1165.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $1165.44",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F130237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lipid profile (baseline and at 1- to 2-week intervals for 4-8 weeks); liver function tests (baseline, and at 1- to 2-week intervals until stable, then as clinically indicated); blood glucose in patients with diabetes; bone abnormalities (with long-term use); pregnancy tests (2 negative tests prior to therapy initiation, monthly during treatment, and every 3 months for &ge;3 years after discontinuation of therapy)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     The American Academy of Dermatology recommends: CBC and renal function tests (baseline and then every 12 weeks); liver function tests (every 2 weeks for the first 8 weeks, then every 6-12 weeks thereafter) (Menter, 2009)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F130250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acetec (IN);",
"     </li>",
"     <li>",
"      Acitrexol (PE);",
"     </li>",
"     <li>",
"      Neotigason (AR, AT, AU, BB, BE, BF, BG, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CZ, DE, DK, EC, EE, EG, ET, FI, GB, GH, GM, GN, GR, GY, HK, HN, IE, IL, IT, JM, KE, KP, LR, MA, ML, MR, MU, MW, MX, MY, NE, NG, NL, NO, NZ, PE, PH, PL, PT, PY, SC, SD, SE, SG, SL, SN, SR, TH, TN, TR, TT, TW, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Soriatane (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13831040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to and activates all nuclear subtypes (alpha, beta, and gamma) of retinoid X receptors (RXR) and retinoic acid receptors (RAR) to inhibit the expression of the pro-inflammatory cytokines interleukin-6 (IL-6), migration inhibitory factor-related protein-8 (MRP-8), and interferon-gamma (markers of hyperproliferation and abnormal keratinocyte differentiation). Resulting actions are anti-inflammatory and antiproliferative, and keratinocyte differentiation is normalized in the epithelium.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F130243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Etretinate has been detected in serum for up to 3 years following therapy, possibly due to storage in adipose tissue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: May take 2-3 months for full effect; improvement may be seen within 8 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: ~72% absorbed when given with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99% bound, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Metabolized to",
"     <i>",
"      cis",
"     </i>",
"     -acitretin; both compounds are further metabolized. Concomitant ethanol use leads to the formation of etretinate (active).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Acitretin: 49 hours (range: 33-96);",
"     <i>",
"      cis",
"     </i>",
"     -acitretin: 63 hours (range: 28-157); etretinate: 120 days (range: up to 168 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (34% to 54%); urine (16% to 53%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DiSepio D, Malhotra M, Chandraratna R, et al, \"Retinoic Acid Receptor&ndash;Nuclear Factor&ndash;Interleukin 6 Antagonism: A Novel Mechanism of Retinoid-Dependent Inhibition of a Keratinocyte Hyperproliferative Differentiation Marker,\"",
"      <i>",
"       J Biol Chem",
"      </i>",
"      , 1997, 272(41):25555-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/1/39958/abstract-text/9325272/pubmed\" id=\"9325272\" target=\"_blank\">",
"        9325272",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Menter A, Gottlieb A, Feldman SR,, et al, \"Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 1. Overview of Psoriasis and Guidelines of Care for the Treatment of Psoriasis With Biologics,\"",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2008, 58(5):826-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/1/39958/abstract-text/18423260/pubmed\" id=\"18423260\" target=\"_blank\">",
"        18423260",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Menter A, Korman NJ, Elmets CA, et al, \"Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 4. Guidelines of Care for the Management and Treatment of Psoriasis With Traditional Systemic Agents,\"",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2009, 61(3):451-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/1/39958/abstract-text/19493586/pubmed\" id=\"19493586\" target=\"_blank\">",
"        19493586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saurat JH, \"Retinoids and Psoriasis: Novel Issues in Retinoid Pharmacology and Implications for Psoriasis Treatment,\"",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 1999, 41(3 Pt 2):S2-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/1/39958/abstract-text/10459139/pubmed\" id=\"10459139\" target=\"_blank\">",
"        10459139",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9250 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-115.25.216.6-3DB58A19CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_1_39958=[""].join("\n");
var outline_f39_1_39958=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708608\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130260\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130261\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130294\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130264\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130265\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13243849\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13243848\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130240\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130226\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874544\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9405608\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130241\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130302\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130292\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130244\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130229\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298678\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130233\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130258\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130235\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130247\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130267\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130248\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130249\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322964\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130237\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130250\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13831040\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130243\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9250\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9250|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/53/42837?source=related_link\">",
"      Acitretin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_1_39959="Pathogenesis of malaria";
var content_f39_1_39959=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of malaria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/1/39959/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/1/39959/contributors\">",
"     Danny A Milner, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/1/39959/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/1/39959/contributors\">",
"     Johanna Daily, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/1/39959/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/1/39959/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/1/39959/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding the pathogenesis of malaria requires investigation of mechanisms for parasite invasion and host defense. The parasite life cycle illustrates the interplay of parasite and host interactions (",
"    <a class=\"graphic graphic_figure graphicRef58397 \" href=\"mobipreview.htm?35/50/36647\">",
"     figure 1",
"    </a>",
"    ). Pathogenesis of P. falciparum is the area of greatest study, since this species causes the most severe clinical disease (other species include P. ovale, P. vivax, P. malariae and P. knowlesi). P. knowlesi malaria can also cause life threatening illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to the pathogenesis of malaria will be reviewed here. Issues related to epidemiology, clinical manifestations, diagnosis and treatment are discussed in detail separately. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE PARASITE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Life cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human malaria occurs by transmission of Plasmodium sporozoites via a bite from an infected anopheline mosquito (",
"    <a class=\"graphic graphic_figure graphicRef58397 \" href=\"mobipreview.htm?35/50/36647\">",
"     figure 1",
"    </a>",
"    ). The sporozoites travel from the salivary glands of the mosquito through the bloodstream of the host to the liver, where they invade hepatocytes. These cells divide many 1000-fold until mature tissue schizonts are formed, each containing thousands of daughter merozoites. This exoerythrocytic stage is asymptomatic.",
"   </p>",
"   <p>",
"    The liver schizonts rupture after 6 to 16 days in P. falciparum (and there is typically a longer liver phase in other species) and release thousands of merozoites into the bloodstream, where they invade red blood cells of various ages (the erythrocytic stage). The merozoites mature successively from ring forms to trophozoites to mature red cell schizonts (asexual forms) over 24 hours (P. knowlesi), 48 hours (P. vivax, P. ovale, P. falciparum) or 72 hours (P. malariae). Within red blood cells the parasites digest red cell proteins, primarily hemoglobin. As hemoglobin is digested, the breakdown products are toxic to the parasite and, thus, hemozoin (a polarizable crystal) is formed in the food vacuole.",
"   </p>",
"   <p>",
"    The intracellular parasites modify the erythrocyte in several ways. They derive energy from anaerobic glycolysis of glucose to lactic acid, which may contribute to clinical manifestations of hypoglycemia and lactic acidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/2\">",
"     2",
"    </a>",
"    ]. They also make the red cell membrane less deformable, resulting in hemolysis and accelerated splenic clearance, which ultimately contribute to anemia. Alterations to uninfected red blood cells, such as the addition of P. falciparum glycosylphosphatidylinositol (GPI) to the membrane, may play a role in increased clearance of uninfected cells and contribute to anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/18/19754?source=see_link\">",
"     \"Anemia in malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ultimately, new daughter merozoites are released from the infected erythrocytes. The remnants of cell membrane and the hemozoin crystal are phagocytized by circulating macrophages, an important first stimulus in the activation of the immune cascade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In addition, free heme is released into the peripheral blood, an important stimulus for endothelial activation; endothelial cell damage also occurs in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Red cell lysis stimulates release of pro-inflammatory cytokines, including tumor necrosis factor (TNF). TNF suppresses hematopoiesis, which also contributes to the anemia. The liver and spleen enlarge over time; the spleen may become massively enlarged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/7\">",
"     7",
"    </a>",
"    ]. Thrombocytopenia is caused by a combination of hypersplenism (ie, increased splenic sequestration and decreased platelet survival time) and, in the case of P. falciparum, consumption of platelets in microvascular sequestration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Coagulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most released merozoites continue in the asexual cycle and infect new red cells, although a few differentiate into male or female gametocytes (sexual forms) which cause no symptoms but can circulate in the bloodstream until they are ingested by a blood-feeding anopheline mosquito. These sexual forms complete their life cycle within the midgut of the Anopheles mosquito, and the sporozoites that form then migrate to the salivary glands of the mosquito, from where they can reinfect humans.",
"   </p>",
"   <p>",
"    In the setting of P. vivax and P. ovale infection, some parasites remain dormant in the liver as hypnozoites and can cause late relapse by reactivating after many months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/12\">",
"     12",
"    </a>",
"    ]. In the setting of P. falciparum and P. malariae infection, hypnozoite parasites do not develop in the liver. However, P. malariae can cause very late relapse due to subpatent infection that can become symptomatic years to decades later.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genetic diversity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveys of the P. falciparum genome from different geographic regions have demonstrated remarkable genetic diversity. The parasite genome is much more diverse than the human genome; single nucleotide polymorphisms,",
"    <span class=\"nowrap\">",
"     insertions/deletions,",
"    </span>",
"    and microsatellites are very common in particular genes (genes that are under immune selection, for example) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using these polymorphisms as markers in genome-wide association studies allows identification of the source of clinical and experimental phenotypes of the parasites, improving understanding of pathogenesis and potential for development of new therapies.",
"   </p>",
"   <p>",
"    Variation in gene copy number among genes known to be involved in metabolic pathways may influence drug susceptibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/16\">",
"     16",
"    </a>",
"    ]. Comprehensive genetic mapping will enable further identification of genes mediating drug resistance as well as potential vaccine targets.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Microvascular disease and sequestration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytoadherence to human cell surfaces is an important component of P. falciparum pathogenesis. As P. falciparum parasites mature from rings to trophozoites within red blood cells, they induce the formation of sticky knobs on the surface of erythrocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The knobs are composed of a combination of parasite produced proteins including P. falciparum erythrocyte membrane protein-1 (PfEMP-1, the product of var gene expression and proposed primary cytoadherence factor), KAHRP, PfEMP-2, and RESA as well as human proteins including spectrin, actin, and band 4.1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Each P. falciparum parasite has &ge;60 different var genes; of these, one protein product is present in individual parasites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The knobs bind to receptors on a variety of cell types in capillaries and venules, including endothelial cells. Notable human receptors include ICAM-1 (vascular endothelium), CD36 (on endothelium and platelets), and CSA (in the placenta); a variety of other binding interactions have also been elucidated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. Endothelial binding leads to sequestration of infected red cells within these small vessels (thereby removing parasites from the peripheral circulation during a prolonged period of the life cycle). This leads to partial blood flow obstruction, endothelial barrier breakdown, and inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sequestration can be demonstrated in any organ of a patient infected with P. falciparum. The most catastrophic clinical manifestation of sequestration is cerebral malaria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/27\">",
"     27",
"    </a>",
"    ]. Renal failure in the setting of malaria may occur in part as a result of mechanical obstruction by infected erythrocytes; immune mediated glomerular pathology and fluid loss due to alterations in the renal microcirculation also probably contribute to renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rosetting is another mechanism of microvascular disease. Infected red cells stick to uninfected red cells and form rosettes that clog the microcirculation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Rosetting is mediated by an interaction between PfEMP-1 within knobs and receptors on the surface of uninfected red cells, such as complement-receptor 1 (CR1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Parasite biomass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular beds harboring sequestered parasites allow accumulation of high levels of parasite biomass in the host. HRP-2 (a P. falciparum antigen expressed on the erythrocyte membrane) can be used as an indirect measure of parasite biomass both in the circulation and sequestered in the microvasculature. The concentration of this antigen has been observed to correlate with severity of clinical disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interaction between host endothelium and immune cells with malaria parasites is complex and not fully understood. The \"cytokine storm\" hypothesis suggests that in the setting of severe malaria, damaging cytokines and small molecules become unregulated and lead to a SIRS-like state with high circulating levels of TNF and nitric oxide. However, evidence of direct correlation between severe malaria and the activity of these markers is limited.",
"   </p>",
"   <p>",
"    Some markers, such as the acute phase reactant C reactive protein (CRP), correlate directly with parasitemia. Cytokines TNF, lymphotoxin, interleukin(IL)-6, IL-10, IL-12, IL-18, and MIP-1 are consistently elevated in the setting of malaria. However, it is not clear whether these precede or follow clinical markers of severe infection.",
"   </p>",
"   <p>",
"    Molecular evidence for endothelial and tissue damage includes elevated levels of lactate, CK-MB, myoglobin, and angiopoietin-2 as well as increased soluble",
"    <span class=\"nowrap\">",
"     ligands/receptors",
"    </span>",
"    (eg, sELAM-1, sICAM-1, sTNF-R1, sTNF-R2, sVCAM-1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/32\">",
"     32",
"    </a>",
"    ]. Microparticles (small circulating bodies released from the surface of human cells) are another interesting component of pathogenesis; more data are needed to understand their exact role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initiation of tissue factor production in the coagulation cascade has been proposed as a unifying mechanism of pathogenesis in severe malaria, based on the following observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/8,33-35\">",
"     8,33-35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thrombocytopenia is a common feature of severe malaria; it may also observed in uncomplicated malaria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/8,33\">",
"       8,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Activation of the coagulation cascade in the absence overt bleeding (eg, elevated D-dimer and thrombin-antithrombin complexes with normal prothrombin time and thromboplastin time) is also common [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Autopsies of patients with cerebral malaria frequently demonstrate fibrin microthrombi admixed with platelets in the cerebral vasculature (as well as other organs) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Nitric oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low nitric oxide, low arginine (the pre-cursor of nitric oxide), and elevated arginase activity in peripheral blood have been observed in severe malaria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/36\">",
"     36",
"    </a>",
"    ]. Metabolic studies have demonstrated that the parasite's arginase enzyme (which converts arginine to ornithine) may contribute to hypoargininemia in severely ill patients, thus shutting down nitric oxide production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/37\">",
"     37",
"    </a>",
"    ]. Children with nitric oxide depletion due to intravascular hemolysis in the setting of malaria subsequently develop pulmonary hypertension and myocardial wall stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/36\">",
"     36",
"    </a>",
"    ]. Replenishment of nitric oxide via peripheral arginine has been suggested as a possible treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     THE HOST",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several genetic polymorphisms and mutations appear to influence the severity of malaria infection; examples are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef55135 \" href=\"mobipreview.htm?9/29/9693\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Hemoglobin and red cell antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobin and red cell antigens can confer variable protection against malaria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/23/20858?source=see_link\">",
"     \"Protection against malaria in the hemoglobinopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A classic example is the Duffy blood group factor, a red cell antigen necessary for invasion by P. vivax [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/40\">",
"       40",
"      </a>",
"      ]. Absence of the Duffy antigen on red cells (largely observed in individuals from West and sub-Saharan Africa) is protective for P. vivax malaria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/40\">",
"       40",
"      </a>",
"      ]. However, cases of P. vivax in Duffy-negative individuals have been identified in Brazil and in Kenya, suggesting that P. vivax is evolving alternate red blood cell invasion pathways to invade Duffy-negative red cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/41,42\">",
"       41,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is strong evidence that sickle cell genetic alterations evolved in part because of the survival advantage against lethal P. falciparum infections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/43-45\">",
"       43-45",
"      </a>",
"      ]. Children with HbAS have a significantly lower risk of P. falciparum malaria, lower parasite densities, and lower rates of hospital admissions than children with HbAA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/46\">",
"       46",
"      </a>",
"      ]. Possible mechanisms are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/23/20858?source=see_link\">",
"       \"Protection against malaria in the hemoglobinopathies\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The potential protective effect of sickle hemoglobin against malaria may be augmented in malaria endemic areas; individuals outside endemic areas may have a lesser degree of protection. In a family living in the United States in which two children had sickle cell anemia and three had sickle cell trait, travel to an endemic region without chemoprophylaxis led to hemolytic crisis in three of the children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/47\">",
"       47",
"      </a>",
"      ]. Thalassemia may indirectly protect against P. falciparum infection by mediating increased susceptibility to nonlethal P. vivax, particularly in young children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/48,49\">",
"       48,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Red blood cells in individuals with thalassemia appear to be susceptible to P. falciparum invasion but are associated with significantly reduced parasite multiplication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. This may be due to the variable degree of persistence of hemoglobin F, which is relatively resistant to hemoglobin digestion by malarial hemoglobinases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/49,52,53\">",
"       49,52,53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8058?source=see_link&amp;anchor=H9#H9\">",
"       \"Pathophysiology of beta thalassemia\", section on 'Protection against severe malaria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ovalocytosis in Southeast Asia appears to confer protection against malarial infection. Possible mechanisms include diminished invasion, poor intraerythrocytic growth, or diminished cytoadherence of infected erythrocytes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/54,55\">",
"       54,55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hereditary elliptocytosis appears to confer protection against malaria, although malaria infection in the setting of this condition has been described [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/56\">",
"       56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/56/43911?source=see_link&amp;anchor=H10#H10\">",
"       \"Hereditary elliptocytosis: Genetics and pathogenesis\", section on 'Resistance to malaria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The haptoglobin (Hp) genotype determines the efficiency of hemoglobin clearance after malaria-induced hemolysis. A particular polymorphism of the haptoglobin genotype",
"      <span class=\"nowrap\">",
"       (Hp2/2)",
"      </span>",
"      has been associated with a reduction in the number of clinical malarial episodes; this was illustrated in a study of 312 children in Kenya [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pyruvate kinase deficiency appears to be protective against infection and replication of P. falciparum in human erythrocytes. Therefore, mutant pyruvate kinase alleles may confer protection against malaria in endemic areas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Tumor necrosis factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphisms in tumor necrosis factor (TNF) genes appear to influence the severity of P. falciparum infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. This was illustrated in a study of about 1000 Gambian children; a sevenfold increased risk of severe neurological sequelae or death from cerebral malaria was observed among those who were homozygous for a polymorphism in the promoter region of the TNF gene (TNF2 allele). Severe anemia was associated with a different TNF allele, suggesting that different genetic factors affect susceptibility to these two disease manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals living in endemic areas appear to develop partial immunity to malaria following repeated infections; the degree of protective immunity appears to be proportional to transmission intensity. Individuals in highly endemic areas (eg, sub-Saharan Africa) acquire nearly complete protection by early adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. Individuals in low transmission areas (eg, Southeast Asia) remaining at risk for clinical infection and fatal disease into adulthood; these individuals are referred to as \"semi-immune.\"",
"   </p>",
"   <p>",
"    Individuals not living in endemic areas (eg, travelers) infected with malaria form a detectable antibody response (which can be measured by ELISA), although this response is not protective against the initial infection of malaria and may serve only as a marker of past exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunity in pregnancy is also important. The risk of parasitemia during the first years of life is higher among children born to multigravid women than primigravid women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. The immunologic basis for this observation is not fully understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Humoral response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The humoral immune response to malaria appears to correlate with severity of clinical infection, with progression in maturation of the humoral response in the setting of ongoing parasite antigen stimulation. Elevated levels of IgG4, IgE and IgM are associated with severe disease in individuals with &le;5 previous clinical episodes of malaria, while elevated levels of IgG (IgG, IgG1, IgG2 and IgG3) are associated with mild disease in individuals with &gt;5 previous clinical episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations suggest that persistence of humoral immunity requires ongoing parasite antigen stimulation. In addition, individuals who leave endemic areas appear to lose some humoral protection; these individuals are \"semi-immune\" and their protection is lessened when they return to endemic areas after prolonged periods without parasite antigen stimulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/3/13370?source=see_link\">",
"     \"Prevention of malaria infection in travelers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Cellular response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to mount a robust interferon-gamma response (predominantly through CD56+ gamma T-cells) has been associated with protection against high parasitemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/68\">",
"     68",
"    </a>",
"    ]. Phagocytosis of hemozoin or trophozoites impairs the ability of monocytes and macrophages to mount oxidative burst, kill ingested bacteria, present antigens correctly, and mature to functioning dendritic cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/4\">",
"     4",
"    </a>",
"    ]. These cells produce TNF and other proinflammatory cytokines, and release peroxidation derivatives of polyunsaturated fatty acids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, these cells have increase in activity and release of MMP-9, which is correlated with TNF- and IL-1 gamma production and leads to disruption of the basal lamina of endothelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39959/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Understanding the pathogenesis of malaria requires investigation of mechanisms for parasite invasion and host defense. The parasite life cycle illustrates the interplay of parasite and host interactions (",
"      <a class=\"graphic graphic_figure graphicRef58397 \" href=\"mobipreview.htm?35/50/36647\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The plasmodium life cycle consists of an exoerythrocytic (asymptomatic) stage and erythrocytic (symptomatic) stage. Plasmodium sporozoites are transmitted by the bite of an infected anopheline mosquito. The sporozoites invade hepatocytes, which divide until schizonts are formed containing thousands of daughter merozoites. These rupture and release merozoites into the bloodstream, where they invade red blood cells. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Life cycle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intracellular parasites alter the red cell, digesting hemoglobin to form hemozoin and making the membrane less deformable, resulting in hemolysis or splenic clearance. The merozoites invade the red cell and mature to ring forms, trophozoites, and schizonts. Schizonts rupture and release new daughter merozoites as well as pro-inflammatory cytokines including tumor necrosis factor (TNF). Most released merozoites infect new red cells; a few differentiate into gametocytes, which circulate until they are ingested by a mosquito to continue the transmission cycle. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Life cycle'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Cytokines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endothelial binding of infected red cells leads to sequestration of infected red cells within small vessels (thereby removing parasites from the peripheral circulation during a prolonged period of the life cycle). This leads to partial blood flow obstruction, endothelial barrier breakdown, and inflammation. Mechanisms of microvascular disease include formation of sticky knobs on the cell surface and rosetting (eg, adherence of infected red cells to uninfected cells, forming rosettes that clog the microcirculation). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Microvascular disease and sequestration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several human genetic polymorphisms and mutations have been observed to influence the severity of malaria infection, particularly hemoglobin and red cell antigens. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Genetic factors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/23/20858?source=see_link\">",
"       \"Protection against malaria in the hemoglobinopathies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/18/19754?source=see_link\">",
"       \"Anemia in malaria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Individuals living in endemic areas appear to develop partial immunity to malaria following repeated infections; the degree of protective immunity appears to be proportional to transmission intensity. The cellular immune response consists of a variety of cytokines including interferon-gamma and tumor necrosis factor. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Immunity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/1\">",
"      Cox-Singh J, Davis TM, Lee KS, et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 2008; 46:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/2\">",
"      Daily JP, Scanfeld D, Pochet N, et al. Distinct physiological states of Plasmodium falciparum in malaria-infected patients. Nature 2007; 450:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/3\">",
"      Brattig NW, Kowalsky K, Liu X, et al. Plasmodium falciparum glycosylphosphatidylinositol toxin interacts with the membrane of non-parasitized red blood cells: a putative mechanism contributing to malaria anemia. Microbes Infect 2008; 10:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/4\">",
"      Prato M, Giribaldi G, Polimeni M, et al. Phagocytosis of hemozoin enhances matrix metalloproteinase-9 activity and TNF-alpha production in human monocytes: role of matrix metalloproteinases in the pathogenesis of falciparum malaria. J Immunol 2005; 175:6436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/5\">",
"      Prato M, Gallo V, Giribaldi G, Arese P. Phagocytosis of haemozoin (malarial pigment) enhances metalloproteinase-9 activity in human adherent monocytes: role of IL-1beta and 15-HETE. Malar J 2008; 7:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/6\">",
"      Ferreira A, Balla J, Jeney V, et al. A central role for free heme in the pathogenesis of severe malaria: the missing link? J Mol Med (Berl) 2008; 86:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/7\">",
"      Bedu-Addo G, Bates I. Causes of massive tropical splenomegaly in Ghana. Lancet 2002; 360:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/8\">",
"      Wassmer SC, Taylor T, Maclennan CA, et al. Platelet-induced clumping of Plasmodium falciparum-infected erythrocytes from Malawian patients with cerebral malaria-possible modulation in vivo by thrombocytopenia. J Infect Dis 2008; 197:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/9\">",
"      Wassmer SC, de Souza JB, Fr&egrave;re C, et al. TGF-beta1 released from activated platelets can induce TNF-stimulated human brain endothelium apoptosis: a new mechanism for microvascular lesion during cerebral malaria. J Immunol 2006; 176:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/10\">",
"      Wassmer SC, Combes V, Candal FJ, et al. Platelets potentiate brain endothelial alterations induced by Plasmodium falciparum. Infect Immun 2006; 74:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/11\">",
"      Wassmer SC, Cianciolo GJ, Combes V, Grau GE. [LMP-420, a new therapeutic approach for cerebral malaria?]. Med Sci (Paris) 2006; 22:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/12\">",
"      Imwong M, Snounou G, Pukrittayakamee S, et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 2007; 195:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/13\">",
"      Volkman SK, Sabeti PC, DeCaprio D, et al. A genome-wide map of diversity in Plasmodium falciparum. Nat Genet 2007; 39:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/14\">",
"      Jiang H, Yi M, Mu J, et al. Detection of genome-wide polymorphisms in the AT-rich Plasmodium falciparum genome using a high-density microarray. BMC Genomics 2008; 9:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/15\">",
"      Mu J, Awadalla P, Duan J, et al. Recombination hotspots and population structure in Plasmodium falciparum. PLoS Biol 2005; 3:e335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/16\">",
"      Nair S, Miller B, Barends M, et al. Adaptive copy number evolution in malaria parasites. PLoS Genet 2008; 4:e1000243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/17\">",
"      Newbold C, Craig A, Kyes S, et al. Cytoadherence, pathogenesis and the infected red cell surface in Plasmodium falciparum. Int J Parasitol 1999; 29:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/18\">",
"      Oh SS, Chishti AH, Palek J, Liu SC. Erythrocyte membrane alterations in Plasmodium falciparum malaria sequestration. Curr Opin Hematol 1997; 4:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/19\">",
"      Aikawa M. Morphological changes in erythrocytes induced by malarial parasites. Biol Cell 1988; 64:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/20\">",
"      Sharma YD. Knobs, knob proteins and cytoadherence in falciparum malaria. Int J Biochem 1991; 23:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/21\">",
"      Sharma YD. Knob proteins in falciparum malaria. Indian J Med Res 1997; 106:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/22\">",
"      Chookajorn T, Ponsuwanna P, Cui L. Mutually exclusive var gene expression in the malaria parasite: multiple layers of regulation. Trends Parasitol 2008; 24:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/23\">",
"      Chaiyaroj SC, Angkasekwinai P, Buranakiti A, et al. Cytoadherence characteristics of Plasmodium falciparum isolates from Thailand: evidence for chondroitin sulfate a as a cytoadherence receptor. Am J Trop Med Hyg 1996; 55:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/24\">",
"      Maubert B, Guilbert LJ, Deloron P. Cytoadherence of Plasmodium falciparum to intercellular adhesion molecule 1 and chondroitin-4-sulfate expressed by the syncytiotrophoblast in the human placenta. Infect Immun 1997; 65:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/25\">",
"      Rogerson SJ, Tembenu R, Doba&ntilde;o C, et al. Cytoadherence characteristics of Plasmodium falciparum-infected erythrocytes from Malawian children with severe and uncomplicated malaria. Am J Trop Med Hyg 1999; 61:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/26\">",
"      Maubert B, Fievet N, Tami G, et al. Cytoadherence of Plasmodium falciparum-infected erythrocytes in the human placenta. Parasite Immunol 2000; 22:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/27\">",
"      Ponsford MJ, Medana IM, Prapansilp P, et al. Sequestration and microvascular congestion are associated with coma in human cerebral malaria. J Infect Dis 2012; 205:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/28\">",
"      Das BS. Renal failure in malaria. J Vector Borne Dis 2008; 45:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/29\">",
"      Chen Q, Schlichtherle M, Wahlgren M. Molecular aspects of severe malaria. Clin Microbiol Rev 2000; 13:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/30\">",
"      Rowe JA, Moulds JM, Newbold CI, Miller LH. P. falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1. Nature 1997; 388:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/31\">",
"      Dondorp AM. Clinical significance of sequestration in adults with severe malaria. Transfus Clin Biol 2008; 15:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/32\">",
"      Yeo TW, Lampah DA, Gitawati R, et al. Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc Natl Acad Sci U S A 2008; 105:17097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/33\">",
"      Taylor WR, Widjaja H, Basri H, et al. Changes in the total leukocyte and platelet counts in Papuan and non Papuan adults from northeast Papua infected with acute Plasmodium vivax or uncomplicated Plasmodium falciparum malaria. Malar J 2008; 7:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/34\">",
"      Francischetti IM. Does activation of the blood coagulation cascade have a role in malaria pathogenesis? Trends Parasitol 2008; 24:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/35\">",
"      Haldar K, Murphy SC, Milner DA, Taylor TE. Malaria: mechanisms of erythrocytic infection and pathological correlates of severe disease. Annu Rev Pathol 2007; 2:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/36\">",
"      Janka JJ, Koita OA, Traor&eacute; B, et al. Increased pulmonary pressures and myocardial wall stress in children with severe malaria. J Infect Dis 2010; 202:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/37\">",
"      Olszewski KL, Morrisey JM, Wilinski D, et al. Host-parasite interactions revealed by Plasmodium falciparum metabolomics. Cell Host Microbe 2009; 5:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/38\">",
"      Weinberg JB, Lopansri BK, Mwaikambo E, Granger DL. Arginine, nitric oxide, carbon monoxide, and endothelial function in severe malaria. Curr Opin Infect Dis 2008; 21:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/39\">",
"      Yeo TW, Lampah DA, Gitawati R, et al. Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations. J Infect Dis 2008; 198:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/40\">",
"      Miller LH, Mason SJ, Clyde DF, McGinniss MH. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med 1976; 295:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/41\">",
"      Ryan JR, Stoute JA, Amon J, et al. Evidence for transmission of Plasmodium vivax among a duffy antigen negative population in Western Kenya. Am J Trop Med Hyg 2006; 75:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/42\">",
"      Cavasini CE, Mattos LC, Couto AA, et al. Plasmodium vivax infection among Duffy antigen-negative individuals from the Brazilian Amazon region: an exception? Trans R Soc Trop Med Hyg 2007; 101:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/43\">",
"      Nagel RL, Fleming AF. Genetic epidemiology of the beta s gene. Baillieres Clin Haematol 1992; 5:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/44\">",
"      Flint J, Harding RM, Clegg JB, Boyce AJ. Why are some genetic diseases common? Distinguishing selection from other processes by molecular analysis of globin gene variants. Hum Genet 1993; 91:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/45\">",
"      Aidoo M, Terlouw DJ, Kolczak MS, et al. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet 2002; 359:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/46\">",
"      Williams TN, Mwangi TW, Wambua S, et al. Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases. J Infect Dis 2005; 192:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/47\">",
"      Glikman D, Nguyen-Dinh P, Roberts JM, et al. Clinical malaria and sickle cell disease among multiple family members in Chicago, Illinois. Pediatrics 2007; 120:e745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/48\">",
"      Williams TN, Maitland K, Bennett S, et al. High incidence of malaria in alpha-thalassaemic children. Nature 1996; 383:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/49\">",
"      Clegg JB, Weatherall DJ. Thalassemia and malaria: new insights into an old problem. Proc Assoc Am Physicians 1999; 111:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/50\">",
"      Enevold A, Lusingu JP, Mmbando B, et al. Reduced risk of uncomplicated malaria episodes in children with alpha+-thalassemia in northeastern Tanzania. Am J Trop Med Hyg 2008; 78:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/51\">",
"      Veenemans J, Andang'o PE, Mbugi EV, et al. Alpha+ -thalassemia protects against anemia associated with asymptomatic malaria: evidence from community-based surveys in Tanzania and Kenya. J Infect Dis 2008; 198:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/52\">",
"      Pattanapanyasat K, Yongvanitchit K, Tongtawe P, et al. Impairment of Plasmodium falciparum growth in thalassemic red blood cells: further evidence by using biotin labeling and flow cytometry. Blood 1999; 93:3116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/53\">",
"      Pasvol G, Weatherall DJ, Wilson RJ, et al. Fetal haemoglobin and malaria. Lancet 1976; 1:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/54\">",
"      Gratzer WB, Dluzewski AR. The red blood cell and malaria parasite invasion. Semin Hematol 1993; 30:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/55\">",
"      Genton B, al-Yaman F, Mgone CS, et al. Ovalocytosis and cerebral malaria. Nature 1995; 378:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/56\">",
"      Boctor FN, Dorion RP. Malaria and hereditary elliptocytosis. Am J Hematol 2008; 83:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/57\">",
"      Atkinson SH, Mwangi TW, Uyoga SM, et al. The haptoglobin 2-2 genotype is associated with a reduced incidence of Plasmodium falciparum malaria in children on the coast of Kenya. Clin Infect Dis 2007; 44:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/58\">",
"      Ayi K, Min-Oo G, Serghides L, et al. Pyruvate kinase deficiency and malaria. N Engl J Med 2008; 358:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/59\">",
"      McGuire W, Knight JC, Hill AV, et al. Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles. J Infect Dis 1999; 179:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/60\">",
"      McGuire W, Hill AV, Allsopp CE, et al. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994; 371:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/61\">",
"      Dondorp AM, Lee SJ, Faiz MA, et al. The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis 2008; 47:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/62\">",
"      Osier FH, Fegan G, Polley SD, et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 2008; 76:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/63\">",
"      Doolan DL, Doba&ntilde;o C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev 2009; 22:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/64\">",
"      Schwarz NG, Adegnika AA, Breitling LP, et al. Placental malaria increases malaria risk in the first 30 months of life. Clin Infect Dis 2008; 47:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/65\">",
"      Mutabingwa TK, Bolla MC, Li JL, et al. Maternal malaria and gravidity interact to modify infant susceptibility to malaria. PLoS Med 2005; 2:e407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/66\">",
"      Mibei EK, Otieno WO, Orago AS, Stoute JA. Distinct pattern of class and subclass antibodies in immune complexes of children with cerebral malaria and severe malarial anaemia. Parasite Immunol 2008; 30:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/67\">",
"      Leoratti FM, Durlacher RR, Lacerda MV, et al. Pattern of humoral immune response to Plasmodium falciparum blood stages in individuals presenting different clinical expressions of malaria. Malar J 2008; 7:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39959/abstract/68\">",
"      D'Ombrain MC, Robinson LJ, Stanisic DI, et al. Association of early interferon-gamma production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children. Clin Infect Dis 2008; 47:1380.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5703 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-F0BCE44B44-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_1_39959=[""].join("\n");
var outline_f39_1_39959=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE PARASITE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Life cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genetic diversity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Microvascular disease and sequestration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Parasite biomass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Coagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Nitric oxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      THE HOST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Hemoglobin and red cell antigens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Tumor necrosis factor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Immunity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Humoral response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Cellular response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5703\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5703|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/50/36647\" title=\"figure 1\">",
"      Malaria life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5703|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/29/9693\" title=\"table 1\">",
"      Gene polymorphism effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/18/19754?source=related_link\">",
"      Anemia in malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/56/43911?source=related_link\">",
"      Hereditary elliptocytosis: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8058?source=related_link\">",
"      Pathophysiology of beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/3/13370?source=related_link\">",
"      Prevention of malaria infection in travelers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/23/20858?source=related_link\">",
"      Protection against malaria in the hemoglobinopathies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_1_39960="Human chorionic gonadotropin testing";
var content_f39_1_39960=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Human chorionic gonadotropin testing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/1/39960/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/1/39960/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/1/39960/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/1/39960/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/1/39960/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/1/39960/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/1/39960/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human chorionic gonadotropin (hCG) is produced by trophoblast. Laboratory tests for hCG are essentially 100 percent sensitive and specific for diagnosis of trophoblast-related conditions: pregnancy and the gestational trophoblastic diseases. Rarely, however, very low levels of hCG are detected in the absence of one of these conditions. Understanding the complexity of hCG molecules and the nuances of hCG testing is critical to managing these patients.",
"   </p>",
"   <p>",
"    This topic will review basic issues related to hCG testing. The clinical use of this test in the follow-up of women with gestational trophoblastic disease is discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24761?source=see_link\">",
"       \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42234?source=see_link\">",
"       \"Gestational trophoblastic neoplasia: Staging and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23015?source=see_link\">",
"       \"Gestational trophoblastic disease: Management of hydatidiform mole\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical use of this test for diagnosis of pregnancy (intrauterine or ectopic) is also reviewed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44808?source=see_link\">",
"       \"Clinical manifestations and diagnosis of early pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1178?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STRUCTURE OF HCG",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCG is a dimer consisting of a 145 amino acid beta-subunit that is unique to hCG, and a 92 amino acid alpha-subunit. The alpha-subunit is not unique and is identical to that for luteinizing hormone (LH), follicle stimulating hormone (FSH) and thyroid stimulating hormone (TSH). The alpha and beta-subunits are coded by separate genes on separate chromosomes (chromosomes 6 and 19, respectively) and noncovalently bound before being released into the circulation.",
"   </p>",
"   <p>",
"    Sugar side chains comprise 25 to 40 percent of the molecular weight of hCG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The alpha-subunit contains two N-linked oligosaccharides attached at amino acid residues 53 and 78; the beta-subunit contains two N-linked oligosaccharides attached at amino acid residues 13 and 30, as well as four O-linked oligosaccharides attached at amino acid residues 121,127,132, and 138 on the C-terminal extension.",
"   </p>",
"   <p>",
"    Several isoforms of HCG exist in the circulation; some are synthesized and others are degradation products. The two most common forms of hCG synthesized by cells are regular hCG and hyperglycosylated hCG (hCG-H). HCG-H contains more sugar residues than regular hCG: 1.5-fold more sugar residues on the N-linked oligosaccharides (16 versus 11 sugar residues for regular hCG) and two-fold more sugar residues on O-linked oligosaccharides (6 versus 3 sugar residues for regular hCG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The additional sugar residues increase the molecular weight from 36,700 to as high as 41,000 and are the basis of the term \"hyperglycosylated\" hCG.",
"   </p>",
"   <p>",
"    Hyperglycosylated hCG free beta-subunit is the only other hCG molecule containing a beta-subunit synthesized by cells.",
"   </p>",
"   <p>",
"    The other 10 types of hCG molecules containing a beta-subunit are not synthesized directly; instead, they are products of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      dissociation of intact hCG dimers (hCG free beta-subunit), or",
"     </li>",
"     <li>",
"      cleavage (nicked regular hCG, nicked hCG-H, nicked hCG free beta-subunit, nicked hcg-H free beta-subunit, nicked hCG missing the C-terminal peptide, nicked hCG-H missing the C-terminal peptide, nicked hCG free beta-subunit missing the C-terminal peptide, nicked hCG-H free beta-subunit missing the C-terminal peptide), or",
"     </li>",
"     <li>",
"      renal degradation of hCG free beta-subunit (free beta-subunit core fragment [only detectable in urine])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the two hCG dimers and the 11 hCG variants containing the beta-subunit, there are two hCG variants that contain only the alpha-subunit: free alpha-subunit and O-glycosylated free alpha-subunit.",
"   </p>",
"   <p>",
"    The two intact dimers of hCG are biologically active; the products of dissociation and cleavage and the free alpha-subunit are inactive, but have a role as tumor markers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SOURCE AND FUNCTION OF HCG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gestational and nongestational trophoblasts are by far the most common sources of hCG, but a small amount of the hormone may also be produced by the pituitary gland and nontrophoblastic malignancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The progenitor villous cytotrophoblast cell is the stem cell of the placenta. It proliferates throughout gestation, differentiating along two pathways to form either extravillous cytotrophoblast (EVT) or syncytiotrophoblast.",
"   </p>",
"   <p>",
"    The syncytiotrophoblast is a specialized epithelium covering the villous tree and has several functions, such as transport of gases, nutrients, and waste products and synthesis of peptide and steroid hormones that regulate placental, fetal, and maternal systems. The syncytiotrophoblast produces regular hCG, which promotes progesterone production by the corpus luteum until placental progesterone production becomes established (after 6 weeks of gestation). Regular hCG also appears to play a role in myometrial spiral artery angiogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41256?source=see_link\">",
"     \"Placental development and physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extravillous cytotrophoblast produces hCG-H, which is the principal form of hCG present during the first two postconceptional weeks, when implantation is occurring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. HCG-H appears to promote invasion of extravillous cytotrophoblast into the uterine wall to form anchoring villi (interstitial invasion) and into the spiral arteries (endovascular invasion) to create a high flow low resistance vessel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. Additional factors are also involved in this process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proportion of total hCG that is hCG-H rapidly declines across gestation: it is 94 percent at the time of blastocyst implantation, 68 percent at the time of missed menses, 50 percent at 5 weeks of gestation, 25 percent at 6 weeks of gestation, 10 percent at 7 to 12 weeks of gestation, and 2 percent through the balance of normal pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/17,20\">",
"     17,20",
"    </a>",
"    ]. The decline is due to differentiation of 2 to 4 nucleus syncytiotrophoblast cells to 20 to 30 nucleus cells with limited cytoplasm and limited endoplasmic reticulum for making proteins.",
"   </p>",
"   <p>",
"    The level of free beta-subunit of hCG is often determined in pregnant women as part of maternal serum screening for Down syndrome. The free beta-subunit variants measured depend on the assay. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/22/7529?source=see_link\">",
"     \"First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum total hCG concentration peaks at 93,598",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    (range 27,300 to 233,000",
"    <span class=\"nowrap\">",
"     mIU/mL)",
"    </span>",
"    at 8 to 11 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Gestational trophoblastic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, HCG-H promotes trophoblast growth and invasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/14-17,24\">",
"     14-17,24",
"    </a>",
"    ]. The invasion may be controlled, as in implantation of pregnancy and",
"    <span class=\"nowrap\">",
"     complete/partial",
"    </span>",
"    mole, or malignant, as in the invasive gestational trophoblastic diseases, choriocarcinoma and invasive mole. The prognostic significance of hCH-H level in women with gestational trophoblastic disease, as well as those with other tumors or disorders of placentation, is an active area of investigation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete and partial mole &mdash; Regular hCG is the principal form of hCG associated with complete and partial hydatidiform mole since syntiotrophoblast is the predominant cell type in benign moles. A small amount of hCG-H is also produced by extravillous cytotrophoblast.",
"      <br/>",
"      <br/>",
"      A total hCG result &gt;100,000",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      strongly suggests complete hydatidiform mole, although the peak hCG in many normal pregnancies can reach this level (as discussed above, total hCG concentration peaks at 93,598",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      [range 27,300 to 233,000",
"      <span class=\"nowrap\">",
"       mIU/mL]",
"      </span>",
"      at 8 to 11 weeks of gestation) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. In the experience of the USA hCG Reference Service [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/14,27\">",
"       14,27",
"      </a>",
"      ], the median hCG concentration for 30 complete moles pre-evacuation was 192,995",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      (range 24,161 to 3,704,084",
"      <span class=\"nowrap\">",
"       mIU/mL)",
"      </span>",
"      and 67 percent of preevacuation hCG results were &gt;100,000",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef72544 \" href=\"mobipreview.htm?15/23/15740\">",
"       table 1",
"      </a>",
"      ). On average, hCG-H accounted for only 4.9 &plusmn; 2.1 percent of total hCG in molar pregnancies.",
"      <br/>",
"      <br/>",
"      Partial moles produce less regular hCG than complete moles. In the USA hCG Reference Service experience, the median hCG concentration in 21 partial moles was 48,900",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      (range 11,600 to 220,114",
"      <span class=\"nowrap\">",
"       mIU/mL),",
"      </span>",
"      and only 14 percent of cases exceeded 100,000",
"      <span class=\"nowrap\">",
"       mIU/mL.",
"      </span>",
"      HCG-H accounted for only 3.6 &plusmn; 1.7 percent of the total hCG.",
"     </li>",
"     <li>",
"      Invasive mole and choriocarcinoma &mdash; In gestational trophoblastic neoplasias, such as invasive mole and choriocarcinoma, HCG-H comprises a high proportion of total hCG since cytotrophoblastic cells comprise a higher proportion of the cells in these invasive tumors than in benign moles (invasive mole has a high proportion of differentiated villous cytotrophoblast, choriocarcinoma has a high proportion of nondifferentiating nonvillous cytotrophoblast cells) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/14,28,29\">",
"       14,28,29",
"      </a>",
"      ]. Moreover, the ratio of hCG-H to total hCG increases as tumor invasiveness increases. On average, hCG-H comprises 4.9 &plusmn; 2.1 percent of total hCG in complete hydatidiform mole, 30 &plusmn; 35 percent of total hCG in invasive mole, and 61 &plusmn; 41 percent of total hCG in choriocarcinoma (",
"      <a class=\"graphic graphic_table graphicRef72544 \" href=\"mobipreview.htm?15/23/15740\">",
"       table 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/14,29\">",
"       14,29",
"      </a>",
"      ]. A high level of hCG-H can help to distinguish invasive from noninvasive mole, although there is some overlap in their normal ranges.",
"      <br/>",
"      <br/>",
"      Serial measurement of hCG levels is standard follow-up of women diagnosed with complete or partial mole. An increasing or plateauing level of total hCG is diagnostic of invasive disease (invasive mole or choriocarcinoma). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23015?source=see_link\">",
"       \"Gestational trophoblastic disease: Management of hydatidiform mole\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In the experience of the USA hCG Reference Service, the plateau in hCG typically occurs at a level greater than 10,000",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      and the increase in hCG is greater than 200",
"      <span class=\"nowrap\">",
"       mIU/mL.",
"      </span>",
"      We have also found that the best marker of invasive mole is hCG-H comprising more than 20 percent of the total hCG. This can be observed on the first day that serially monitored hCG concentrations first show a plateau or increase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Choriocarcinoma &mdash; Choriocarcinoma consists of sheets of anaplastic cytotrophoblasts and syncytiotrophoblasts without chorionic villi. Some intermediate trophoblasts may also be seen. In the experience of the USA hCG Reference Service, the highest total hCG among 82 cases of choriocarcinoma was 597,000",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef72544 \" href=\"mobipreview.htm?15/23/15740\">",
"       table 1",
"      </a>",
"      ); the level of hCG correlates with tumor mass [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/1,14,24\">",
"       1,14,24",
"      </a>",
"      ]. HCG-H accounted for 61 &plusmn; 41 percent of total hCG. Because cytotrophoblast cells produce hCG-H, as much as 100 percent of the hCG produced in choriocarcinoma can be hCG-H.",
"     </li>",
"     <li>",
"      Placental site trophoblastic tumor &mdash; Placental site trophoblastic tumor (PSTT) is rare gestational trophoblastic neoplasm originating from intermediate cytotrophoblast cells. It is associated with low levels of hCG relative to tumor size because there is a lack of syncytiotrophoblastic proliferation. The free beta-subunit of hCG is the main form of hCG in PSTT. This occurs because tumor cells, unlike normal trophoblast cells, lack the ability to efficiently combine beta and alpha subunits. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24761?source=see_link\">",
"       \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13816?source=see_link\">",
"       \"Gestational trophoblastic disease: Pathology\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pituitary gland",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal pituitary gland produces a small amount of hCG. The level of hCG attributable to pituitary production ranges from 1 to 32",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/14,30,31\">",
"     14,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pituitary production of hCG is most notable around the time of menopause (natural or surgical) and prior to ovulation, which are times when LH levels peak. One possible explanation is that a small amount of hCG is produced along LH because the single LH beta-subunit gene is buried among the seven back-to-back hCG beta-subunit genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nongestational malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some nongestational malignancies contain genes for the beta-subunit of hCG. Activation of these genes results primarily in production of low levels of hyperglycosylated free beta-subunit, which may become useful as a marker or prognostic factor for these tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. hCG may act as an angiogenic factor during tumor development, analogous to its role in uterine adaptation in early pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3326936\">",
"    <span class=\"h1\">",
"     DECLINE OF SERUM HCG FOLLOWING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Return of the serum hCG concentration to undetectable following pregnancy termination varies widely from 7 to 60 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/36\">",
"     36",
"    </a>",
"    ]. The period of time depends primarily upon the hCG concentration at the time of termination. The hCG concentration peaks at 8 to 11 weeks at approximately 90,000 mIU. This is in contrast with term pregnancy, for which the hCG concentration is lower. The decline in serum hCG is rapid for the first several days (half-life 9 to 31 hours) and then proceeds more slowly (half-life 55 to 64 hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Method",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tests for hCG use two antibodies to distant sites on the beta-subunit of hCG molecules. When hCG is present, it is immobilized by the capture antibody and labeled by the tracer antibody using an enzyme (lanthanide) or a radioactive label. A sandwich consisting of immobilized antibody-hCG-tracer antibody is formed. After washing away excess material, the amount of now immobilized label is measured and is directly proportional to the amount of hCG joining the sandwiches together. This is called an immunometric assay and is the mechanism of all commercial hCG assays.",
"   </p>",
"   <p>",
"    Although all assays detect regular hCG, they do not necessarily detect all hCG variants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/40\">",
"     40",
"    </a>",
"    ]. For example, many over-the-counter pregnancy tests do not measure hyperglycosylated hCG, which accounts for most of the total hCG at the time of missed menses when these tests are typically performed.",
"   </p>",
"   <p>",
"    At a minimum, testing for total hCG should detect both regular and hyperglycosylated hCG. The hCG variants detected depends upon the only commercial assay used; the only commercial assay that detects all hCG variants is the Siemen's Immulite Series. It is also important to know the sensitivity of the test. Clinical tests for pregnancy may only detect total hCG levels &ge;20",
"    <span class=\"nowrap\">",
"     mIU/mL.",
"    </span>",
"    Therefore, when following hCG levels to negative (&lt;1",
"    <span class=\"nowrap\">",
"     mIU/mL)",
"    </span>",
"    in women with gestational trophoblastic disease, it is important to use a sensitive hCG test that detects both regular and hCG-H.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     False negative test - hook effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;At levels of hCG above 500,000",
"    <span class=\"nowrap\">",
"     mIU/mL,",
"    </span>",
"    a \"hook effect\" can occur resulting in an artifactually low value for hCG (ie, 1 to 100",
"    <span class=\"nowrap\">",
"     mIU/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/23\">",
"     23",
"    </a>",
"    ]. This is because the sensitivity of most hCG tests is set to the pregnancy hCG range (ie, 27,300 to 233,000",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    at 8 to 11 weeks of gestation); therefore, when an extremely high hCG concentration is present, both the capture and tracer antibodies used in immunoradiometric assays become saturated, preventing the binding of the two to create a sandwich [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/23,41\">",
"     23,41",
"    </a>",
"    ]. Since the nonsandwiched tracer antibodies are washed away with the excess material, the test result will be negative. For this reason, a suspected diagnosis of gestational trophoblastic disease must be communicated to the laboratory so that the hCG assay will also be performed at 1:1000 dilution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Testing for pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical use of this test for diagnosis of pregnancy (intrauterine or ectopic) is reviewed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44808?source=see_link\">",
"       \"Clinical manifestations and diagnosis of early pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1178?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CAUSES AND EVALUATION OF PERSISTENT LOW LEVELS OF HCG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining the meaning of a low level of hCG can be challenging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/40\">",
"     40",
"    </a>",
"    ]. It is important to determine if the hCG represents an actual early pregnancy (intrauterine or ectopic), active gestational trophoblastic disease (complete or partial mole, invasive mole, choriocarcinoma, PSTT), quiescent gestational trophoblastic disease, a laboratory false positive (also called phantom hCG), or a physiologic artifact (pituitary hCG). For example, a false positive hCG test result or pituitary hCG is commonly found in women who also have a history of gestational trophoblastic disease. Unless tumor is evident, it is essential to exclude these possibilities before initiating chemotherapy for assumed persistence of disease.",
"   </p>",
"   <p>",
"    The following sections will guide the clinician in the evaluation and interpretation of the persistent low level hCG test result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent low level positive hCG results can be defined as hCG levels varying by no more than two-fold over at least a three-month period in the absence of tumor on imaging studies. The hCG level is under 1000",
"    <span class=\"nowrap\">",
"     mIU/mL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A",
"    false positive hCG test result or pituitary (physiologic) hCG is commonly found in women with history of gestational trophoblastic disease. Unless a tumor is evident, it is essential to exclude these possibilities before initiating chemotherapy for assumed persistence of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     False positive test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The capture and tracer antibodies used for hCG testing may be goat, sheep, or rabbit polyclonal antibodies or mouse, goat, or sheep monoclonal antibodies. Humans extensively exposed to animals or certain animal byproducts can develop human antibodies against animal antibodies (HAAA), whether immunoglobulins A, E, G, or M. In addition, humans naturally generate human anti-human immunoglobulin antibodies that can cross-react with and bind animal antibodies; these are called heterophilic antibodies. Humans with recent exposure to mononucleosis are prone to develop HAAAs; those with IgA deficiency syndrome also often have heterophilic antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/42\">",
"     42",
"    </a>",
"    ]. Each human antibody is bivalent, so if an HAAA or heterophilic antibody is present in a person's serum, it can bind and link together the immobilized and tracer antibodies of the hCG test, making an immobilized capture antibody-heterophilic",
"    <span class=\"nowrap\">",
"     antibody/HAAA-tracer",
"    </span>",
"    antibody sandwich, which results in a false positive hCG result. The detection of hCG in the absence of pregnancy has led to many men and women misdiagnosed with cancer, confusion and misunderstanding, and needless surgery and chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/43-52\">",
"     43-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To avoid false positive tests, manufacturers incorporate animal serum and nonspecific animal antibodies into all their test ingredients, with capture antibody, tracer antibody, and other components. This excess of nonspecific antibodies overwhelming saturates heterophilic antibodies and HAAA in human serum samples and usually eliminates their interference with the assay. However, even in recent years, the USA hCG Reference Service has been referred five to six false positive serum hCG cases each year from people being tested with a wide variety of different tests. In extreme circumstances, any commercially available test can give a false positive result. False positive cases examined by the USA hCG Reference Service are described in the table (",
"    <a class=\"graphic graphic_table graphicRef71962 \" href=\"mobipreview.htm?20/5/20574\">",
"     table 2",
"    </a>",
"    ). The false positive serum hCG level (as measured by the assay giving false positive results) ranged from 6.1 to 900",
"    <span class=\"nowrap\">",
"     mIU/mL.",
"    </span>",
"    Most cases were in the setting of an incidental pregnancy test at the time of physical examination or prior to surgery or other major medical procedures. Ten cases were false positives following history of gestational trophoblastic disease. This understandably created confusion, as these false positive cases were incorrectly interpreted as recurrence of gestational trophoblastic disease.",
"   </p>",
"   <p>",
"    There are two main methods for identifying false positive hCG:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most readily available approach is to show the absence of hCG in the patient's urine, since large molecules like an immobilized capture antibody-heterophilic",
"      <span class=\"nowrap\">",
"       antibody/HAAA-tracer",
"      </span>",
"      antibody sandwich fail to cross the glomerular basement membrane. A true hCG elevation should be present in BOTH serum and urine. At the USA hCG Reference Service, we have never detected any hCG immunoreactivity in urine in patients with false positive serum hCG tests. A sensitive urine hCG test should be used to avoid missing low level true positive tests. Alternatively, to detect low concentrations of hCG, urine samples can be tested on the same instrument used to quantitate hCG in serum samples; these tests are typically sensitive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/17,53\">",
"       17,53",
"      </a>",
"      ]. Avoid using a point of care urine test, as these tests tend to be insensitive to low levels of hCG.",
"     </li>",
"     <li>",
"      A second useful way of identifying a false positive serum hCG result is to send the serum to two laboratories using different commercial assays. If the assay results vary greatly or are negative in one or both alternative tests, then a false positive hCG can be presumed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who have false positive hCG test results are at risk for recurrent false positive hCG assay results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/54\">",
"     54",
"    </a>",
"    ]. They are also at risk for other false positives, such as CA-125 and thyroid antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/55\">",
"     55",
"    </a>",
"    ]. They should make their future health care providers aware of this problem and it should be noted in their medical records.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Quiescent gestational trophoblastic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quiescent gestational trophoblastic disease appears to be due to the presence of inactive, noninvasive trophoblastic cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/28,53,56-58\">",
"     28,53,56-58",
"    </a>",
"    ]. Highly differentiated syncytiotrophoblast cells are the predominant cell line. The majority of cases follow complete hydatidiform mole, but quiescent gestational trophoblastic disease has also occurred after treatment of choriocarcinoma, invasive mole, and partial mole.",
"   </p>",
"   <p>",
"    Regular hCG levels are low; in our experience, the levels are always below 212",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    with no more than two-fold natural variation over time (at least three weeks). Because few cytotrophoblasts are present, little or no hCG-H is produced: the ratio of hCH-H to total hCG is usually less than 2 percent (",
"    <a class=\"graphic graphic_table graphicRef72544 \" href=\"mobipreview.htm?15/23/15740\">",
"     table 1",
"    </a>",
"    ). In our series, 97 cases had no detectable hCG-H and four produced measurable hCG-H accounting for 5.0, 5.3, 10, and 10 percent of total hCG (",
"    <a class=\"graphic graphic_table graphicRef59756 \" href=\"mobipreview.htm?42/58/43937\">",
"     table 3",
"    </a>",
"    ). Imaging studies will be negative since total hCG &lt;212",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    represents a minuscule trophoblast cell mass; &gt;2000",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    is required before a tumor can be seen by magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cases of quiescent gestational trophoblastic disease resolve with the spontaneous demise of the cell mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/14\">",
"     14",
"    </a>",
"    ]. Some cases have persisted for as long as two years, although the majority resolved within six months.",
"   </p>",
"   <p>",
"    Prior to being correctly diagnosed, many patients with quiescent disease were treated with chemotherapy or hysterectomy under the assumption that invasive disease was present (",
"    <a class=\"graphic graphic_table graphicRef59756 \" href=\"mobipreview.htm?42/58/43937\">",
"     table 3",
"    </a>",
"    ). Treatment of quiescent disease is unnecessary; moreover, we know of no case in which these therapies fully suppressed hCG (ie, hCG &lt;1",
"    <span class=\"nowrap\">",
"     mIU/mL)",
"    </span>",
"    and at least one patient has died due to complications of the chemotherapy regimen. The failure of chemotherapy to eradicate hCG producing trophoblasts is likely due to the lack of proliferation in the trophoblast cells comprising quiescent disease. The failure of hysterectomy has been attributed to a possible extrauterine source of the cells.",
"   </p>",
"   <p>",
"    We recommend that women with quiescent disease be placed on estrogen-progestin contraceptives and avoid pregnancy until hCG has been undetectable for six months. HCG should be monitored regularly for at least nine months, given there is a 22 percent risk of progression to active disease, primarily (60 percent) in patients previously treated for choriocarcinoma. At least three consecutive rising hCG values are necessary to diagnose the onset of invasive disease (or a rise in hCG-H &gt;20 percent). In our experience, a rising hCG-H level became evident prior to a significant rise in total hCG and was the first evidence of active disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Pituitary hCG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural pituitary hCG is the likely diagnosis in women in the menopausal transition and postmenopausal women with persistent low level hCG results. Based on our experience, normal levels of pituitary hCG in these women can be as high as 32",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. The presence of pituitary hCG can be confirmed by placing the patient on a high (50 mcg) estrogen dose oral contraceptive pill for three weeks to inhibit release of GnRH and, in turn, pituitary hCG production. If hCG is suppressed after this period of time, then the pituitary gland is the origin of the hCG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/14,61-63\">",
"     14,61-63",
"    </a>",
"    ]. The table (",
"    <a class=\"graphic graphic_table graphicRef71962 \" href=\"mobipreview.htm?20/5/20574\">",
"     table 2",
"    </a>",
"    ) shows the USA hCG Reference Service experience with menopausal",
"    <span class=\"nowrap\">",
"     transition/menopausal",
"    </span>",
"    hCG cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Placental site trophoblastic tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placental site trophoblastic tumor (PSTT) should be considered in women with an intrauterine mass and persistently low elevations in serum hCG levels after a normal term pregnancy, although PSTT usually presents years after an antecedent gestational event. In 21 cases of PSTT reviewed by the USA hCG Reference Service, the median regular hCG concentration was 30",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    (range 1 to 231",
"    <span class=\"nowrap\">",
"     mIU/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39960/abstract/64\">",
"     64",
"    </a>",
"    ]. Thus, it can be challenging distinguishing PSTT from quiescent gestational trophoblastic disease.",
"   </p>",
"   <p>",
"    HCG free beta-subunit appears to be the main form of hCG produced by PSTT. In our experience, the ratio of free beta-hCG to total hCG averaged 61 percent. This test is widely available, as it is also used as a marker in Down syndrome screening (1",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    = 18",
"    <span class=\"nowrap\">",
"     mIU/mL).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Early pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy should be suspected in all reproductive aged women with missed menstrual periods or abnormal uterine bleeding and a positive hCG test. The diagnosis of intrauterine (viable and nonviable) and ectopic pregnancy is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44808?source=see_link\">",
"     \"Clinical manifestations and diagnosis of early pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Active gestational trophoblastic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Gestational trophoblastic disease'",
"    </a>",
"    above), active gestational trophoblastic disease is typically characterized by a high, not low, concentration of hCG. Even though there is only a small chance that persistent low levels of hCG are due to active gestational trophoblastic disease, it is important to exclude this diagnosis. If the hCG contains a high proportion of hCG-H, active gestational trophoblastic neoplasia is likely (1",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    is equivalent to approximately 11",
"    <span class=\"nowrap\">",
"     mIU/mL).",
"    </span>",
"    The diagnosis and management of active gestational trophoblastic disease are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24761?source=see_link&amp;anchor=H12#H12\">",
"     \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\", section on 'Human chorionic gonadotropin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several isoforms of human chorionic gonadotropin (hCG) exist in the circulation. The two main forms are regular hCG and hyperglycosylated hCG. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Structure of hCG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main source of hCG is trophoblast related to pregnancy or gestational trophoblastic disease, but it can also be produced by the pituitary gland and some nontrophoblastic malignancies. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Source and function of HCG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperglycosylated hCG plays a role in cellular invasion, including development of anchoring villi during pregnancy and tumor invasion associated with invasive mole and choriocarcinoma. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Source and function of HCG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunometric assay is the mechanism of all commercial hCG assays. False negative hCG tests can occur with very high hCG levels (\"hook effect\") and false positive tests can occur from interference in the presence of human antibodies against animal or human antibodies. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'False positive test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Persistent low level (under 1000",
"      <span class=\"nowrap\">",
"       mIU/mL)",
"      </span>",
"      positive hCG results can be defined as hCG levels varying by no more than two-fold over at least a three-month period. A false positive hCG test result or pituitary (physiologic) hCG is commonly found in women with history of gestational trophoblastic disease. Unless gestational trophoblastic disease is evident, it is essential to exclude these possibilities before initiating chemotherapy for assumed persistence of disease. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Causes and evaluation of persistent low levels of HCG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A false positive hCG test can be identified by showing the absence of hCG in the patient's urine. Another method is to send the serum to two laboratories using different commercial assays. If the assay results vary greatly or are negative in one or both alternative tests, then a false positive hCG can be presumed. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'False positive test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Quiescent gestational trophoblastic disease appears to be due to the presence of inactive, noninvasive trophoblastic cells. Regular hCG levels are low (below 212",
"      <span class=\"nowrap\">",
"       mIU/mL)",
"      </span>",
"      with no more than two-fold natural variation over time (at least three weeks). Little or no hCG-H is produced. Serial hCG measurements should be performed because about 20 percent of patients go on to develop active disease. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Quiescent gestational trophoblastic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of pituitary hCG can be confirmed by placing the patient on a high estrogen dose oral contraceptive pill for three weeks to inhibit release of GnRH and, in turn, pituitary hCG production. If hCG is suppressed after this period of time, then the pituitary gland is the origin of the hCG. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Pituitary hCG'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/1\">",
"      Elliott MM, Kardana A, Lustbader JW, Cole LA. Carbohydrate and peptide structure of the alpha- and beta-subunits of human chorionic gonadotropin from normal and aberrant pregnancy and choriocarcinoma. Endocrine 1997; 7:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/2\">",
"      Kobata A, Takeuchi M. Structure, pathology and function of the N-linked sugar chains of human chorionic gonadotropin. Biochim Biophys Acta 1999; 1455:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/3\">",
"      Cole LA. The O-linked oligosaccharide structures are striking different on pregnancy and choriocarcinoma HCG. J Clin Endocrinol Metab 1987; 65:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/4\">",
"      Cole LA, Kardana A, Andrade-Gordon P, et al. The heterogeneity of human chorionic gonadotropin (hCG). III. The occurrence and biological and immunological activities of nicked hCG. Endocrinology 1991; 129:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/5\">",
"      Valmu L, Alfthan H, Hotakainen K, et al. Site-specific glycan analysis of human chorionic gonadotropin beta-subunit from malignancies and pregnancy by liquid chromatography--electrospray mass spectrometry. Glycobiology 2006; 16:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/6\">",
"      Narayan P, Gray J, Puett D. Yoked complexes of human choriogonadotropin and the lutropin receptor: evidence that monomeric individual subunits are inactive. Mol Endocrinol 2002; 16:2733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/7\">",
"      Birken S, Kovalevskaya G, O'Connor J. Immunochemical measurement of early pregnancy isoforms of HCG: potential applications to fertility research, prenatal diagnosis, and cancer. Arch Med Res 2001; 32:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/8\">",
"      Lei ZM, Reshef E, Rao V. The expression of human chorionic gonadotropin/luteinizing hormone receptors in human endometrial and myometrial blood vessels. J Clin Endocrinol Metab 1992; 75:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/9\">",
"      Herr F, Baal N, Reisinger K, et al. HCG in the regulation of placental angiogenesis. Results of an in vitro study. Placenta 2007; 28 Suppl A:S85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/10\">",
"      Zygmunt M, Herr F, M&uuml;nstedt K, et al. Angiogenesis and vasculogenesis in pregnancy. Eur J Obstet Gynecol Reprod Biol 2003; 110 Suppl 1:S10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/11\">",
"      Zygmunt M, Herr F, Keller-Schoenwetter S, et al. Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab 2002; 87:5290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/12\">",
"      Cole LA, Khanlian SA, Riley JM, Butler SA. Hyperglycosylated hCG in gestational implantation and in choriocarcinoma and testicular germ cell malignancy tumorigenesis. J Reprod Med 2006; 51:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/13\">",
"      Kovalevskaya G, Genbacev O, Fisher SJ, et al. Trophoblast origin of hCG isoforms: cytotrophoblasts are the primary source of choriocarcinoma-like hCG. Mol Cell Endocrinol 2002; 194:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/14\">",
"      Cole LA, Dai D, Butler SA, et al. Gestational trophoblastic diseases: 1. Pathophysiology of hyperglycosylated hCG. Gynecol Oncol 2006; 102:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/15\">",
"      Handschuh K, Guibourdenche J, Tsatsaris V, et al. Human chorionic gonadotropin produced by the invasive trophoblast but not the villous trophoblast promotes cell invasion and is down-regulated by peroxisome proliferator-activated receptor-gamma. Endocrinology 2007; 148:5011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/16\">",
"      Sasaki Y, Ladner DG, Cole LA. Hyperglycosylated human chorionic gonadotropin and the source of pregnancy failures. Fertil Steril 2008; 89:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/17\">",
"      Cole LA, Khanlian SA, Sutton JM, et al. Hyperglycosylated hCG (invasive trophoblast antigen, ITA) a key antigen for early pregnancy detection. Clin Biochem 2003; 36:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/18\">",
"      O'Connor JF, Ellish N, Kakuma T, et al. Differential urinary gonadotrophin profiles in early pregnancy and early pregnancy loss. Prenat Diagn 1998; 18:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/19\">",
"      Sutton-Riley JM, Khanlian SA, Byrn FW, Cole LA. A single serum test for measuring early pregnancy outcome with high predictive value. Clin Biochem 2006; 39:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/20\">",
"      Kovalevskaya G, Birken S, Kakuma T, et al. Differential expression of human chorionic gonadotropin (hCG) glycosylation isoforms in failing and continuing pregnancies: preliminary characterization of the hyperglycosylated hCG epitope. J Endocrinol 2002; 172:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/21\">",
"      Chakraborty C, Gleeson LM, McKinnon T, Lala PK. Regulation of human trophoblast migration and invasiveness. Can J Physiol Pharmacol 2002; 80:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/22\">",
"      Batzer FR. Hormonal evaluation of early pregnancy. Fertil Steril 1980; 34:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/23\">",
"      Cole LA. Immunoassay of human chorionic gonadotropin, its free subunits, and metabolites. Clin Chem 1997; 43:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/24\">",
"      Cole LA, Butler SA. Hyperglycosylated human chorionic gonadotropin and human chorionic gonadotropin free beta-subunit: tumor markers and tumor promoters. J Reprod Med 2008; 53:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/25\">",
"      Genest DR, Laborde O, Berkowitz RS, et al. A clinicopathologic study of 153 cases of complete hydatidiform mole (1980-1990): histologic grade lacks prognostic significance. Obstet Gynecol 1991; 78:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/26\">",
"      Menczer J, Modan M, Serr DM. Prospective follow-up of patients with hydatidiform mole. Obstet Gynecol 1980; 55:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/27\">",
"      Khanlian SA, Cole LA. Management of gestational trophoblastic disease and other cases with low serum levels of human chorionic gonadotropin. J Reprod Med 2006; 51:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/28\">",
"      Khanlian SA, Smith HO, Cole LA. Persistent low levels of human chorionic gonadotropin: A premalignant gestational trophoblastic disease. Am J Obstet Gynecol 2003; 188:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/29\">",
"      Kelly LS, Birken S, Puett D. Determination of hyperglycosylated human chorionic gonadotropin produced by malignant gestational trophoblastic neoplasias and male germ cell tumors using a lectin-based immunoassay and surface plasmon resonance. Mol Cell Endocrinol 2007; 260-262:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/30\">",
"      Birken S, Maydelman Y, Gawinowicz MA, et al. Isolation and characterization of human pituitary chorionic gonadotropin. Endocrinology 1996; 137:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/31\">",
"      Cole LA, Gutierrez JM. Production of human chorionic gonadotropin during the normal menstrual cycle. J Reprod Med 2009; 54:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/32\">",
"      Naylor SL, Chin WW, Goodman HM, et al. Chromosome assignment of genes encoding the alpha and beta subunits of glycoprotein hormones in man and mouse. Somatic Cell Genet 1983; 9:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/33\">",
"      Policastro PF, Daniels-McQueen S, Carle G, Boime I. A map of the hCG beta-LH beta gene cluster. J Biol Chem 1986; 261:5907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/34\">",
"      Krichevsky A, Campbell-Acevedo EA, Tong JY, Acevedo HF. Immunological detection of membrane-associated human luteinizing hormone correlates with gene expression in cultured human cancer and fetal cells. Endocrinology 1995; 136:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/35\">",
"      Acevedo HF, Tong JY, Hartsock RJ. Human chorionic gonadotropin-beta subunit gene expression in cultured human fetal and cancer cells of different types and origins. Cancer 1995; 76:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/36\">",
"      Steier JA, Bergsj&oslash; P, Myking OL. Human chorionic gonadotropin in maternal plasma after induced abortion, spontaneous abortion, and removed ectopic pregnancy. Obstet Gynecol 1984; 64:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/37\">",
"      Billieux MH, Petignat P, Anguenot JL, et al. Early and late half-life of human chorionic gonadotropin as a predictor of persistent trophoblast after laparoscopic conservative surgery for tubal pregnancy. Acta Obstet Gynecol Scand 2003; 82:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/38\">",
"      Mock P, Chardonnens D, Stamm P, et al. The apparent late half-life of human chorionic gonadotropin (hCG) after surgical treatment for ectopic pregnancy. A new approach to diagnose persistent trophoblastic activity. Eur J Obstet Gynecol Reprod Biol 1998; 78:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/39\">",
"      Midgley AR Jr, Jaffe RB. Regulation of human gonadotropins. II. Disappearance of human chorionic gonadotropin following delivery. J Clin Endocrinol Metab 1968; 28:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/40\">",
"      Muller CY, Cole LA. The quagmire of hCG and hCG testing in gynecologic oncology. Gynecol Oncol 2009; 112:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/41\">",
"      Flam F, Hambraeus-Jonzon K, Hansson LO, Kjaeldgaard A. Hydatidiform mole with non-metastatic pulmonary complications and a false low level of hCG. Eur J Obstet Gynecol Reprod Biol 1998; 77:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/42\">",
"      Knight AK, Bingemann T, Cole L, Cunningham-Rundles C. Frequent false positive beta human chorionic gonadotropin tests in immunoglobulin A deficiency. Clin Exp Immunol 2005; 141:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/43\">",
"      Cole LA. Phantom hCG and phantom choriocarcinoma. Gynecol Oncol 1998; 71:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/44\">",
"      Cole LA, Rinne KM, Shahabi S, Omrani A. False-positive hCG assay results leading to unnecessary surgery and chemotherapy and needless occurrences of diabetes and coma. Clin Chem 1999; 45:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/45\">",
"      Rotmensch S, Cole LA. False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations. Lancet 2000; 355:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/46\">",
"      Cole, LA, Butler, SA. False positive or phantom hCG result: a serious problem. Clin Lab Intl 2001; 25:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/47\">",
"      Baulieu JL, Lepape J, Baulieu F, Besnard JC. Falsely elevated results of radioimmunoassays using double antibody method: arguments for a third anti-rabbit IgG antibody present in certain human sera. Eur J Nucl Med 1982; 7:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/48\">",
"      Vladutiu AO, Sulewski JM, Pudlak KA, Stull CG. Heterophilic antibodies interfering with radioimmunoassay. A false-positive pregnancy test. JAMA 1982; 248:2489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/49\">",
"      Hussa RO, Rinke ML, Schweitzer PG. Discordant human chorionic gonadotropin results: causes and solutions. Obstet Gynecol 1985; 65:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/50\">",
"      Garrett PE, Kurtz SR, Hurd JK Jr. False-positive results for choriogonadotropin in serum. Clin Chem 1983; 29:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/51\">",
"      Olsen TG, Hubert PR, Nycum LR. Falsely elevated human chorionic gonadotropin leading to unnecessary therapy. Obstet Gynecol 2001; 98:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/52\">",
"      Cole LA, Khanlian SA. Easy fix for clinical laboratories for the false-positive defect with the Abbott AxSym total beta-hCG test. Clin Biochem 2004; 37:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/53\">",
"      Cole LA, Sutton JM. HCG tests in the management of gestational trophoblastic diseases. Clin Obstet Gynecol 2003; 46:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/54\">",
"      Committee on Gynecologic Practice, The American College of Obstetricians and Gynecologists. ACOG. Committee opinion: number 278, November 2002. Avoiding inappropriate clinical decisions based on false-positive human chorionic gonadotropin test results. Obstet Gynecol 2002; 100:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/55\">",
"      Cole LA, Khanlian SA. Inappropriate management of women with persistent low hCG results. J Reprod Med 2004; 49:423.",
"     </a>",
"    </li>",
"    <li>",
"     Cole LA. Use of hCG tests for evaluating trophoblastic diseases: Choosing an appropriate hCG assay, false detection of hCG, unexplained elevated hCG, and quiescent trophoblastic disease. In: Gestational Trophoblastic Disease, 2nd, Hancock BW, Newland ES, Berkowitz RS, Cole LA (Eds), Chapman and Hall, London 2002. p.130.",
"    </li>",
"    <li>",
"     Hancock, BW, Tidy, JA. Clinical management of persistent low-level hCG elevation. Trophobl Dis Upd 4:5.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/58\">",
"      Kohorn EI. Persistent low-level \"real\" human chorionic gonadotropin: a clinical challenge and a therapeutic dilemma. Gynecol Oncol 2002; 85:315.",
"     </a>",
"    </li>",
"    <li>",
"     Newlands, E. Presentation and management of persistent gestational trophoblastic disease (GTD) and gestational trophoblastic tumor (GTT) in the United Kingdom. In: Gestational Trophoblastic Disease, 2nd ed, Hancock, B, Newlands, E, Berkowitz, RS, Cole, LA (Ed), Chapman and Hall, London 2002. p.229.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/60\">",
"      Cole LA, Ladner DG, Byrn FW. The normal variabilities of the menstrual cycle. Fertil Steril 2009; 91:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/61\">",
"      Cole, LA, Khanlian, SA, Muller, CY. Normal production of human chorionic gonadotropin in perimenopausal and menopausal women and following oophorectomy. Int J Gynecol Cancer 2008; 198:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/62\">",
"      Cole LA, Khanlian SA, Muller CY. Detection of perimenopause or postmenopause human chorionic gonadotropin: an unnecessary source of alarm. Am J Obstet Gynecol 2008; 198:275.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/63\">",
"      Cole LA, Sasaki Y, Muller CY. Normal production of human chorionic gonadotropin in menopause. N Engl J Med 2007; 356:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39960/abstract/64\">",
"      Sumi Y, Ozaki Y, Shindoh N, Katayama H. Placental site trophoblastic tumor: imaging findings. Radiat Med 1999; 17:427.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3209 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_1_39960=[""].join("\n");
var outline_f39_1_39960=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STRUCTURE OF HCG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SOURCE AND FUNCTION OF HCG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Gestational trophoblastic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pituitary gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nongestational malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3326936\">",
"      DECLINE OF SERUM HCG FOLLOWING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      False negative test - hook effect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Testing for pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CAUSES AND EVALUATION OF PERSISTENT LOW LEVELS OF HCG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - False positive test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Quiescent gestational trophoblastic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Pituitary hCG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Placental site trophoblastic tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Early pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Active gestational trophoblastic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3209\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3209|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/23/15740\" title=\"table 1\">",
"      HCG levels in GTD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/5/20574\" title=\"table 2\">",
"      Persistent low hCG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/58/43937\" title=\"table 3\">",
"      HCG in quiescent GTD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44808?source=related_link\">",
"      Clinical manifestations and diagnosis of early pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/22/7529?source=related_link\">",
"      First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24761?source=related_link\">",
"      Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23015?source=related_link\">",
"      Gestational trophoblastic disease: Management of hydatidiform mole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13816?source=related_link\">",
"      Gestational trophoblastic disease: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42234?source=related_link\">",
"      Gestational trophoblastic neoplasia: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41256?source=related_link\">",
"      Placental development and physiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_1_39961="Management of fever in sickle cell disease";
var content_f39_1_39961=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of fever in sickle cell disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/1/39961/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/1/39961/contributors\">",
"     Zora R Rogers, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/1/39961/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/1/39961/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/1/39961/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/1/39961/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/1/39961/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is a common presenting symptom in many manifestations of sickle cell disease (SCD). In particular, fever is frequently the first indication of serious and life-threatening bacterial infections. It is also present in other serious SCD-associated conditions, such as acute chest syndrome or vasoocclusive crisis. As a result, patients with SCD and fever should be evaluated and treated promptly to avoid significant morbidity and mortality.",
"   </p>",
"   <p>",
"    Although patients with sickle cell anemia (hemoglobin SS; HbSS) and the closely related sickle cell-&beta;",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia (HbS-&beta;",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia) are at highest risk of bacteremia because of their predictable early loss of splenic function, many centers evaluate patients with the variant hemoglobinopathies sickle-hemoglobin C disease (HbSC) and sickle cell-&beta;",
"    <sup>",
"     +",
"    </sup>",
"    thalassemia (HbS-&beta;",
"    <sup>",
"     +",
"    </sup>",
"    thalassemia) in a similar fashion when a predetermined level of fever develops.",
"   </p>",
"   <p>",
"    The management of the patient with SCD and fever will be reviewed here. Overviews of the other clinical manifestations and their management of SCD are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link\">",
"     \"Overview of the clinical manifestations of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE FOR MANAGEMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with SCD, the major cause of death historically has been infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In the United States, prior to the availability of Haemophilus influenzae type b (H. influenzae) and pneumococcal vaccines, young children (below five years of age) with SCD had a 13 percent risk of developing bacterial sepsis or meningitis with mortality rates of 30 and 10 percent in patients with sepsis and meningitis, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/2\">",
"     2",
"    </a>",
"    ]. Although mortality has significantly decreased since the introduction of vaccines, particularly since licensure of the conjugate pneumococcal vaccine (Prevnar) in 2000, about one-quarter of deaths between 1999 and 2002 in children with SCD in the first nine years of life continue to be due to infectious causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=see_link&amp;anchor=H34#H34\">",
"     \"Overview of the management of sickle cell disease\", section on 'Causes of death'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with SCD disease are more susceptible to infections because of functional asplenia. Autoinfarction caused by sickling of red blood cells results in a nonfunctioning spleen, which is unable to filter bacteria from the blood stream. Functional asplenia increases the risk of invasive infection by encapsulated organism, such as Streptococcus pneumoniae (S. pneumoniae) and H. influenzae. Prior to universal vaccination for S. pneumoniae and H. influenzae, young children with HbSS had a 400-fold increased risk of pneumococcal sepsis and a two- to four-fold increased risk of H. influenzae sepsis compared to age-matched children without SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/42/9895?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and management of sepsis in the asplenic patient\", section on 'Role of the spleen in host defense'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Cooperative Study of Sickle Cell Disease (CSSCD) described 20 of 64 infants with HbSS between 8 and 13 months of age with functional asplenia, detected by the inability of their spleens to normally take up radiolabeled technetium sulfur-colloid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/5\">",
"     5",
"    </a>",
"    ]. An increased number of pocked or pitted red blood cells, a laboratory indicator of functional asplenia, was present in 94 percent of patients by 60 months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/5\">",
"     5",
"    </a>",
"    ]. More recently, baseline data from the Pediatric",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    Phase III Clinical Trial (BABY HUG) showed using both of these techniques that only 12 percent of 193 infants with a mean age of 12.2 months had normal spleen function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the recognition of the increased risk of bacterial infection with SCD, preventive measures (eg, immunizations) and the use of daily prophylactic and empiric antibiotic therapy for fever have reduced the mortality rate in patients with SCD. This was best illustrated in the Dallas Newborn Cohort, a prospective study of 711 children identified by newborn screening, born in Texas on or after November 1, 1983 and treated at a single center up to 18 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/7\">",
"     7",
"    </a>",
"    ]. The overall mortality rate was 0.59 per 100 patient years compared to rates of 3 per 100 patient years for children less than five years of age reported before the implementation of prophylactic penicillin and routine pneumococcal vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This improved survival in childhood has continued, only to be balanced by increased rate of death in young adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the universal use of pneumococcal conjugate vaccine in the United States has led to a decrease in the incidence of invasive pneumococcal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/10-13\">",
"     10-13",
"    </a>",
"    ] and death from an infectious cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/3\">",
"     3",
"    </a>",
"    ], young children with SCD remain at a high risk for invasive pneumococcal infection, defined as an incidence of &ge;150 cases per 100,000 people per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/13\">",
"     13",
"    </a>",
"    ]. In Tennessee, the rate of invasive pneumococcal disease in children under two years of age with SCD decreased from 3650 to 335 cases per 100,000 person years between the 7-valent pneumococcal conjugate vaccine (PCV7) prevaccine to postvaccine periods of 1995-1999 and 2000-2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/10\">",
"     10",
"    </a>",
"    ]. Similar reductions from 2044 to 134 cases per 100,000 person years were seen in children under five years of age. Thus, patients with SCD remain at risk for bacteremia from S pneumoniae as well as organisms that are not prevented by immunization, such as Salmonella, Escherichia coli (E. coli), and Staphylococcus aureus (S. aureus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/12,14,15\">",
"     12,14,15",
"    </a>",
"    ]. More recently, an increase in invasive Streptococcus pneumonia infections with non-vaccine strains has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In conclusion, despite the universal availability of pneumococcal and H. influenzae vaccines and the general use of penicillin prophylaxis in the United States, children with SCD and fever remain at risk for invasive infections from pneumococcus and other organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACUTE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because fever may be the first indication of a serious bacterial infection in a patient with sickle cell disease (SCD), patients",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parents should be counseled to seek prompt medical attention for a predetermined elevated temperature. This should occur even if the fever rapidly goes away with or without antipyretics.",
"   </p>",
"   <p>",
"    Although not rigorously studied, most centers suggest medical evaluation when the patient's temperature exceeds 38.5&ordm;C (101.5&ordm;F) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients should be evaluated within four hours of the onset of the fever and, if possible, the assessment should be performed by medical personnel who are knowledgeable about SCD and the particular patient's baseline hematologic values and status.",
"   </p>",
"   <p>",
"    The immediate evaluation and management of patients with either a history or measurement of an elevated temperature consists of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A brief history for symptoms suggesting systemic or localized infection.",
"     </li>",
"     <li>",
"      An abbreviated physical examination focused upon the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Vital signs, cardiopulmonary status to look for signs of hemodynamic instability or intrapulmonary pathology such as acute chest syndrome (ACS).",
"     </li>",
"     <li>",
"      Degree of pallor to detect signs of accelerated anemia, which can be associated with aplastic crisis or splenic sequestration crisis.",
"     </li>",
"     <li>",
"      Signs of localized infection.",
"     </li>",
"     <li>",
"      Spleen size to detect splenic enlargement and any change from baseline, which may be associated with splenic sequestration crisis.",
"     </li>",
"     <li>",
"      Neurologic examination looking for evidence of acute stroke. While not associated with fever, acute stroke is a common enough complication of SCD that it must be considered whenever a patient with SCD presents for medical evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood culture, complete blood count including white blood cell count and differential, and reticulocyte count [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Parenteral antibiotics that are active against common bacterial pathogens. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Empiric antibiotic therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once antibiotics have been administered, then consider:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chest radiograph only if signs of symptoms of pulmonary consolidation (ie, chest pain, tachypnea, hypoxia, decreased breath sounds) are present. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Further evaluation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Lumbar puncture and cerebral spinal fluid culture only if meningeal signs are present.",
"     </li>",
"     <li>",
"      Urinalysis and urine culture only if signs or symptoms of urinary tract infection are present.",
"     </li>",
"     <li>",
"      If there is evidence of extreme pallor, severe pulmonary or neurologic symptoms, or significant acute increase in spleen size, a type and crossmatch for packed red blood cells for simple or exchange transfusion should be obtained.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Empiric antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric parenteral antibiotics are promptly administered after the initial laboratory studies are obtained. Antibiotic therapy is initiated before imaging evaluations are performed or test results are available, within 60 minutes of triage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an observational study of children with Hb SS, the rapid administration of empiric antibiotic therapy appeared to reduce rates of meningitis and deaths due to pneumococcal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/21\">",
"     21",
"    </a>",
"    ]. One study of nonimmunized children who did not receive prophylactic penicillin reported that 8 of the 23 children with pneumococcal septicemia died and 15 developed meningitis prior to the initiation of a clinical program empiric antibiotic therapy of rapid administration of empiric antibiotic therapy. In contrast, after establishment of this clinical program, there were no deaths and only two cases of meningitis in the 11 children with pneumococcal septicemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/42/9895?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical features and management of sepsis in the asplenic patient\", section on 'Empiric antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotic recommendations are based upon the epidemiology and antimicrobial sensitivity patterns of the pathogens most likely to cause infection. In the United States, the most common bacteria include S. pneumoniae, Salmonella, E. coli, and S. aureus.",
"   </p>",
"   <p>",
"    Several observational studies from equatorial Africa reported infection with S. aureus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/22-25\">",
"     22-25",
"    </a>",
"    ], Klebsiella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/22,24,25\">",
"     22,24,25",
"    </a>",
"    ], and Salmonella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/22,26\">",
"     22,26",
"    </a>",
"    ] were more common than S. pneumoniae. However, a subsequent large case-control study of hospitalized rural Kenyan children under 14 years of age found S. pneumoniae (41 percent) to be the most common isolate in children with SCD and bacteremia, followed by non typhi Salmonella species (18 percent), and Haemophilus influenzae type b (12 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/27\">",
"     27",
"    </a>",
"    ]. Admitted children with SCD had a 26-fold increased risk of being bacteremic than those patients admitted without SCD. The results of the last study suggest that the organisms that cause bacteremia in children with SCD in Africa are the same as found in developed countries.",
"   </p>",
"   <p>",
"    In the United States, the following antibiotic therapeutic approach is most commonly used in patients with SCD and fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      is administered intravenously (IV) at a dose of 50 to 75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum single dose 2 g). In regions with a high prevalence of antibiotic resistant S. pneumoniae, higher doses of 75 to 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum dose 2 g) may be given. Although there have been rare reports of intravascular hemolysis with repetitive dosing of this agent, it is still the antibiotic of choice in this setting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      is generally reserved for patients with suspected meningitis or who are too hemodynamically unstable for a lumbar puncture. Vancomycin is administered at a dose of 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV (maximum dose 1 g). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/35/38458?source=see_link&amp;anchor=H15#H15\">",
"       \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\", section on 'Empiric regimen'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4634?source=see_link&amp;anchor=H9034264#H9034264\">",
"       \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Initial antimicrobial therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who are allergic to cephalosporin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      is given at a dose of 10 to 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV (maximum dose 1.6 g). Note that the crossreactivity between penicillin and cephalosporins is small and many penicillin-allergic patients tolerate cephalosporins without problem. Drug allergies should be carefully documented in patients with SCD, and if possible, an individualized plan for management of febrile illness should be developed.",
"     </li>",
"     <li>",
"      The identification of a localized infection (such as acute otitis media) does not alter the need for empiric parenteral antibiotics because bacteremia with the potential to progress to septicemia may also be present.",
"     </li>",
"     <li>",
"      Blood culture and empiric parenteral antibiotics are recommended in persons with SCD even in the presence of a documented viral infection (influenza or respiratory syncytial virus) because of the risk of secondary bacterial infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Further evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the initial laboratory testing and administration of empiric parenteral antibiotics, further evaluation and management are dependent upon the clinical status of the patient.",
"   </p>",
"   <p>",
"    Fever is a presenting finding in other manifestations of SCD including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute chest syndrome (ACS) &mdash; Chest radiography and evaluation of oxygen saturation by pulse oximetry should be considered if the patient exhibits any signs suggestive of acute chest syndrome such as: (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/26/16810?source=see_link\">",
"       \"The acute chest syndrome in children and adolescents with sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Respiratory signs or symptoms including cough, rales, rhonchi, wheezes, retractions, or tachypnea",
"     </li>",
"     <li>",
"      Chest wall pain that is not typical for the patient (eg, not due to either asthma or painful crisis)",
"     </li>",
"     <li>",
"      Unexplained upper abdominal pain (not due to a painful crisis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aplastic crisis due to parvovirus B19 infection &mdash; Common manifestations of aplastic crisis include fever, extreme pallor due to exaggerated anemia, and tachycardia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link&amp;anchor=H11#H11\">",
"       \"Overview of the clinical manifestations of sickle cell disease\", section on 'Aplastic crisis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vasoocclusive crisis &mdash; The acute onset of pain involving the chest or chest wall is a common finding in a vasoocclusive (painful) crisis. This may be accompanied by fever that is usually less than 100.5&ordm;F. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of the clinical manifestations of sickle cell disease\", section on 'Acute painful episodes'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A review of the patient's last comprehensive evaluation and comparison of steady state baseline hematologic parameters to current values may be helpful in determining the cause of fever. A fall in hemoglobin of two or more grams below baseline may suggest acute chest syndrome, splenic sequestration, or an aplastic crisis. An elevated white blood cell count may be normal in a patient with SCD or suggest an invasive infection. Past history of SCD complications should also be reviewed, as a previous history of pneumococcal bacteremia increases the risk of recurrence and must be considered when deciding on the need for hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Decision about admission'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Inpatient versus outpatient management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Decision about admission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The universal recommendation to admit all patients with SCD and fever may lead to the predictable but undesirable outcome of parents choosing to seek medical attention only if the child is very ill or has a persistent fever. However, no set of criteria has been firmly established that accurately predicts which patient with SCD and fever will have invasive bacterial infection requiring hospital admission. Reports of risk factors for invasive bacterial infection were primarily published prior to the use of pneumococcal conjugate vaccine, but still may serve to guide clinical decision making [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/14,19,31-38\">",
"     14,19,31-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A regional network of pediatric hematologists with expertise in the care of children with SCD established guidelines for the comprehensive care of these patients including indications for admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/17\">",
"     17",
"    </a>",
"    ]. Our institution was one of the participating institutions and our criteria for admission are in accordance with these guidelines.",
"   </p>",
"   <p>",
"    We admit patients with SCD and fever for inpatient management when several of the following conditions are present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children younger than two years of age with hemoglobin SS (HbSS) or hemoglobin S-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia (HbS-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia) &ndash; The risk of bacteremia is increased in young children who have these genotypes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/10,14,19\">",
"       10,14,19",
"      </a>",
"      ]. In patients with HbSC disease who are less likely to have invasive bacterial infections, age alone is not an indication for admission. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management in variant sickle cell syndromes'",
"      </a>",
"      below.) &nbsp;",
"     </li>",
"     <li>",
"      Temperature greater than 40&ordm;C (104&ordm;F) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/19,34-38\">",
"       19,34-38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      White cell count (WBC) greater than",
"      <span class=\"nowrap\">",
"       30,000/microliter",
"      </span>",
"      (microL) or less than",
"      <span class=\"nowrap\">",
"       5,000/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/19,34-38\">",
"       19,34-38",
"      </a>",
"      ]. Both are associated with an increased risk of bacteremia in febrile patients with SCD.",
"     </li>",
"     <li>",
"      Hemoglobin that is two",
"      <span class=\"nowrap\">",
"       gm/dL",
"      </span>",
"      or more below baseline in patient with HbSS or HbS-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia.",
"     </li>",
"     <li>",
"      History of previous episode of bacteremia &mdash; Patients with SCD who had a previous invasive infection are at an increased risk for subsequent infection, particularly with Streptococcus pneumoniae [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/31-33\">",
"       31-33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who have indwelling central venous lines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Signs of systemic toxicity, hemodynamic instability,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      meningitis.",
"     </li>",
"     <li>",
"      Children treated with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      instead of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      because of the shorter half-life of these antibiotics.",
"     </li>",
"     <li>",
"      The presence of other manifestations of SCD that require in-patient management, such as acute chest syndrome, painful crisis, aplastic crisis, or splenic sequestration. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=see_link\">",
"       \"Overview of the management of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Concerns about the ability of the family to recognize changes in the patient's condition, be contacted should a culture become positive,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      return for follow-up as directed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Inpatient management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inpatient management of patients with SCD and fever includes the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemodynamic monitoring (ie, blood pressure and heart rate) and, as needed, supportive care. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10346?source=see_link\">",
"       \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Monitoring of oxygen saturation (transcutaneous oxygen saturation). Provide supplemental oxygen to maintain the oxygen saturation at patient's baseline value, generally above 90 percent. Aggressively wean oxygen as soon as possible to avoid prolonged oxygen saturation above 94 percent, as this may suppress red cell production.",
"     </li>",
"     <li>",
"      Continuation of antibiotic coverage (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      as discussed above) and readjustment of antibiotics when culture results are available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If culture results are negative, antibiotics should be discontinued when the patient has been afebrile for 24 to 48 hours even if a need for continued hospitalization remains.",
"     </li>",
"     <li>",
"      If culture results are positive, the treatment for bacteremia is based upon antibiotic sensitivity and local standards. In our practice, once the blood culture becomes sterile after initiation of treatment and there is no other focus of infection, oral antibiotics are started when the patient has been afebrile for 24 to 48 hours. A 7 to 10 day total course of antibiotics is used to complete the treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment for acute chest syndrome (ACS), which is indistinguishable from pneumonia in patients with SCD, should include a macrolide antibiotic (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      ) in addition to the above antibiotic regimen. Treatment of meningitis, urinary tract infection, and osteomyelitis is not different than treatment in normal hosts. Treatment for each of these infections is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/26/16810?source=see_link\">",
"       \"The acute chest syndrome in children and adolescents with sickle cell disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/35/38458?source=see_link\">",
"       \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27674?source=see_link&amp;anchor=H5#H5\">",
"       \"Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month\", section on 'Antibiotic therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24730?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of hematogenous osteomyelitis in children\", section on 'Overview of treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Maintenance of adequate hydration with fluids, generally administer at a maintenance rate. Increased fluids may be required if the patient is hypovolemic or if insensible losses are increased (such as with persistent fever). Overhydration should be avoided, especially in patients with respiratory symptoms, because excessive fluids may precipitate or exacerbate acute chest syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/26/16810?source=see_link\">",
"       \"The acute chest syndrome in children and adolescents with sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Further evaluation, if necessary, is based upon the patient's clinical condition. As an example, in a patient with persistent fever and epigastric or severe abdominal pain, abdominal ultrasound, liver function tests, or serum amylase and lipase may be performed to assess if the symptoms are related to an underlying abdominal process such as cholelithiasis, cholecystitis, hepatitis, or pancreatitis.",
"     </li>",
"     <li>",
"      Patients can be discharged if there is no growth in their blood cultures for greater than 24 hours. In patients with SCD, the time to detect bacteria in positive blood cultures is generally less than 24 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/39\">",
"       39",
"      </a>",
"      ]. At discharge, patients may receive a dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      for an additional 24 hours of coverage. In addition to negative culture results, criteria for discharge include",
"      <strong>",
"       ALL",
"      </strong>",
"      of the following conditions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/17\">",
"       17",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The patient is afebrile",
"     </li>",
"     <li>",
"      There is no evidence of any other active complication of SCD",
"     </li>",
"     <li>",
"      The patient is clinically stable, without any evidence of hemodynamic compromise",
"     </li>",
"     <li>",
"      The patient is taking adequate fluids by mouth, and is able to take oral medications, especially prophylactic penicillin in patients less than five years of age. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prevention of infection'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Providers have established a clear method for immediate recall and readmission, if the culture should become positive after discharge",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Outpatient management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who do not meet the above criteria for admission, outpatient management can be considered. Patients are treated with an initial dose of parenteral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , which provides antibiotic coverage for 24 hours. They should be observed for two hours after drug administration while the blood count results are obtained.",
"   </p>",
"   <p>",
"    At the end of the observation period, patients are discharged to home if they meet",
"    <strong>",
"     ALL",
"    </strong>",
"    of the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient is clinically stable.",
"     </li>",
"     <li>",
"      There is a specific plan for follow-up the next day. Depending upon the clinical setting, this may be a telephone assessment for continued fever and general clinical status, or a mandated repeat clinical visit with a second dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       patient/family",
"      </span>",
"      must have a working telephone number recorded in the medical record at which they can be reached to return should a positive culture be reported.",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       patient/family",
"      </span>",
"      must be able to recognize worsening of the patient's condition and have a reliable means of transportation to return should that occur or if recalled for a positive culture.",
"     </li>",
"     <li>",
"      There are no other health problems that require inpatient management.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The safety of this therapeutic approach was illustrated in a randomized controlled trial of 86 children with SCD and fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/34\">",
"     34",
"    </a>",
"    ]. After evaluation in the emergency department and a single dose of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , patients (age range 6 months to 12 years) were randomly assigned to inpatient or outpatient treatment. Children who were treated as outpatients returned 24 hours later for a second dose of ceftriaxone. Children who were considered to be at high risk for sepsis (defined by temperatures greater than 40&ordm;C (104&ordm;F), white cell count (WBC) greater than",
"    <span class=\"nowrap\">",
"     30,000/microL",
"    </span>",
"    or less than",
"    <span class=\"nowrap\">",
"     5000/microL,",
"    </span>",
"    and the presence of pulmonary infiltrates on chest radiography) were excluded from the study and were all treated as inpatients. No patient in either study group developed sepsis, compared to 7 of 86 episodes in high-risk patients who were excluded from randomization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PREVENTION OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive measures that reduce the risk of infection are primarily focused on young children with sickle cell disease (SCD). These measures can only be effective with early identification of infants with SCD. In the United States, infants with SCD are identified through universal newborn screening for all hemoglobinopathies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2088?source=see_link\">",
"     \"Newborn screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Newborn screening is coupled to follow-up that includes early initiation of penicillin prophylaxis (if indicated by genotype), referral to a pediatric hematologist, genetic counseling, and a program of parental education about the common complications of sickle cell disease. This education includes a plan for seeking medical attention for a predetermined elevated temperature, and institution of the following preventive measures to reduce infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/17,40\">",
"     17,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immunization",
"     </li>",
"     <li>",
"      Prophylactic penicillin",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with SCD should receive all routinely recommended childhood vaccines. Care must be taken that pneumococcal and H. influenzae vaccines are given at the earliest possible age. At every medical contact, a review of the patient's immunization should be performed to ensure that their immunizations are up to date. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link&amp;anchor=H2#H2\">",
"     \"Standard immunizations for children and adolescents\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pneumococcal vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The universal use of pneumococcal conjugate vaccine in the United States has led to a decrease in the incidence of invasive pneumococcal disease in children with SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/10,11,18\">",
"     10,11,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, both a 13-valent pneumococcal conjugate vaccine (PCV13) and a 23-valent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    (PPSV23) are now available. As of early 2010, PCV13 has replaced the 7-valent conjugate vaccine (PCV7). Current recommendations are that all children with SCD be immunized with both PCV13 and PPSV23. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=see_link&amp;anchor=H16#H16\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Vaccine schedule'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13926?source=see_link&amp;anchor=H5#H5\">",
"     \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Administration of both the conjugate and polysaccharide vaccine provides protection at the earliest possible age and subsequently broadens protection against most of the invasive pneumococcal serotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/41\">",
"     41",
"    </a>",
"    ]. The pneumococcal conjugate vaccine (PCV7 or PCV13) can be administered as early as six weeks of age and elicits an effective immunologic response during the first two years of life. The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    (PPSV23) includes a greater number of serotypes but is not immunogenic in children younger than two years of age.",
"   </p>",
"   <p>",
"    In the United States, we recommend administering both vaccines using the American Academy of Pediatrics (AAP) guideline as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/13,42\">",
"     13,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pneumococcal conjugate vaccine (PCV13) is administered as four doses before 23 months of age on the same schedule as is routinely given to all children. The first three doses are administered at two, four, and six months of age. The first dose can be given as early as six weeks of age. A minimum of four weeks between the three doses is acceptable. The fourth dose should be given at 12 to 15 months of age but at least two months after the third dose. Children who had been fully immunized with PCV7 should receive a supplemental dose of PCV13. &nbsp;",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12422?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      (PPSV23) is given as two doses: the first dose at 24 months of age (at least eight weeks after the last dose of PCV13). A second dose three to five years after the first dose of the pneumococcal polysaccharide vaccine also is recommended; this was used in clinical trials, and probably provides additional protection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients younger than five years of age who did not receive the full complement of pneumococcal immunization based upon the above schedule, catch-up doses of vaccines should be given. The timing and number of doses depend upon the number of total doses of the conjugate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    polysaccharide vaccines that have been given by five years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=see_link&amp;anchor=H16#H16\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Vaccine schedule'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other vaccinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to other routine immunizations given to all children, the AAP recommends that children with SCD should also receive the following vaccinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/18,28,44\">",
"     18,28,44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meningococcal vaccine &mdash; In the United States, early meningococcal vaccination is recommended for asplenic children, including those with SCD. A two-dose series of quadrivalent meningococcal conjugate vaccine (MCV4; Menactra or Menveo) may be given at least two months apart, starting between 2 and 10 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/44\">",
"       44",
"      </a>",
"      ]. A single booster dose of MCV4 is advised every five years thereafter. The efficacy of the meningococcal vaccines in asplenic children has not been clearly established, but they are recommended for this group because they are at increased risk for meningococcal infections. Vaccination is most important for those with HbSS or HbS-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia because these hemoglobinopathies tend to cause functional asplenia at a young age. Other details regarding meningococcal vaccination are outlined in the table (",
"      <a class=\"graphic graphic_table graphicRef71265 \" href=\"mobipreview.htm?9/48/9999\">",
"       table 1",
"      </a>",
"      ) and discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=see_link&amp;anchor=H19#H19\">",
"       \"Meningococcal vaccines\", section on 'United States'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Influenza vaccine &mdash; Influenza vaccines should be administered annually during flu season beginning at six months of age. Influenza vaccination may potentially decrease the number of febrile illnesses, thereby reducing the number of febrile episodes that require evaluation and treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=see_link&amp;anchor=H9#H9\">",
"       \"Prevention of sepsis in the asplenic patient\", section on 'Influenza vaccine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Analysis of Healthcare Cost and Utilization Project (HCUP) 2003 to 2005 state inpatient data indicated that although children with SCD were hospitalized for influenza 56 times more often than those without SCD, neither the length or cost of hospitalization differed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/45\">",
"     45",
"    </a>",
"    ]. Thus there was no difference in the severity of hospitalized cases of influenza between the two groups. As a result, effective influenza vaccination may decrease the hospitalization rate by decreasing the number of febrile illnesses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Prophylactic penicillin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have demonstrated that prophylactic penicillin decreased the incidence of invasive pneumococcal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Prophylactic penicillin is recommended for young children who remain at high risk for pneumococcal infection despite the widespread use of the PCV13 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/10,44\">",
"     10,44",
"    </a>",
"    ]. In our practice, children with HbSS and HbS-&beta;",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia are all prescribed twice daily oral penicillin prophylaxis. The risk of functional asplenia is much lower in children with HbSC and HbS-&beta;",
"    <sup>",
"     +",
"    </sup>",
"    thalassemia, so penicillin prophylaxis may be omitted in patients with these variant hemoglobinopathies. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Management in variant sickle cell syndromes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Beyond five years of age, a randomized controlled study demonstrated no statistically significant increase in episodes of bacteremia or death in patients who stopped taking penicillin at age five [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/43\">",
"     43",
"    </a>",
"    ]. Thus, penicillin prophylaxis can be safely discontinued at age five, following a second dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    (PPSV23) three years after the first dose, if the child has not had a prior severe pneumococcal infection or surgical splenectomy.",
"   </p>",
"   <p>",
"    In our practice, we use the AAP recommendations for prophylactic penicillin in children with SCD as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Birth to three years of age &mdash; Penicillin is administered twice a day at a dose of 125 mg.",
"     </li>",
"     <li>",
"      Over three years to five years of age &mdash; Penicillin is administered twice a day at a dose of 250 mg.",
"     </li>",
"     <li>",
"      Over five years of age &mdash; Offer the family the option to discontinue penicillin if the child has received the second dose of the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12422?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      (PPSV23) and has not had a severe pneumococcal infection or surgical splenectomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with penicillin allergies should receive prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    BID.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT IN VARIANT SICKLE CELL SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCD represents a variety of syndromes, which result from inheritance of the sickle cell gene as a homozygote (hemoglobin SS; HbSS) or as a compound heterozygote with other mutant beta globin genes, such as Hemoglobin SC disease and sickle cell-&beta; thalassemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=see_link\">",
"     \"Variant sickle cell syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18532992\">",
"    <span class=\"h2\">",
"     Hemoglobin SS",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCD manifestations including susceptibility to serious infections are the most severe in patients with hemoglobin SS (Hb SS). In these patients, it is imperative that preventive measures to reduce bacterial infections are implemented and that prompt evaluation and treatment with empiric antibiotics are initiated for all febrile episodes. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Prevention of infection'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Acute management'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18532999\">",
"    <span class=\"h2\">",
"     Hemoglobin SC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to those with HbSS, patients with Hemoglobin SC (HbSC) disease are less likely to develop invasive bacterial infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/14,48,49\">",
"     14,48,49",
"    </a>",
"    ], because they maintain some splenic function during early childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/50\">",
"     50",
"    </a>",
"    ]. In addition, patients with HbSC who develop bacteremia are less likely to develop sepsis and septic shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/14,49\">",
"     14,49",
"    </a>",
"    ]. Although there are case reports of fatal bacterial infection in children with HbSC disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/51\">",
"     51",
"    </a>",
"    ], the risk of death due to overwhelming sepsis is significantly lower than that of patients with HbSS.",
"   </p>",
"   <p>",
"    As a result, in our center, patients with HbSC are not routinely prescribed twice-daily prophylactic penicillin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/49\">",
"     49",
"    </a>",
"    ]. Patients and families are counseled to seek medical therapy for any febrile episode with a temperature above 101.5&ordm;F (38.5&ordm;C). The decision to initiate antibiotic therapy is based upon the clinical evaluation of the patient and the use of similar criteria utilized for treating children without hemoglobinopathies. However, in many centers, the evaluation of children with HbSC and fever includes obtaining a blood culture and administration of empiric parenteral antibiotics. In general, these patients do not require admission for uncomplicated fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18533006\">",
"    <span class=\"h2\">",
"     Sickle cell-beta thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with sickle cell-beta thalassemia, severity of the disease varies with the production of hemoglobin A (HbA), and management varies accordingly: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with sickle cell-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia (HbS-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia) do not produce any HbA. Their clinical course is similar to patients with HbSS disease. They also develop functional asplenia early in childhood, thus, they have a similar risk of invasive bacterial infection as patients with HbSS. As a result, they are treated in the same manner as those with HbSS disease with prophylactic penicillin, immunizations, and empiric antibiotic therapy when they are febrile. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prevention of infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with sickle cell-&beta;",
"      <sup>",
"       +",
"      </sup>",
"      thalassemia (HbS-&beta;",
"      <sup>",
"       +",
"      </sup>",
"      thalassemia) produce variable amounts of HbA and in general have less severe SCD complications, although limited data are available regarding their risk of infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/49\">",
"       49",
"      </a>",
"      ]. In general, they are treated in a similar manner to those with HbSC. In our center, patients with HbSC are not routinely prescribed twice daily prophylactic penicillin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/49\">",
"       49",
"      </a>",
"      ]. Patients and families are counseled to seek medical therapy for any febrile episode with a temperature above 101.5&ordm;F (38.5&ordm;C). The decision to initiate antibiotic therapy is based upon the clinical evaluation of the patient and the use of similar criteria utilized for treating children without hemoglobinopathies. However, in many centers, the evaluation of children with HbSC and fever includes obtaining a blood culture and administration of empiric parenteral antibiotics. In general, these patients do not require admission for uncomplicated fever [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/1/39961/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is a common presenting feature of many clinical manifestations of sickle cell disease (SCD). In particular, fever can be the first indication of a serious and sometimes life-threatening infection in patients with SCD.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with SCD are more susceptible to invasive bacterial infections, particularly encapsulated organisms (eg, S. pneumoniae and H. influenzae) because they have functional asplenia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Rationale for management approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite preventive measures to reduce the incidence of bacterial infections, such as immunizations and prophylactic antibiotics, children with SCD remain at risk for invasive bacterial infection. In the United States, the most common bacterial agents include S. pneumoniae, Salmonella, E. coli, and S. aureus. In other parts of the world, S. pneumoniae is less frequently isolated, even in countries where universal pneumococcal vaccination is not available. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Rationale for management approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Empiric antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Management of febrile episode",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with SCD and fever over 101.5&ordm;F (38.5&ordm;C) by history or measurement should be promptly evaluated by medical personnel knowledgeable about SCD. A brief history and physical examination focused upon identifying signs of systemic or localized infection, hemodynamic instability, and other manifestations of SCD such as acute chest syndrome should be performed. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory tests should be obtained promptly and include blood culture, complete blood count, and reticulocyte count. Cerebral spinal fluid is obtained for culture only if there is a clinical suspicion for meningitis. Urinalysis and culture should be obtained only if symptoms suggest a urinary tract infection. A type and crossmatch is obtained if extreme pallor, severe pulmonary or neurologic symptoms, or significant acute increase in spleen size are present. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After the initial laboratory tests are obtained, we recommend prompt administration of empiric parenteral antibiotics in all patients with SCD and fever (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Selected antibiotics should be active against bacterial pathogens that are commonly found in the local community. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For empiric parenteral antibiotics, the following regimen is most commonly used in the United States:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Parenteral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      as a single dose of 50 to 75",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      (maximum dose 2 g), the dose of which is increased (dose 75 to 100",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum dose 2 g) in regions with a high prevalence of antibiotic resistant S. pneumoniae.",
"     </li>",
"     <li>",
"      In patients who are hemodynamically unstable or suspected to have meningitis,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      is added (dose 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV, maximum dose 1 g).",
"     </li>",
"     <li>",
"      For patients who are allergic to cephalosporins,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      can be used (dose of 10 to 15",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum dose 1.6 g). Most patients requiring this therapy should be admitted for observation due to the shorter half-life of this antibiotic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The identification of a localized infection does not alter the need for empiric parenteral antibiotics. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Further evaluation is obtained only after antibiotics are given and if clinically indicated (eg, chest radiography for symptoms suggestive of pneumonia). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Further evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are more likely to have invasive bacterial infection should be hospitalized. We recommend that patients with SCD be admitted for inpatient care if they have several of the following risk factors for invasive bacterial infection (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ): (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Decision about admission'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Age less than two years with hemoglobin SS (HbSS) or sickle cell-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia (HbS-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia)",
"     </li>",
"     <li>",
"      Temperature greater than 40 degrees C (104 degrees F)",
"     </li>",
"     <li>",
"      White cell count",
"      <span class=\"nowrap\">",
"       &gt;30,000/microL",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       &lt;5000/microL",
"      </span>",
"     </li>",
"     <li>",
"      Hemoglobin is &ge;2",
"      <span class=\"nowrap\">",
"       grams/dL",
"      </span>",
"      below steady state value",
"     </li>",
"     <li>",
"      Previous invasive bacterial infection particularly with Streptococcus pneumoniae. &nbsp;",
"     </li>",
"     <li>",
"      Indwelling central venous line",
"     </li>",
"     <li>",
"      Signs of systemic toxicity, meningitis, or hemodynamic instability",
"     </li>",
"     <li>",
"      Other complications of SCD (eg, acute chest syndrome, splenic sequestration) are present that would benefit from inpatient management",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In addition, other indications for hospitalization are treatment with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (because of their shorter half life), concern about inability to contact the family or ability to reliably return if the culture becomes positive or the patient's condition worsens, and if other complications of SCD are present (eg, pain requiring parenteral opioid to control) that require inpatient management. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Decision about admission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inpatient management includes initiation of hemodynamic monitoring, oxygen saturation monitoring, supportive care (if needed), continuation of empiric antibiotic therapy, and readjustment of antibiotics when culture results are available. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Inpatient management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients can be managed as an outpatient if they do not have any of the above criteria for admission, they are clinically stable, there is a specific plan for next day follow-up, and there is a method of immediate recall if there is documented bacteremia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Outpatient management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Measures to reduce infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive measures to reduce infection in children with SCD include immunizations and prophylactic penicillin.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with all SCD genotypes should receive all routinely recommended childhood vaccines. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Immunization'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link&amp;anchor=H2#H2\">",
"       \"Standard immunizations for children and adolescents\", section on 'Overview'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the United States, all children with SCD below five years of age should receive BOTH the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12422?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      . (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pneumococcal vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that children with SCD receive annual influenza vaccine starting at six months of age (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Other vaccinations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"       \"Seasonal influenza vaccination in children\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the United States, we recommend that all children with hemoglobin SS (HbSS) and sickle cell-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia (HbS-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia) who are younger than five years of age receive twice daily prophylactic oral penicillin because of the high prevalence of invasive pneumococcal infection in these patients. (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Prophylactic penicillin can be omitted in children with hemoglobin SC (HbSC) and sickle cell-&beta;",
"      <sup>",
"       +",
"      </sup>",
"      thalassemia (HbS-&beta;",
"      <sup>",
"       +",
"      </sup>",
"      thalassemia) as these patients are at a lower risk for invasive pneumococcal infection. (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Prophylactic penicillin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/1\">",
"      Barrett-Connor E. Bacterial infection and sickle cell anemia. An analysis of 250 infections in 166 patients and a review of the literature. Medicine (Baltimore) 1971; 50:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/2\">",
"      Overturf GD, Powars D, Baraff LJ. Bacterial meningitis and septicemia in sickle cell disease. Am J Dis Child 1977; 131:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/3\">",
"      Yanni E, Grosse SD, Yang Q, Olney RS. Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002. J Pediatr 2009; 154:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/4\">",
"      Powars D, Overturf G, Turner E. Is there an increased risk of Haemophilus influenzae septicemia in children with sickle cell anemia? Pediatrics 1983; 71:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/5\">",
"      Pearson HA, Gallagher D, Chilcote R, et al. Developmental pattern of splenic dysfunction in sickle cell disorders. Pediatrics 1985; 76:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/6\">",
"      Rogers ZR, Wang WC, Luo Z, et al. Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. Blood 2011; 117:2614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/7\">",
"      Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood 2004; 103:4023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/8\">",
"      Powars DR. Natural history of sickle cell disease--the first ten years. Semin Hematol 1975; 12:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/9\">",
"      Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood 2010; 115:3447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/10\">",
"      Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2007; 44:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/11\">",
"      Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics 2008; 121:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/12\">",
"      Narang S, Fernandez ID, Chin N, et al. Bacteremia in children with sickle hemoglobinopathies. J Pediatr Hematol Oncol 2012; 34:13.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Pneumococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th Ed, Pickering LK, Baker CJ, Kimberlin DW, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.571.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/14\">",
"      Zarkowsky HS, Gallagher D, Gill FM, et al. Bacteremia in sickle hemoglobinopathies. J Pediatr 1986; 109:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/15\">",
"      Workman MR, Philpott-Howard JN, Casewell MW, Bellingham AJ. Salmonella bacteraemia in sickle cell disease at King's College Hospital: 1976-1991. J Hosp Infect 1994; 27:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/16\">",
"      McCavit TL, Quinn CT, Techasaensiri C, Rogers ZR. Increase in invasive Streptococcus pneumoniae infections in children with sickle cell disease since pneumococcal conjugate vaccine licensure. J Pediatr 2011; 158:505.",
"     </a>",
"    </li>",
"    <li>",
"     Mountain States Regional Genetic Services Network. Sickle Cell Disease in Children and Adolescents: Diagnosis, Guidelines for Comprehensive Care, and Protocols for Management of Acute and Chronic Complications. 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/18\">",
"      Section on Hematology/Oncology Committee on Genetics, American Academy of Pediatrics. Health supervision for children with sickle cell disease. Pediatrics 2002; 109:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/19\">",
"      Rogers ZR, Morrison RA, Vedro DA, Buchanan GR. Outpatient management of febrile illness in infants and young children with sickle cell anemia. J Pediatr 1990; 117:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/20\">",
"      Wang CJ, Kavanagh PL, Little AA, et al. Quality-of-care indicators for children with sickle cell disease. Pediatrics 2011; 128:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/21\">",
"      Powars D, Overturf G, Weiss J, et al. Pneumococcal septicemia in children with sickle cell anemia. Changing trend of survival. JAMA 1981; 245:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/22\">",
"      Okuonghae HO, Nwankwo MU, Offor EC. Pattern of bacteraemia in febrile children with sickle cell anaemia. Ann Trop Paediatr 1993; 13:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/23\">",
"      Kizito ME, Mworozi E, Ndugwa C, Serjeant GR. Bacteraemia in homozygous sickle cell disease in Africa: is pneumococcal prophylaxis justified? Arch Dis Child 2007; 92:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/24\">",
"      Akinyanju O, Johnson AO. Acute illness in Nigerian children with sickle cell anaemia. Ann Trop Paediatr 1987; 7:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/25\">",
"      Aken'ova YA, Bakare RA, Okunade MA. Septicaemia in sickle cell anaemia patients: the Ibadan experience. Cent Afr J Med 1998; 44:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/26\">",
"      Akuse RM. Variation in the pattern of bacterial infection in patients with sickle cell disease requiring admission. J Trop Pediatr 1996; 42:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/27\">",
"      Williams TN, Uyoga S, Macharia A, et al. Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study. Lancet 2009; 374:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/28\">",
"      Bernini JC, Mustafa MM, Sutor LJ, Buchanan GR. Fatal hemolysis induced by ceftriaxone in a child with sickle cell anemia. J Pediatr 1995; 126:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/29\">",
"      Smith-Whitley K, Zhao H, Hodinka RL, et al. Epidemiology of human parvovirus B19 in children with sickle cell disease. Blood 2004; 103:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/30\">",
"      Kellermayer R, Faden H, Grossi M. Clinical presentation of parvovirus B19 infection in children with aplastic crisis. Pediatr Infect Dis J 2003; 22:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/31\">",
"      Magnus SA, Hambleton IR, Moosdeen F, Serjeant GR. Recurrent infections in homozygous sickle cell disease. Arch Dis Child 1999; 80:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/32\">",
"      Hongeng S, Wilimas JA, Harris S, et al. Recurrent Streptococcus pneumoniae sepsis in children with sickle cell disease. J Pediatr 1997; 130:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/33\">",
"      Knight-Madden J, Serjeant GR. Invasive pneumococcal disease in homozygous sickle cell disease: Jamaican experience 1973-1997. J Pediatr 2001; 138:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/34\">",
"      Wilimas JA, Flynn PM, Harris S, et al. A randomized study of outpatient treatment with ceftriaxone for selected febrile children with sickle cell disease. N Engl J Med 1993; 329:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/35\">",
"      McIntosh S, Rooks Y, Ritchey AK, Pearson HA. Fever in young children with sickle cell disease. J Pediatr 1980; 96:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/36\">",
"      Lobel JS, Bove KE. Clinicopathologic characteristics of septicemia in sickle cell disease. Am J Dis Child 1982; 136:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/37\">",
"      Cole TB, Smith SJ, Buchanan GR. Hematologic alterations during acute infection in children with sickle cell disease. Pediatr Infect Dis J 1987; 6:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/38\">",
"      West DC, Andrada E, Azari R, et al. Predictors of bacteremia in febrile children with sickle cell disease. J Pediatr Hematol Oncol 2002; 24:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/39\">",
"      Norris CF, Smith-Whitley K, McGowan KL. Positive blood cultures in sickle cell disease: time to positivity and clinical outcome. J Pediatr Hematol Oncol 2003; 25:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/40\">",
"      Serjeant GR. The role of preventive medicine in sickle cell disease. The Watson Smith lecture. J R Coll Physicians Lond 1996; 30:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/41\">",
"      Vernacchio L, Neufeld EJ, MacDonald K, et al. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr 1998; 133:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/42\">",
"      Centers for Disease Control and Prevention (CDC). Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010; 59:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/43\">",
"      Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. J Pediatr 1995; 127:685.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Infectious Disease American Academy of Pediatrics. Immunization in special clinical circumstances. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering, LK (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.69.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/45\">",
"      Bundy DG, Strouse JJ, Casella JF, Miller MR. Burden of influenza-related hospitalizations among children with sickle cell disease. Pediatrics 2010; 125:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/46\">",
"      John AB, Ramlal A, Jackson H, et al. Prevention of pneumococcal infection in children with homozygous sickle cell disease. Br Med J (Clin Res Ed) 1984; 288:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/47\">",
"      Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986; 314:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/48\">",
"      Buchanan GR, Smith SJ, Holtkamp CA, Fuseler JP. Bacterial infection and splenic reticuloendothelial function in children with hemoglobin SC disease. Pediatrics 1983; 72:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/49\">",
"      Rogers ZR, Buchanan GR. Bacteremia in children with sickle hemoglobin C disease and sickle beta(+)-thalassemia: is prophylactic penicillin necessary? J Pediatr 1995; 127:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/50\">",
"      Lane PA, O'Connell JL, Lear JL, et al. Functional asplenia in hemoglobin SC disease. Blood 1995; 85:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/1/39961/abstract/51\">",
"      Lane PA, Rogers ZR, Woods GM, et al. Fatal pneumococcal septicemia in hemoglobin SC disease. J Pediatr 1994; 124:859.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5937 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-D86B8ADF8C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_1_39961=[""].join("\n");
var outline_f39_1_39961=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE FOR MANAGEMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACUTE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Empiric antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Further evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Inpatient versus outpatient management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Decision about admission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Inpatient management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Outpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PREVENTION OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Immunization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pneumococcal vaccination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other vaccinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Prophylactic penicillin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT IN VARIANT SICKLE CELL SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18532992\">",
"      Hemoglobin SS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18532999\">",
"      Hemoglobin SC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18533006\">",
"      Sickle cell-beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Management of febrile episode",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Measures to reduce infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/5937\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/5937|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/48/9999\" title=\"table 1\">",
"      Meningococcal vaccination indications in the US",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27674?source=related_link\">",
"      Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/42/9895?source=related_link\">",
"      Clinical features and management of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2088?source=related_link\">",
"      Newborn screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13926?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4634?source=related_link\">",
"      Septic shock: Rapid recognition and initial resuscitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10346?source=related_link\">",
"      Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/26/16810?source=related_link\">",
"      The acute chest syndrome in children and adolescents with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/35/38458?source=related_link\">",
"      Treatment and prognosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24730?source=related_link\">",
"      Treatment of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=related_link\">",
"      Variant sickle cell syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_1_39962="Urothelial CIS C";
var content_f39_1_39962=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58125%7EONC%2F69860%7EONC%2F75477%7EONC%2F55750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58125%7EONC%2F69860%7EONC%2F75477%7EONC%2F55750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urothelial carcinoma in situ (CIS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urothelial carcinoma in situ (CIS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 299px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urothelial carcinoma in situ (CIS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 308px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE0AbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6dpRQKKsgPrRS0CgAxSGnfSkwKAGldwxnFVpBsGF5Iq5iq8wbbhB16mmi4PUgguHeTYyEYqS4t1mwd20juKp3KyvIFhcJ/ebvVhWdIh1LdMmnbsbuNmpRG2uYptikkHitACqduQ0x9utXTSZnV3Drmkp1JUmQUfWj+dLQMTtRRSkUAJigj0paTt7UAFJS0dqACiij8KADtRUUsJeaJxI6KmSUHRvrUtAxKU9qQEEcUtACUmQCPelo4IyCD70AJ/KilopAJSdqWjtQISkpaTFABSd6U0UAMYhQSax7+6eVSEUiPON1XNVD/Zm8s4rmbxru3sTdwy5jQ7ZImHAGfvCrirnXh6aepejbKNsYqqjPJryzxRr95BrUv2O+jjwxVEZvvY6113iC+e40a1RW8t2JMojYhT6D/wDXXm2uWU93KH+xRy+XnDgHp6HFdeHgm7yPVoU+VOTO78KePpr21WOadHuEBVhgEcd62Z/HS2bbJ0SRjyNueB7141oBtdPurmGaGWJimzcrDOG68jkYrpII/tV/BayfdwFR15JHb61U8PBS8inhqUtXE9U0nxXa6jGGeNkB7pyAfcdRW21vDdKsqE7WHBFct4U8NGxjuI5AUJYEtnOePTtXXWtuttAsSEkD1rinyp+6eTiPZwl+6GW1usCbQxYZ79qnIx2pFXbu5ySaU1BzN3dxtNNP+lJQCGmmmnfhTT0plIYaQ05qYaZSNj8qO1FFBzCUtGKOlAC96KKKBhVa6kkCYjXvyas0UDi7O5lkPuGQVU9Sa0I41EYx+dLKm8AEU5iEXPam2XKfMkNijEY65NSd6M5FFSQ3cKKKSgQtA700MC5UHkdadQOwCsHxH4osNCCi7bLt91F6mt4+leAfGWZtO8UvLdP+7kiBhB6e4+tFm9jvy7D08RW5ajsj0B/ipoEUDSTtNGQOmzrWZpfxq8N31+LcmaIFtokYcV4hJN9vthhSVJ71QuotMtrmNnbY7EDauMfU06LpyfLNO57dbJaK96D09T7IguoJ40khmRlcblIIOQanHQZ6181SeI9PtbfTHtNUuLeZAI9w5jb6ivUbX4kaZpcelWmryu092mY5I1ypHTJrWWHmknHW/keLXwEqfw6nolV/tSLMYnyHHt1qre69pli9ul3eRRPcFREhPLZOBx6Z71eliDnJHPrWKZxJW+JCG4jWTYWGTzUjMAm4nj1qnHafNkk5Hc1YnRGiIc7UHXmjQbUbqxni5C3TFHLrjIFXIbyKRihdVcc7Sea838S+NtC0fW49Me6drqQgLHHGWPPTpVPWfE2l6dOsd1fKt1jKxcbvxHatvYydtNz0FhFUSex65wR60iqsa7UUBfQV5FD8T4LS03QRTXAzhzjIT3zXeeG/EkerIoYBXYZX0NRKlOKu0YVcFVpJtrQ6OkoB4yaKzOMQ+tZ891Ms+2JQy1oEZBBqsLVVbhv/AK1NWLg4rWRMjMyZYYPpTqUcDFRTzRW8e+eRI0HdjgUiN3oP70GoZbiK3gaWSUCIfNuJ4xWJF4w0eW4MInw3Ytxu+lFmzSFGpNNxTaRt3C74yBmsTxDbXC+H7w2MJmn8viNeC+DnH1rRbVrMR7hKCOuO9Z954s0iyGbu48hfVxgVcbrZGlONVP3Y7HkXh/UfEN9feVc6FcNZvkFvKZAB6H/Oa6SKK4snaX+z5miKlSHTOP8A9Vei2WtWWoQLJYXCXCsu4FDkH8atW8TIpaRi0jcn2rWVdN/DY63jpLSUT53n8L3FxqjvBOBHJIXICncQT0xXq+g+DI9Hu4bhGEzBt22Uk4J64P8ASuzMMZcPsQuOA2BkVV1OAtC8il96rxtPIoniZT02M6mMdS0Voi5SHpWJoF8rR3Cz3G9kfB3cEcdMVp295BdKGtpElXvtbOK57HJOm4uxPTTTu1JSIGmk7040hpjGmmHFPNNNMpDGprCnscdabkHoaZSNaiijvQcwuKO9FH86ACjvS0YxSABRSHr70tAwoPA5opCAetAACCODkUtGABgcCigApMEE85z2paWgBuADkdaWij8KBh/KvMfjP4R1bxHaWj6LBa3Ii3GaCc4L+hU9j16V6dwKM5BqoTdOSmuhdOo6b5kfKPivRZ9B09XgtpwwUB4g27ae4B9K5rwho1rqct3daz9pjdQRAu3K7sHGfxr1XxFDr03ii+E9pIlp5pVCV+UqOhzXTaf4WjGjfbL/AGeUgMmF6Eema7rqlHZXfVH0cqsakIuctOx4ZZRPBcJDfkOgcEERlsY7167/AGNo+uWdjLdRq0lqha2lRtuGI4Bx2yAa6PQtI8PeJ0dAgjuIVwRAdhU+oqhH4ds/D/iCTTrKUvE8RuHRxzuGOeOOeal1bvS6aMqmIhUfsndWOX8LeDPsV+tz4hmuFWxnaeRrmU+Wsf3g27oyn8ah8X/G21vdRtP+EcurmG1jLidnTbuHbj3PSpPGN0dUuofDGtRyzaJetvtL6BjvtX6EED7yZxke9ctH8MdA0rUIv7d8SWf2YvwibgzD0PHBrRRjKXPV+S6f1+RyOnP2l2r2O88A+J9W1W5udY1TUmh0i2G8uThTjtjv6V0Nx42tvEcZfRr1ZLaM4k2cYJ6ZrK1q20gaJb6Rp0Ey2JG4CP8A5aYHGW6AemfWuBHhG4u9JNrPewaXB5mVtrchjsHdm/ib9Kjkp1PeenY61TUpe05dV0PTEt4ppVnaKNpl+67ICw+h6iq+oaPa3Zf7TaW8kjDBZ4wT+dZHgrwwmgmYxajd3ayqoVZjkIB6Cul1FJDZTLHcm3lKkLMOqH1rN+7K0WbeqOb1eDTNIsB9qMVvHwmQoXn2qSxu7qx1C1u7XBsZctJk/c9G+lQW9pNc2jw+K1ivIoGEkdzwQ31A71h+NNVa50trXw+VdgwSaEJucIemB6ZxW0Y3fJv37FOXutvY9q0vxnpV3Bn7VGzKPm2HNdBbXttdW32i3mR4f74PAr5stfB73egtZ3kr2t3c4MOCQUPUAjuCetdDqU2p+DfBmlWuoee2pXjSRpEH3Ywo+bI4yTWE8PG9oS1PKq4SnzJJ2uezX2qQi3Y2siSOeBjkZrk28V2VnqccNzeLHKwLDnIP5V4k2qa/oUyqszSu6CUwOpyB7jsetZWp+IrrUp7e/mULcwkRgLnpnI4J6g1rTwd9b6G0cLCmnG9z6OuvHOn2FysV3cwoXIwrtyCenHYVzvxBuxqW03FlqAtYgjrNFcokTc5z1zn8PSvNfHsb3klpqTWzW8syASiUhQ3HDgg/jUFgbvVbAaXdefdRMw8t8n5GHIPHGM9qSw0UlJMSwaXvRWx6fH4o0u6snginkCxDBDoRgHj8RXn3iTw7Bc3K3i31woiG+IKAVHuPrx+Vdnp2m6ZFY7NVsFhfbksORkeprKN/YXpnttPhlMdvxsZcFVHf6VVNKDvA6qTUbx6MytA8ZPqU/wBiELsvRnDYI9/SteXTrXxB5i2N8kpjByqOGI/CvO9V1L+xb+WONI1iYY3SHaGBHTH41H4Ev2066u7zy3LrEdrBvlQH+8fSuiVC3vQ0Kc3smd9YX48BKsrTbFBxszkMT/OvQvDnxCtNXsBcJBKV3Fc7cZI615DP4fHiHR5bq3v7aWZTuR5PmRT3DY6V1GnxvpPgBy00d5fRgx/uE2KpOSB9PpWFWlCeu7uc9aNOeko/M3YPiJrMfiie1utFZtJQE/aVOCBg42j+LPTFa3iHx/b2Ohi5itppJ5PlES4DLnua8t8F6zJe22ow3VtLLcJHuXaNrHnnjv6/hWTdW0jiRGecM/zbtxB56GsK1OFOSTRtQy6nXu10K9r45tP7ae6Ka3dXysyyo7LhUOATgdTx0xXpfw08Y2FzrUOn2UgKXOcRLCwKkDPzEjj+teP3/h54dIu9Z1WZkuYXCwzw/ekY5xu/LrXXfDXxYt1ZmG7nj+1ocLIByy+47mtKlCLi5Q2MHQdnSf8AX4n0hSdqqaPO1xpsEjkFiMEg5zVw1wHjSXK2hppDS0n1oBCEU09KdTT1plIilqMdeKmYZpm3BplI2DQKWgUHMJR2paKQAKKP50UDCiiloASlpKWgBKBRS0AFMmlSGJ5JGCooySe1PrD11ZXhniuXC20gxGyfwnHU+tNK7NKcOeSTCz8UaReXj20F5E0qdRuH5Vtg5AIOQa+YbnwfqFprFzNpN9aXBzhx5hVk/CvfvA8k39hxwXcnmXEOFZs54IyP0retRjBJxlc6sThY0480ToDSCnD3oxXOcRleItEg1vTZ7SV3i80bWeM4bFZE2ivFpNpptukn2KBPL2Mcs3oc11dHeqU5JWNYVpQPOLvS5fCPh3UNT06yuLieMiRoo3AZkBGefbr+Feb/APCx7vU77UWSNonlxCdx546beOlfQOuErpN0F++Y2A47kV8l6PZ3lv48FvqJwwlUMo4UY6YHbPFdeHtU5pTWp6ODl7R3kup6noRSXS44W2LexszByMlSR2qpqXhFbtHaURXEbDLxuDyfVTVaWeay1+MyhVhkcDceAwbjA9T/AIV2YcKxSNhnGcE5xUuT+LzPYnem/ce61PPfDep60/imXTp9OaLSolMS/JgKoHynceuf61o3fgX+0buKW61NjFGxMYC7WA9Dz+tdlHE8iI0xQy4wSgwDj0p235sKeB1rR1mpXgrHPa6s2JGoRUVBhEAUfhTmAb5SNwP8OM1Xg1G0luDbLMhmGfkzzWf4u1S80bSJLvTbKS9uAQqxx5yM9+OcD2rJRk5JdQbstSlr+q6TBdQaLPKtvdT8xJsIBOcDnp1rl49Jg0TxfDqT3ipc5LC33hTJ2OK1tQsotc8NQ6r4jthp2q2qGSORQWaMdc49fb1rlfCehWmp3s63krapZsu4GTKvGSeuQeDXXCKUW7+T6kqbta1zT8W+I5ZPEFik1u1tDwbe6Zj8xOMow7YPevVL9rTxL4RFjc3tvb3qrxMxBKepB+leRXVxovhiGdbSK+up2lZFivZCyAr3H6c9aW5ur/VNCmMtsuiXCATbnG6ORMEnHGR60Tpc3K46W6mMqanvutTq9Xs7GGGy03RrcXUaAi4vZGwztjt+JrhvHSSaaLGNrGafeWKeUg27vQkA81y5adJLW60/WbaW+jYljNuA9sZGK6218ReLLe2t5vs1pqkc7+Uoi+cK31HStY05Qa1v+BfNaPKSR+FdZ1rRg+ryOLuJwbeIuB8mOVOOB7Vc0e81Pw1c29leQmOxkYgs0Rx+Dd8UzWJPEIvreeHzUtTt8xIG+438Q9xjvUvinW55rOMRfY0jVx+7uXDFwPqKXvSVnaz/AAKVyz8QfFiabY24glQCfIBAyWHsPSqvhjUTb6TJdzQTFmXO58x7k/H8Kl8Op/alow+xQW8sRDI8aCVSPbPT8K3dR1W21PRZtFe8hS6A2ebInUg8VFlFclvUG5J6bHIx6laeI7gWd3o1tJaDBwGJkHvn1rtbW18PQaTNoUSWCQyIVKF8MQem7vXmr+GreJhB/aM9ndCQGV7fLK3sTxiqXiPTRZeJftdzLO/lsrERA5kUdGz054/WtJU1J2i7feRKN9Wjr/AusweGryfSLyx8u2kkIaTduw3QZ45X/Gust9R0ednsZS8aODyqkKT+NcVp3iDw5fxyeYpsm3hiJQG3n14rtrV7HULWF7SBNRTPVVYEEfhWVVK/M00HKuhe8PaPYQvOHaQlgNqq2M/8CrlPEi3MF7JHMpTn5MnIK/Wty+13U9OskkvbMxsztwsu1UXt1HJq7c2ieJtCWWeFyzKTE+cke4ZeormqQlLWXU1oV3Rnzy1R59FdOuUV9m7jDKGU/geDVvQdTa4vRbXukWxEILpPbQrG4I5Ge2PcUiaNdWEzJPOJFA4Ow7s+mKp6Lc60ReyQ6HepKI28qZiMH2AI68dqmhSqQut16nbi6uHqJT2l6Hb+B/Fc9nrFxBfQTeTNuMQikyjYPXYejY6kde9ei6D4is9ZtTNEJYCCQUnXawIr5w1T+2rp7fVr62j0qS2wGlJMRZs8cf4VNqet3V+ImtL17a6C/M0cgMbnvx2zW1TCqTutDyJYWFa8lufT8ciSJujZWX1BzSkjvivAfCHj/XdKjeDVla5gRSVBTDZ9VccH6Gut0P4h6brN1HCNQNtN0EdymAW+tc0sNOPocrwM1qtj1AkAU3cuevNVzOTaGUqGwMkKc5+lRZ37WU5BGQawOSzRcOKYaahOMU80xo1aP50UCg5haKKKACiilpAJS4oooGFH4UUUAFHaiigA70hUMMMoPsaWkdlRSzsFUdSTgUDPlX4vaFrPhLxfJqFlNKILiVpYpUyAQTna3bjpXqfwP8R3eu6beNLCySxY3owwrE91rr/FHiTQLdBZ6hPayTSDMcUoDDPY1V8Jb0vpFt9ieYqnZsAAUHrn6Gu2db2lK0469z1FKpKg+dfeddbO8kKtIm1j1FLPNFbwvNPIscaKWZmOAAOSTXkmq/GuxtNU+wwWjTu9w1srZ2hGBwN3sfUV5p8RPEnje8ja0bURNA7F2gtV2SJ7MASSvofzrGOGm5JS0OaOEm3d7fefUtpcQ3dtFc2sqSwSqHR0OQwI4INS14Z+zbe6xPBcrqMkz2bpmISfwkHB/wAPwr3Os6tP2cnG9zGrTVOVkV7yAXEBXv1FeSav4ctrTU3mUZuXZn3zDLnnOM/jge1exnkV5n8QFtZNaiaW8KXMcZRIfN2qQxHzFe54wD71dCTTsdWXzanyo5mVNPv9WsILmdo54VLwxngSE9h78Vg+NL7U9J8W6Je2CKYbgfZpg+duC/OcdDzwafqYs7/xbpGmPvjnSPzkukOSCrcoR+ue1a3xA1mfSp9Nt7OwS6S7uBC7OGIQcenf/Cu6KalFJXunoepOWr1OoQnnaDgHile6himjtzJGbh08zy8/Nj1xUSTqsyQlgGK7tuecCqz+FZ7jxf8A2osy7QiZU9iBggVzRSd+Z2HUko7kY0G1N99pt7cJdndiRck5PetVl/sbRzd38zMsKEs+OXI7AetWppU06UyONxVNwAPOa8h8Za9rGr6gIxH5NvH/AAgnjJqlep8T0QRhKq0o7G9H4tj1qK8iubLbauAoWV8lh3B/+tT47q20zw5/xLbFRayth1UnDKeCc9TXn1jLqt3fm1mUPanIEaxjAwOGyOR9c12/hLWZ7ZLXS3tw6IGG7AIXJz/Wt/ZSjr03saVORLlhHVDrPw9o96UjeXfAx8xYWOHRj15o8Zs+mJG8d5ZWsDALiQgOx9uDke1bd5pwuGbymEUhHyyKnzD8eteey+HrifUItO8QxXV1beYfLuI25BPU55/Grh77u3t0MJabFeRodQaNHuraBgfnZbYMWz05Aq/f+GrPR72J28QzWAblIsFjn146DPrVnWbuLQtltbaHBaTFNsM5yzAgYDZPBNZjWPizxDAklxpj3QGVhmChSPUFh+Fa6vW9l8iZSS1Zvawmtx2UVxbaparGqAAt8qy/n3Nctp/he814sJ7i3iZCSisST9V9BXS2Vrez28Gl+JdKM0KElZY2w8XbqDzWjJ4I025s2XS72a2mU/ekJfdnsRxj8KhVFTVr287Dk769C54G0i70FJo7tPlbA2g7gT/ewK5HWNC1pPFbtJpspjmkyJY0yjjPUEdPoa0tT1/UPBtlDpxRL6RQWE7ZAAP8I+nrW34c8btqmkSS3OINp2uQ2AD2x61F6kL1LXTJUZTa5dzldJbVV1a8l1WztNMtkASMXRAcnPUZ5OfXpVi/8XW8l+tpd6Tb3CIAodk+99KrWnh+S88Syyao8l7Zujus4PG7HAY/0ra8O+CVN1FPqV35lvGxco4Ck/j6Dirk6e7f3Fr3b8/Qng1PQYQgXSNNibqQ0AJX6122n+I7u3hVLe0tRGRkeUgX+VefX/haJdZ+02V35trv3+S/BU+n0rqYyY4hHGu4+oFc9WMHa2oeyhNaxL3iTxY0OnNJc6Sl4emx+h/Q1zNh47tU0yV7izTRZgMIgXzPodnHH1rqtYukstDhhCxtcOucYyw9jXnh8JT395JdPMySSDdsPA9yT61NJU2uVqxMKC5XNKyKtx49u7+8WO41K2MfCqJrPapHvg5FdckepNaiORIbiO5Ta72kuXjz/EueapaZ4M06GZZLr97Ip3Hjj9a6qZAxUW8YI4HTj8qupKGighJW0RxcXgSG1tJpdZ1y4voF+bc42lFH97PWpbfT/DmpWpWxjj/dA48ocnHt1rqLmQoHjvYN0ZG11Ug7gfrXIT3Fl4d1N7rTtDibHKyJuVgfp0pKUp7vX5WKi5R1/Ew9J1eynuZLW1tryKX7uyaMlXx6ZHFXbl7SC4Dy20UdyvOWTDfhWjZ+OtYGqWiyWiWunyfLvmUEZPox5H0q3qMNzqcuzWdB85M/LLAdrKD0II6ilKD5r7fM6KeKaVqiTOc0+0vo5JP7G1u+sVIz5QkLxj8zkV6D4Qv9ZsYorbWJ2mZn/dzFSVZfrXnmtaHJo93Fd2M2pPaK+6WOGHzSmD0JB7+4rptL1yPWtKntvD95PaXMfSMxkbQexB7fSiUJOOuvnb8zOt7Ko2oL5HsFldW93F5ltKsi99p6VNmvnG+07xFYzT3kt/JpkiqDJIkhCPzwQOoNdd4Y8W69baLHPfX0F+Cx2tIoyR6ZGDWE8PyrmUk0cP1GUnanqe7ikpcUAVznjhQKKRTkn2pALRR9aKACl6gEjmiigYUGvHvj/wCJdW0PTIo7N5oIpZF2yw9x/EGPasPwHe634ivtIu769v7G0tZjMlqGybhsYBYnovtW6w8nD2l9DsjhHKHPc99/CsifxJo9vdG3nv4I5QcYZsV5j4j+JT2Op3Xh6VGhuGQMZ924AMcYB/rXm/iK7gvLyGVvNhmZtol3fewcZK+nT0rWlhHL4tEb0sAmm5v7j6hk1Sxjt1na7hELdH3DB+lc34u1B/MgEZL2sseVKn5W5r5wTUPEWl63brl5baSUbUzvQrkZHtX1DounQ3HhiziuozgpvO7qMnNKrQVC0r3uN0qeFkpvXU+Z/jLpd0NVtdVszK6TAQso6o4Py4+v9K+gvhdZXVt4dspNTUC+MCiT1B9PyxUh8H2U2oJO+y4hUgqGbI4ORx6+9bkxFnqCFCFg8vDA9OvFFWuqlNU10FiKyqXjB7nnHiH4XRxa62o6NbwXUd27CW2uOFiLHPmKw9D0HXmvJtS8K6n4U8Tf2rd3TMlqd1zLIP4cYCg/xHpX1jFKs0e6Mg18pfETWm8a+O5dLimeXToJypVSVT5T8xPc9+a0w1SpUbUtktRYSpOUuV9Dtvgzq13Pdz6g5kEE5BzxhlJxjaOh4zXvHmJsL5G0DOa+VNQ1e28MRJaeG7IwqW3BmkJHLfxe+O1eg/C7xNqQutSbUG8ywkmISOSTAiA6kZ6DNZVKftL1I6I6sbg5ySm/itqj2eKZZS2wEqP4uxr58+O8Ml14pspbRsyxHy2A6jkEV6t4x8dWHhvRvtaoZw3Eax9Grx3w/cX/AIv1y51zUrVra23ZgjPVz6/QVeEg4N1XsjnwdBxlzS0Oj8H6JbXNpba3PC41F4jwW4UE84FdRx8ykcg5FZMmv6ZYq8KyhXhiMhiU/MVAzwPwo8PazFrujw6nDE0Il48tmyVIPTPeifNL3nseilZ6mOFEfi6/1rUZfI060hFuGYcAnH9Sa0fiHBfy+FNKvtLmnUi68xjCxDFSMKfpn+dXfEQspvD9xFqILWzFSVXvzWgNRg/sWDEirawQ5LDkbR0qufWM0ttDKom7epyc/jIXPi6HQobLzpcIs8pOBHwCfyrbubPQ1vne3jhmbGdzndyO/NZkX9j6kk+qWe0SSErKY4wrnA/iNZ+lww3ircI8qICRtbBOaJR/lVrb+p0UoxtrJr0OnMcUqvDD5QLfxKoU4qr/AGZFZMJ41j8w/ewvOKZbwPIvmwbcITu3tyAO9X7vy7hEki6sPmC5/OhabGezsivZ3BWQs2VUnlgKfK3nEshH4DGazncgssZ46Ee9YcniSWxfZJaO0Z6Oh4H1qlBy2NHTV7nQavaR6rbC3eNHAOGRuQw9vQ1Vj0GJJI9s80cSEYQE5H05q5pN4t5Ek4UhW+8Aeh+taaQESAsWJVtpBpXcNDNyt7pXvJMqfs1spc8ZwM/ia4DxHo+vyaj51vqMLgHcsQkAK+31ruJ9X0g3bQPdxiYZUjdgA+ma5668O2l+3madfj72flfOD74qqT5Hd/ihra2xVvtWv7jw+8ep6RbyzwAEiVAxdR1OOuayba3i8R2CPplouny2nL20ana5J+8PyrubCw+zWsSXLebcQjaZD1NLZ2ttbTH7HDFFJIRu8sYz9apTSTSX+QrKLUoGHFDPpmkz3EyFZI4yVTP3j7+nNZsXiWXdEl2NjBRuIHBr0CaGErtkUFCMMeoP1rndb0jT5JzI08UDHqG6H3FTScNmjR1XOV2Vr68it4vNh+V3HUDOav8Ahu/ujYTXF5GUwx8sngsMZyRTtGt9MRANwvGXJARhVi9Z2QFtqhc7UUcAf1pNxfupCl72nQz7i6SdVubp1T58BnOAK0IVBRWik3qw+Ujpj615H4z1aW5ukUMzJETuCnG38O9ex+E7aOLw7pqxAvLLGH3Htnn8OtOpT9lFN9RSqp6IdbRFnUsxwOPet23UR27Ntxt74zWZJc28d95EciuVHzEdz3rRa4L2qKhyhOTjqa55XZz1buxjavKYLO6lABkCk8VwGjRaj/bEVzb3LqoYO+5iQUyM8GvR7xTcsUZAoY4OfSo0s9Ntbfy4VAOMHaMmtoTUYtW3GpWRz3xHGmTR2MepWMjTyZktrlOImfpsc5pPDHiW6uL8aRqOny2d6BhFOTFMoHVD7D3NdNa3kM1sunX0QKbgE8wcEeh96bfXMH9mT3FrNBPcWUbMscOMjAOBgevFRzLlUGiNYaMsTXdjGBcXMwtpVbZ9oU9D6MP61PbXcTExXi2cyOMGZMLvHZsgV5losmoJp8M164uJ5AZ5oGThVPY9jxj866vSjpiJHJLbPbFhmNo2bac9iPSpcVdpdDaeG5YqW/5oq/EjwbqOsT2t3pQW6RU8t4Wk4IzkHPpVaDwXraWcNqdPhjK9HilG1fZga0Nbs/FEN6lx4Wv4fI2/PayjC/UHFSeF/iBdXSNDqYto5hwJFOQx9qt87p2VmkZ06lWDvTeqOh+H/wAUdP8AFLXdvIn2a6thubJ+V19R+VWdX8eW1tOYQSGGCTHzgHp1rx3wfoGI/E1tHkSvcmKNuVGACRz6ZaslHSbRDaazNLBcJMbcTYyVA/hb8RW31Wm5u22hnHC0r8zR9IeGvFWn6q6WwuEW7KlljZhl1HcCulr5o8GeDb5fE/h24huwyRzZaVW4Mec4Hv1496+l1HABOT69K48TSjTklF3PPxdKNOXu9RaPyoornOU4D4yeJNR8M+HorzS7eR38wBpAMog96yvBXxJkl8NNfeIwMqNxljGBj3FdtrXiTQbS6/szVby3WWYbTDL0bPbniuC8azeBtGmtBqBnsFuMjyLdGAlHfIHAHNdVJRlBQcXfud1JJw5Zw+Zt6vNbeP8AQZILa13wkpJl+d4BHTH1/nWL4kvLHwuF0+0YveyKyFh0zjO2unS90vw34F+2eH7dUszGZY1JxwecnNeI2V3BrGoPrUt6921u5mKqh2qxOOSep9hWlGHPf+VHVhLt6aR7GTpv2LWvFDale28oki5ZVbIYDjnPSr2uXGnXWrWq2txE0GNszNxsOfXpmodQtptR8Vs+jQvbWjNyFH7t1I5bPfPpTNZ0mwhv7OyMzxoGR5wYi3mEEHDH6entXodVr0+464tNc1tT2jwL4J/cRX2qNG0Zw8cSfNn0JPp7Cu510umnP5GVwOi+lY/hHxRbarO2n7RHcRRhwAeCvHT06ir3ijVrKy0y7Se4VZfJZtinLdPSvGm5yn7x5VaVWVf31r2Pn638W6zp/wATl02VhHa+avlxKO2Mg5719H3sD3UKPCE3MoyG6EelfM62xvvFPhzxA3+omeDzGPYFj1/OvqXgcDGB0roxdo8rS6GuOk4yj3Mm6t2jiaGwn8m5dTt+XI3Y6n2HpXhniy30vwhbrpmlo1zeyFje3uBud85I9hk179d3FvBKjyth1zgV4T4t0h21a6mjxcwSSMwKnlSTnBrGlJ7PbqdGVxU6nNJ7bebOCVbS41aFLq4O+Z1wgGShJwM9q2/Guox+H7vTfIuWMtqcPEo4fPOT7npVC60BoNZgv7iKOGGMoU5yWI5+parPiKG0e9guZIS98fnCydhnjIHevUiotxa2sehNzldN9Tf0rxXBqccUFzZFEILr5gyB7Y9a3NPu5rprG5ig8mEyGNkXpgetZPhW9edJI72JGjRN4CLjOO2PWqV34zsrnR2NpDLC8E2XjGDweh/OsZUuZ8sUZufI9R/xC8PTWnii01Oym8sMBtGe69QfbmrGoa5c2lhepa28drFAIpYii4BV8bge3U07xh4nhfwrpd1LE4E5zG7HLIe9bmlaR/bPhCGJlVZryNkWQnOQOVP0zWaco2dVabfcx80FSV/iRU8VQ3OpeGYXtNx5R2VBklSO2PrWb5mo+GfBBW/hSWSZgDGTuxGRjB9D1+ldNLeWvhPTra31m5ij4SBWycFugArE8SeI9NvtQvtDeCRlEG7ggDPHT06j8qqm20o2ur3MG7s50WE9rZLcWhMlrcIskfzcH1z7jp+Fbvh6OdbFtwKAsNgI5x3rPvfD2tWtvbzaQ03kpzsV+qk56dK6W1cvb2zzxtFOyDcrjv3FaVJ3jpqbx00uT2szQCRVI3EY+b+lVtPuLgTsu48H5Ceh9qzPEV9cWsKmBwnP3iAfyqppOsLqlr8/7i6ztY4wrH1HpWfI3G5fKri+MtSv9NuYZolCR4wd4OCc9Cf5VzqeIo71izKsTDhujKTXdaZeTXO+x8QWy3FoeBIB8y/0NF/4L8OWKfbWtBPCTkNC5X8xmrhUhH3ZLXyMZTlF2NLw7Gn9hxzQqFEg3A9s1I87A3Ubrhp1ypz0b1rHh8WaC13Fp1tcPayAiJVeM7DnoNw4FamsiW0tma4gdmVTJGF+bcMcgGsWnzarchWbszze/sbhNQeK5txGCdynGOM8nPrXReE9Ne2vDJEu2IZLHtjsPrWGvj++gkxNbJKmcrG44Ue5rovEHjEx+GLa6gi8ue5yqRqPukdTiumftLcttx6nVNG7Zds4xmoLWESXvlo2HOSBXnfgy4uppZL/AFS8lKxnczO5wo9K6vS/E2m3mpxCCcgg9SMA1zzpuF1uUk2tB+oeJLTS53gmQuwOHO4AD2964zx+Xnt4r20Mn2RxtLJyY29DXfeJvCS3l8Lm02ssoyR17daNA0C40tTBMv7qU48tuep96uE4QSnHcnni43T1POvhu0sepPLI7SJGjZbGNzHoK9Kht3usOykJn9a308MWaSFGkQqpBAiG3r7eteTfEbx3daV4iuNK0QpbpbkIzFcs7fj0xS5vbz9wzjWT0idZeeDNFvbwXF1a75fvMofarEeoFb9paWSQGDfLGSuB5bYC+wryXwv8R7i7uo7bVkWQO23zVXawzxyBwRXpcMctw2Y1LD6dKmpGcdJsap3V7kun+GfLBLzgx92J/WrV5NbWSoltL5zKMKPT8ar2+nXF5L5cYJUHDMT8orz/AOIkWqLrj2dtHLNp8YAURgjf6n357VMIurKzYnZStKVz0SOCV4Tc3kqeX12o2c+3FEV4yq4ihRd3c84Feb+CNK1exD+YZVhbkqcgZzxx9K9Dt/MSMBsPkcnvRUhyO17jST3Gum8lmG4n07muW8K+GWtPEOpalcu8YLOLdUIw4bOd3fA9PWusdiTmIEsMkCsC1lEJu7q5Lo0O3dkduaSlJJpdTRU1JN32OD8Tadq83iOAfaJPsynzBJG/IPcsPWvR9C1KW08KFzD9tu45GEURcAuD2zXFaroljea2l/BqkSpO+7aeoI649q9J0yH7LYQoQCpbOSM7gOeRVVbJRXQqo1KDct2xmh3t1d2y3F7pk+nSkn90W5HoRjt9cVzZ0bU9Q1eS8ltbmAxXA8tFkULMuecgD+frXaW7skrTQxlkk6oozj6U+4luJrZhhrco3ynOSRWanyt2Rza3RmQxKlsZGXC7QeK5zxPo41GycRqplLiQsBnngZYfSu08LX9tqvhmIT7U89APlXlG6HOfcVmNpz2d2zSEbtxx/dbb7+laxbjJ90XGrzNpmDqD3mh6dph0CMyajPPFE5A4UFgCQB0+tdDpHxOgtvG2paPqAd7ZCEinUliSvBJHbkGqMLR3N3NNBhjC4ZFQ9CpyV/SuYnsba08Ww6p5ZmN5I7BgvCM3r+Zq+SNS6ktSZ0lL3ZbHu9t4m0e5KiPUINzYAVmwT+dQ69r9tptnJOby0SPGFaWQKNx6DNeOapJ4VuNafT9cW6tdRiKiOSFSoyRkYYdue9cn4rk1nwb4htrCR11bRL3aVhul3B1JwVz/AHhng1jDCqTSv/XkcjwtOMtGS/E+G68RSwXsX2YRWr5kuUnEnDHuR710+u3em+JvBIM8BvE0mRXUvwU4wckclax7X4WXlr4me80K7iGkS8yQk/NsPWJl6H612Wk6fYaFpt5ZOgBuiQVzuwAOPrXTKUVGKi7tbW/E6o2kttTnfDXiH/hKNNvbG5jVYQhjTbxx06Z49RVM6bJFoEumWvzSR4mUqPvkHnj6dqk8KaLdaX40e0ubaMWNxAxt54IdqnngMR/WuntdNhj1N0u2YQMGV1zhhkY4Pb60ScYS93bc3Urxemp57p3iLUtB02Y2IjnXcDJ5o7njIFa8WmprUdlqt5JJbpcMHlXH3T7H3xVzSPsVg2v6L9mS9aQ7El8sb4h6sO/ODVG3vLzSNHvLLXYEmRJAlpLbjPmfUDtWjaveKs/zRELvSxueDrWaz+Jkd9az7o7lhE0S5ORjgj2ArtvifprG3le2wJp42jBPqR61jfDDU7S3ura0No0WoyhiBMu1kj4wAO1dt8Sna28Lz3SIHaFgwH6VxVZP20V8jnqT5MRHseY+GPCE2reHH0aWTy/JtwhkHXcORj9K6G78Va3omltDcPb3MsShATw5PQdMg1L4K8Q29vbvLJLGhm/5Zsccjgj/AD615h8VtakufFklt9oaGxiKqAFwMlQdx75zxWsYurUcZLTf/M0kuapaa06DdO13xFe3OrOJLttqB1jkO47s9j0z1rkbK/1u61NoF88zO2dzEjb6k16P4Clg1TQrmGDZ5ikq8i5y3oa0ta0ya0t457NxL5akyqAA2PXPfFdHPGMnGxvey3MbSdHvpkW4ne2eZGClwdz474z0FZPjO4Nn4ijgaylkikAYSpk5bGCPTjA4r03wfNpGsWBR4kS52/61H5z/ACrm9W8Da6dVmvtA1byg4LSWk4+Vm6fKTxzWSqLnanoS8RbXaxY8Irstnmlt/KPRS4x/OtPSvC+lWNxf3aQBpLg7lWRQVUE8hfbmqPgTStdttTuE8VXdoU8vKQh0MjHI5wvQV114q+cy2/A6Ae9YVJcsnGL+4TqKtK5w/jfSVvfCstrbwqPJIeMKvK49AKZYX+r6HpPh6wW0km+QKfLX5o8knOfbjNdzJaPGVVlYKcMSvpTlszA5iDB85ZSp4/8A10KquXlauDa5uYxdf8P2vim2htdTllhlMiyI8eAyMOeP5VjeIIrLQ/F1quo2cbQ3sRtvtmMNg9j+lP8AGi3llrWnanaswQx7CM8B1Jyv4jmtbx9pMmv6bZ+Xh5ocSqCduQw5H16VcLx5bv3Xf5Gd05GT4k12/sxb2OgC2eNTtaSYEkdOwqxa3y3MaEqfNHEijhWbvgU1vDdw0iGeQKwA+Zf4qiu/C+r3VtN/ZbrbOjZZ3bBP+etZwd3Z2SO6f1eEPdeppXVlDcQhprV1B67CMD8DWbDpmkB/IgdVuXPdwuT9PWsa58LeLfsrQ3mr2TICCfMcsP0FcY+karaXzTWV7b3E0LgiJCSWwffqK6IU09pmCqHd6h4P120dZtIkaRM8qJQePz5rj9c1rxT4Y1J5Lu1nk0+XAlhljzEfUqw+6a9W0+8a4022llhNpdFAZEyeDUn2mdgRu3oeqONyke4PFZxrNP30mU1Oa3POGsdCgv8AS77UtWitvOiF3CrxkuATwGYDHWvSLK60/WihGowfZmIIYvn8u1YHjXwSPE2nxXOkxBL6NCht4xwU9h6d6oeBvDeoaRYSRX1rMwD7kTYRjjnOaqbjUhzc2qMIJXab1Os8Q/DO11C3Nzo1xH5hw2yQbl/Aj1rlZNHj1zTm0rVozYarYsQBH91lP8S+x/nVrR/Eer2HigrBHKunriMxONq8dwa9ciGn65ax3SpGJ9pVZCo3KT1FYyq1KVlJ37PsZVJToL39Y9z528XaNJoOiLFamWWOQ4ldQc8dM+1eXQi+S4RohIZVbHAxn0FfX3iSwktUOxI5IfdBu+nvXA63p9lqtrJE3+jTOOGVQp/PFdNLE3WqNoP2qUkV/hj4ylstPz4iCoygCMBsscd+OldRqPxN0AwSTeaGY8BDkYPYn0ryy3+GuozGZxewxWyDcZDJgAVkRQeHbfUPsssl3qc3+qMltwhPoCRzSdClOTknf0JlThKV2tT1XSfGtrqFyYo7pRM3zBCQcgehpni3wN4d8a3329bubT9Wk/1hjUMshxjJX196saN4c0jTbWJvsEdszDcEK/vB9fetFHRpUWxjVBnAbHJPvWPMoyvSbQqlOMtVoZXhT4R6VoFwLvUbtrt0OY1Zdir710et65bWltLDYxxxRxqTJPj7oxzj3qtdaLeXpL3OqsRj7itgZ9M5rPGgxPpF5Z3bELcxtD5g525H3vzqW+d81SVzOKW8nex5x4k+ImoTyLZ6S7Wdu3CBeXce/YVpfD59V1G/ulluJJbbbyzE4Vq5248G6jFqkdrLAJpR8vnoxwAT1B7cV6deyx+F/CrQ6fGQkaEs5PzMenX3NdVXkjFQprc3i30NJ5IIESMytNsB+7yKqLcv822PtkbTzXl//CU38zuTO6IuAyJ/DnoP/r12Pg3UdRvRgsDGU5YjvWMqMoK7NeVJXOthmzFuC7TtyeO/1qtpGlJqUmoW9xNgSRHdt5I/zmotSa6S0k8nJm2naB3OOK57wFre3VrrT3ila5ETSSO3A54we+az5G4uS6Gb0hJJ7lrRvC1ulo7WSx30sbFommO3J6AcfTvXIeJNa8Y6Td20moy2trLMT5VnEykoO4PrXqE7xaNYTSoGS2tUMrbRubgE8e9cTpLaL43hlk1aHzrW2bMdzKdjxkn7u70rSnO7cpq6JlzPWLNPTfE8R0q2lmn/AHtw2Ah6r6/h0rT/ALXeeMzXDCOEMEZ84xmoV8M6anlGON/3Ts8a7sgZ7fTik1fS01CwlhhJVkYMnHGfeotBu62NlKNtVqaegQ6TFpBWzmeayZmMEp4ZJMndG47Hn8qvQaz5EFxZ38ZkWRWaE7QQH78/SuV8MwTfZ7+6toby1uYj/pNkRlWfH3gD68jimaF4gk1+8mhgW5Fxb5LRSQcqDxWsqd2762OZKMtGxfDLW+jrNJqMq2731yDboTlnwcHj0561JfRajp3juz09YSdJmjZ/MYd+TnP5cVOvhddY8TQarK86Rx7B5TqAqFeyn04zipPE11B4n1WzsreS+jisrlSdQgXzIsnja2OV5HcUOScvVa+XYJ1HB6FjQr7RfEDnVLu2soL6zlMQnuAMfKcBc/yrf8R2SXsdtNPAsrRgtgKDsx0YV5/qx0jwx4gn0e6gnkXVbkSMGHyKCcDjg9Tnjmuk+Ivi2XwraWslnCtwIyI5QG5C+/4GolBylHk67E2tJNHFSeKtTksVhtbgwxxlhLuYRZO7qx6+gq0NRuL+wDTyCaSM7g6HJIHUAjqK3rGz8Pz3l1p1wsEi3e24dJOfLZhwfVQRWhD4UtdPSRLaBYznLRoP1rZ1Ka2VjVS5ZakXhnUhqOloRvyDtwTggjsal1jTG1aQSxuEvF+XJ6OPQ1i6HE9jq99GSdkn7xRjGMcGuqilUShywUY3Z9KxkuSd4mknpdHAeKdPuoLJZYopEvINxS8TO+ID+EkdV69c0fDaTUNVmuXucSvFGcAEDLDocdqveP8AxLBBpE10huJ41ZY38lQCQe7Z7e9Yvw18Yac+uNeCYwvGn71JQBuQsB174yK296VJ3WonJq6i9X0G+Arj+x/FK3OqTs2rGXatuxJdgc5yT34r6I16zGraDc267SJo8jP514Lofw71fxB8RdR1fUJzHZpc745I2B8zPQj0GK9ytmXSo4oJr6OUKAjbzghQDz9a5sW4uUXF6nBiZKck4/Ej5p8caLfQ2UP2BpGmt3ZZArZYg9/0p/hJz4u0ttP1uOVLy2UCDUEUl8Z+5J03D9RXZeKWlttZla323Nmzcbhggnr2z9Ky08Z6ZY3q2ZhkwThmP3A3pnrXbzylDRanfyqWrOi8JaEmh2S2pvLaS5lYyZHylx2Azg1v3OkzX1ncxSw7fNQgEn5hx6Vgz/2H40svsDzJHLFgR3EEmXhOP4h1xXNXF/D4Enitbq/1DU2kJYYICqnTO09fzrn5ZTd7+92sQ7r3SfwpY6ro+u3HmxoliAwlZsbT6Ee+a7DSvFkTawtmim4iIAaQfwH6elZmo6laXUKDBP2m28+N1/iQjGR7juDXHWBi0fXTO10sk0ib0i5B4PUnp2PFOVqr97extGkpRvJbnoE3hGwk8WyeJYJrhb3ySHQPmM9vqPp0rQ0PU7TWNKbULSVmWKUxSbuqEdTV1bq3ttNfUnP+jGI3D8H7m3J4HWsLwXY2Vlod/La3ST2GozedBjg7TnII7Hkj8Kwu5Rbl0sl/kc17aI17TWINWR7vTLqO5s42MRZP7w6itMTOj28bIqqrZ3iuf8P6BaaBp7WOmmXynZpfnOSx9Kd4d8VQa1qE2nXKRwXMRO0BuuPXPelKCd3DZBJabGgsum3t5Np94I51QjzYnBG1vX/9VReItTi0fWNLjugUhuXMSN/Co4ABrjPiAL7Tr+e7si8U6sjMFP31/qOn5Vc8fXEmteENFvdm3zXXHqknQjP1z+QrSNK7i76MVldPuJ4c0vxPp2t6hJrUkstmSQrSS7lkIbgpzkcdeldTdtIQTGsi5O7GeRx7Vr3dlNdaHBKsm6TywWXP3uBnHvmuLk1yzivXs575YLtfl2zKQrH0z2pczqvmt9wU3zLXocN4w1zUJHu7a2xgNsMZ447mqPgaG5utdWAKpRCHDKNoUD+teh3tnY6hKv2u2SQ4GXA6j6jrV3S7KwsWJtYViiOPujJP1Jro9sow5Ujoba1Na4niggWaa3jmcEBj3NUbrXtJtEE1zaQRp0IlfA/CqWt3cphYRAKMYXGMZrxTWLu5udQkS5DNco3yhsjH1rKjQ9puCppRvI+g7HxnbvG76fbwKCOGjYHJ7c15J4h+KHjt9ZNkFisYDKFQJbbiy5/vHOfwqHwJFcyXe2Tb0JkReQBXp/h+G0mbbcyL9pVsxo44I9R703CnRbbjczqUKaXMl+p5P8TdG8V6prDXdtFcXGmuFMcducBDj5sqO+cnNem/Bi21az0uKHU3cyHPyO24queBn1r0+2trW6TegAYqN6ipbexhsFLxR5KjgCuepiueHs7HHLEqzjbciv3eCBlnjWaM8ZPaqyeH9LuYI5DByRke1Q3+t26TgTMyp08pl+9VqDXrEgqrhQo4FYWkloY8tWMbxT+RTvPB2m3VvLBKHMUilWTPBFZdr4A0nSrfNoqRtHyhMYO2rmseKHjcW+np5lxIPlb+Fa8k8VeO9Ts75op4Z5Y42xIzkgEd8dhW1GFapombUY1p6ylY7HWPtFo8otbwyPj5iFBI+tecy+L5La9dJtYWUrwcQkge2RWzour2fiCFvs08kEzDmN+p+hFcxqXga7+3GSJo5UYY54P/ANeuylGKvGZ6SXKu52cfiR5bKKWSd5oXyNyoOfbpmuj0PVrO5swnmsrgYO0/zFc54f0eSw0eKzmiMxHJOM4+lXF0+OGXMDbXb+Anaf8ACspKD0QSjGSs1Y6TYhG7zAwH8VUr+yi1GBra4wY5BtIJwPzrF1TxFbaCNjW/2i4xk7jgKPesey+IL3F0onsY2hYhcR55z0A9aUaU370UYWfQfffDC7gvTIhDWo+YOHBJGOld1oWnWmnWwSNB93J9TToL8WwXazGPp5bHOM9s0NNBAxuVjJ3DGG/oaic5zVpENzasxk8LF22gHuATXG3vm6f410+304HzNQfzLtmAJEac7R6ZNdALu6luyfkVHPQdSTVjwSdN1u9mv7VRJLbM1u0xGOFPOPbP5078ibY2+WN2cr8Z5tQh02OXTIZHiWTEoXJAXBxuA7VkWSw6rpa2EKRWyNGrSwrEF3NgfMT6g4ro/GHiS+0jxjpdha2zyQXbYkdVzxnp09OaTxNd2OkSw3KaWZVlbbgHy0XHritKbajGNtehdNpehK1zJpWkWSS4kPCEqcHbnitu5aSPTImhUCKTrzzXNeIrpL66sIEidRdoJFY/dUZx/SuigiIsR5jsI+VAAyAfT2qJLRN7lu1kzsbKK2u1ELZzjKt3U+xpBC9gZQuwt1Em0Avj1xWX4a0O/wBF0aC1v7pbqa33hJozk7Qflznqcdaj8Sa9Ho1nFdalM0cbN5ayFMru98dKy5by5Y6nAkpO6ehstd293CwYBS/OCO9YWjaTbaK9yul2aQy3BaR5VbOWI4yD6VLc6ja3Onie2dUDx7kkU7k6dRXkvgG+uLfxnNcS3V5PbXhZEeJvMgSQnOWXqvT261pTpOUZW6dC+RRWxueGP+E3n8Qaa3iOxgubNJ3SeeWOPzdoJAl9R2HHXFdF4p8ME+M01XawtbmLbO7OBHGFAG4g9enSuLjg8QSfEm1u9ZWewLOod4Y2aGZRxxjgBh19DzXV+KPFlppOlf2b4g068udGuWa3uXzzAezA9SCDkfSt5qSmnG2q6Eq69+LMbSTpN34/8QRWlnci/Wwyk7S7oZdoX5guOM9jkjitPwl4gm1G0vPtLOJrafynRgcqM4GD3q/4DsItO8NXbabq8Wo6ZJODDMq/Mij+FvTtkfj3qp4xttf0WJRYWi3kc6GVpkQ5DdcHHXjpmk3GUnBeW/l6/ka05raXUW+jna5uIANkhVyhHHOOlcfp3iQ30d1aMxV4kIJPVvf9K6fwFrz+JrOW0uEK3tqokG/r1wcHuP5VxWoeG7nSPF+quilbeW3kmjOMgd8VdNauE1Zo6lOzsjpNC0qHVdGv7O+klSK8j2blwCOcnrWbrvwz0q08J6i2gLP/AGgIuZJW3GRQwZgAPp+lL8OLya4sLwPvYQPu3nqoOBg+nWu3laeeS3FrGxdP4c/KAfX260SlOnU0ZFSCn7yNC78Ur4a+FFrq21VungSMZ4BfGM/jXhOm+KNV1UXd1NdS3E0r/MoY4A5OBXrPxcsptR8E22lWwi86GRHlQNn/ADgVl/CX4foLa4mm/cNvCgt95gPvcelRRdOnTdR7tmVG1KLm9L/0jG0fU3js3l1JTLKEO0E/eHUA+hrldQsIdeuRJHGkFwSR5YO5cn0Net+N/COmzzqdPdbeZBjcB8smPUDv71iS+G1FtaNDFA96uA7oMFsdOvf3ranWh8S0bNVPnVzhND+0+G/GNncShxBKn2a4DptOPWtf4rxNNdaffWi+fCyGJgM5xnI5FdrH4bS7WH+2Hl89QVJhbnnt05+tVtbv7jwnfWdvfaalxpbAbLhDhlPo3v8AWkqic1KOr/MHbYl0fSWXwZoRnXN9bRsrRt18p/4f5GuI8WaRcJcxagIG8u2yCwB+Zc5HH5/nXqKeJNNkuoUJDNKPk3fwnHFRaok3222WNo/szTqLhCvDJn5hWEZSjU535/iVCcowdNrzJk1CyTw3pEeoyQ2sN7a+SkLtgnI5Xn2rD1TSLux0/S7TQ5H8uEspAGS5zkZ9uTWn4s8NP4nvpYLsIEtpC9kquFyoxkKPpWtFauIbb5mVrcAEDqeOOahTULNP5GdN6asnjZ7e5gZgQQBuXtk9RXC+JvDd4NcOu+HYw9yHzPEDteM9NwH8SnvWh46+2veaddWJkWSPOAhxk8Hnt2rrNKujKkd+0fyzRgNuHfoR+BpxbpJTXUmV7abklnINRgjivoImn8vY6sMg5HIqjfaHa3HhwaQxdLQtuRgctGc9R+NSTXcMV+rIyxhj36hhWzbvHcMY3AUDJ49T6Vjdx2Imra20Keo6jJpGkyZHmx28ZckDkqBycVwbw6H4uVdSiWVZT8jmM7WBHZhXokgiSYxTqGUjaVPQqR3rz7S/DU3h3UdRNpKktjcDMO44YEHgH6DPNa0Wkm07MqklfYvRf2bo8EdiJ/L3HKiVuT7+wq0wcKCRwenvXM+LbN7myS7kuNs8K7TGozvGf51h6frWoyAaeC8mzOzYcED0z3rZUudcyZ0LQ7+REI/eAY9MVy/ij7DFLGZrVX3D5XA2sR+HX6Vc0mxvom331w54yIyc5q9JAky4mRXXqARnFSrQl3NbX2Ynhi3tf7Paaxj8tH+8xHPFePeO9S1fTvFNwZZZYgWzCw6be2K9vsFKlY4/kQHAVf8ACo9X0Oz19Ht7yGOZFOcgcq3sadOqoTbezM5XWzMz4N+Nby40/UE1R98kCgo+MF/YV1lv4xEt3Ik1wQ5+RUUcZP8AWues/DlvpMTizhKGXhiecAeleaW/2iz8QSK5lEbTfePOOaSpQqylJEKjTm7tas9J8RXWpR37T3C74RjZjOQvr9a0NIVLpgu8ZZcgscVNHqcGpaRe2zSq5Toe6/5NcnrMF/bfZJ7bcYlyJAP4hxg1KXN7uzNKavFwlobt3bSxXP7vcoPTB61W1DTodRjZb6MsTwWxg1Q8L+IF1aK9tfuT277goPUdOP8APapx4khgujBNLImW2guuUY/WpUZRem6L9nfRlKy8L2NheLdJKIth4/h/WuvKWT2rXMkxiSPGTJjbn6ivNfGGg3eseI7d2lmNqQCRn5Ac9B+Aro/ElhLqHhWfTbR2RwySLg/e2/w/jWk1zON5bmcovluuh0NreWrkSW9ys0f8QVskVha5pt7Jdme0bdFu3Bwckeg9RXm2iLfWepxJEJ45d670Y4xk9CPSvX7YYclNxHcjinOPsZaO4lG/vRZzN/odxqMYZ2MczDafX681b8P+EYrF45LhxOyEEL06d6vLqEAuzEzHcCVVm4B9q2ICZo1KA7sY6dKmdSaVglpqx7BHbjkHnpT7a7FuXjyGQ8lW5UfnVWRLlMsI8hfQdqwYftq68LiMsAD8yHkH0FZKN07i5FPQ6m0s1uY7i4jUAKwUBeMZHJqhpk+l+BPCzwq7uplxnALsepY/rW3a6cLfQJ7q4J85wWRc4HsSPrXmdxBNfeP3F1aLcadsUFGORIwXOcdsGlC07qT0MlD2rdtbfodXr1y0tr9rtAGdE3DcM5U81p6LdW9/okRmt3j3KS6uMgt9DWRqdzbQ2m+6JjtB+9m/h2xgdPr/APWqPwjqN/rWnyXl5Atrbk5toAORH2JPvSteN+xrOCskbd7YQz2NvJIg3QMWjKgDb7D2rN07V7achYZguCVcEZB9DXS3Zt20nKvtBH864XStANjdM5wEZtyrg9z0qqdnF3ZNO0k7nrtvdxiMRSjaQflz/jWNrFlBc211p2pQi80y6GXT0PqD2IpNWlgtLWaWffhF3fJ1+oqh4U1r+3dPa4t1cFZDEpZdu4j2rOMWlzo41CK+Zz+lQeHfC+sDRl1h2aeMbLG4myACSQRxjd9K2ovAOlHX4NU0+d7KfOZEj4SYejCrer+H9L1G9tb3VdJhlvrbDROwwQRz+NWra9F2jSW5C+UcPHjlf/rVpKpJ6xbv1GlJrRl6X7VpyyQKyyqql0XGc+wFc7cyR6roE9wbBi4Ry1rcJjcR1TB45zxWlqOqW9hYPdzhIkBDGRQfXAq1ZXCXEm65j8yJkIYHlcZrOPuq9h2lFXsch8M7bSja6jHpENzZNK6mezmY4VscEZ6dPfpWl4P8T6lq/ivXNA1GwktDp+2SGQg4kTpk57/SukulsoAY0iMRZcb16sPc1iS6zqemQGNyk8edqysvzbc8jPrirlNVG3bfuT7OdVe4repwHj7U4fB3iMwaTbrDe6ioZLgD+BjyAPcis3wTrF5r2qGw1Qkx3SO0Luu0K69UH94HkcdK9F8f+DrXxaul3CqRc2yg28inA28HafWqtt4bTT9XtpWeJbi1XEQbqB1OK3jVh7O1veN6VS8dXZnL3kcHhDwFPJZLK11q955TFiCECEnNXdDv7i5ssSqY59uG29D7/rWv4n0a1utOEM5822tkM8ZDEfMR8x/SuT8O332xY5oAY4Vdo0GSR0GQT64xVJqcHLr/AFY2oLfzZ07yG4ieRiC5PzDPeuue+g8PeBWvZU3tsMgQY5J7D2rx/TLmRPiLe2Ee8RzZyvbOAc//AF66/wCIOsabb3ul+HbuRsmFVcA8Ix6VlKleSj8/kTiYqbjBdzldJ+Iw1PVFhmtUSMuFEiE/KSffqK7Wa7hgRLid0iSNwS/AA5ArgH8PWen30EsRSaPO/wCQ85HqP611Wt2B1vw7PBEdvmIGH1HOK2qRhdcuiNFGyOU8Y/EXUf7Ylj08JbQxy7V3AEsR3z/QV6F4d1W08X+HDb6nGu+4UK/Ofmx056eorgtL8JW2t2tvc3rzQTqMSJtBORxnn8Oldnoeh2+ioq2jM5LAjdzk/wCNFX2Siox0aMeRNWehzR8NCHVFtRK0a2z7XyPmOO30p3j25nMfk2M0i3MZ3KiEkyL3474rq/Et5b6XnUtV3xOh8qUsvVuxrktRk8q/t9SlSWSG55ikjAIAxxn9f1ohJyakzWLUkmNim1U6/oHiCLT7m5jtI0V0h++W5GGB5HBPOORXqTqfOd2VkDNuKdCo61xXhHV1uby6udKDPbw/OSw4HsT+dejafJE9rPM5G5lPJ/hFc1abdrq1jCvH2crx1TMS6k0+2T/iYyL9jk/iYdG7c9jVuU2zadCLKRJLbHy7ORg1h3BstasZYEmjmjRuHQhtp9ap+HNJvNIuruOZ82bjdGM5XPt9e9LlXLq9UVyK9zM8S2Oo2er28ttG0tpK4AdRnac8hq7S1Voh5WGyRnJ9etSRSrLGIShYOd2Dzxj+dKI7qJxIqm4iBDh1xlB0ww9PcUSm5JJ9CXJrSRUjnln1yW0mjJjCjy5ePmGOKh1GEKp2ths8j0qxe362EwvBF5kJHzDrgen+fSua8a3VvfaOLuyuiio+c4OD6qccinCPM12HBtNFXXdAF+yvGSS2A+HK4A7r71p6bpFtYWxaNYkn2jdK5LMxrz678QTPp9pFY3LkqxWTaSCTxg/TrXaaDqJudPRpiGkHBPrW84zjFXehs4uRl6pNLbXBH2pncnOC3H5f0qF9b+zwO5jy2PlHc1oX1na3V5vKEuW3YHr7elX4LKBXR/JjDIMA7ckDNNyjZXRteysYGlPrN9epKkbpF95t3HHsOtddpzyWsbM0WVYnJ9DXn3jfxbcW6eRprvbocjen3n/HsKPA3im8CxQ3zGZJTj5jkr7g/wBKcqUpR5rGbvJWO317xbY6KkBvi584lV2KCF+tYuoafZandw3lv8ucPx0rc1LwpZeIIHtL6LeuQ28NtI9xjvWdaaG2gxmx86W4RfuySdQvYH6VknGK916iouPM0jG06J9JGsSShiIlMjD+8DUfgPxs2rarJpV9HCI5tyxsvIUgcda6a5txLZXdu5X97CU3OcAe5rzTw14ZvLPX4Z4jDLBFKGE0b7hwD/nFarlqRk5bjkm3Yk0GyufD/izWry4jdLSEvwRw3PGKrXPiFtTvDFclNg5wEAwO3Ner7LbUJLpL+MsjwkyKOh45NeUW2k+F576RBqmp2T7wq7oBIPYEirpTU25SWoOfJZWPT7D97aRxj5tqgg+2OtZupWl8sn2i0mICfwgitaVE0TSiYwbwpCqAgYBwOuK86tvF17calscRgMcMrdAawpQcruJSlzPTY6m51iyRrdtbtlEzNsWRB1wOp/SukgkzEGhw8TjcGHcHvWE2k2d+YZriESNH9wFsr/8AXFblrO6qIjsCAYAI6Cok1ZWCcUm+XY47xbp9xBK12kTSwsAziM/MpH688U7wnr0jXaWhEyM8ZcZIYccnJ7DFdb4ibToNNLSRXN3KfuxRnA+pbtWDoyxahY6hby6HJYR3MBQ3Yk3YB6ZJAI5rVT5qeqMJVNDpbLUGvY5ZLdkmjUkHByoPuR0p2maVItyLm+O15nAjQ98/xY/pVT4YaPZadoV29lfi7S4nCvKR8q44JxWvPqOmz6uyw3K3Edkhe42nO3IxjPqa5anxOMehEajTcYqw/wAS3ymdbOCZWijVVY8YLdh+map/YrZrySePYpWMF2ztGK5LxJds9mz2rCOcRtKAo3AOwyOB6DAqro//AAlcfhrTZLW0jvLq7uQLlbnjEJzyeRj69s04wvHc3lD2FNa62HeKTH4hslt9LnW5EMuZVh4zgcA56jNdd4dE9poUS3KpJfBP3i7uCB29q5SLwrrek65dDQIbWLSJJMiV7gbynpzyB+tdtqry/ZRHYSW8cwQZUY6dzjrg1dRqyjF3X9bmTmpfCcz441RrXSswAqpPCtxnHX8queFtTXUdCt5oWbcm5WDjmnalYR6vbG2nFu90qkwsTyCR/IkVm+EXeyt5dJvrV7a5RtykjhvXnvT5YuF1ujbnvHk+Z6NqdtJdQRi2JEgYYY9Aff2pbVnSEQTwJEyc4jGFPuMU+9juLRWuLZhNaqNzr/GuP51W0rVLfU4opreVXjyTjPK/4Vjry+RwJ3Wmpqo4a2ELqxwcqTzg1nQWGmWEwvYy6zTFhMrEnf3OB9atsVUYOQG+6x9ah3HcFk5Ykgn/ABqU2iVG+xyXijSddMrXPhy4ivbFwC+l3SgqxHOUJ/lmrPhfU9VmiJutJnspFfaY5U4b/dPcV05WXaDGnyDj5Bnbiq97qi2NuHcvJb5y7AZ2fWtfac0eVotN7bnPeNbXXr2S1Ogapb6dJHnzIp48iRuvJwePatXwxPqF5oXl6/ZwQ38RKMIiHSZOzj/CrN5b2evabcIXMkU0eNoPJHqretcz8P30yOS8tNJ1lr2O3cpJBIpBRgcZBP0Psad+anbt5fr/AJitf1R3Fuyxw7RGP3a/IoHb6VkeMJ7ZdMTU7u2nV1IXMX319D9K3IfJuAPmKlTg57GqWs6VeNp91b20katKpETOu5VbtkelYxklJGd4qV3uYFrdWmueHrqSyfzFCiNlZeV4Oc1wPgq+tbbwtNaXBSOa3upIwD1L5/wq54YutX0dNesb3TTaaj5XmKUUiOUKfvL26VSH2fxJp8+oaZaqmpWrrLdQKcFxjBbH4fyzXcocvMntodlO2/Qk8D6bPeeMH1K4mLSD53HQEdB/Krfjzw8ZfEL6i8Z82YZV3bIGRgceoqz4Ouomk+12cZFxCHVolOPNH90/Qjiuc8U6zqGoanBqFkty+nE7ZFUZaGUcFXHb+oqlzOrpppY1n/E5uhhTCCGKI31wYrhFKmIqfmwf078966HwndMY7q60+G7uhCu4wxISGBOM/wBa6qO/0xtK+039hFJJ5WD5sYJ4zxz/ACrL+H3xNiuNa/sq60qCxtXDeS1qCAMDPzDvn1pynKcXaOxE6k4rRElz4onW7t4Dp1xDbMuA8sBUg9etdFY3YMlvLK4WPcPnAzg9v1qPSPiD4c8U6jLpD2E9s+4tG8qgh8D26H61qRf2YxMMJiSRePUexxXPP3dJRaZKqOUbONjD8dyx+IbA6bcM6xqwE0qkHgZxgHqc4NVZ9F+x+BLfThMJtsbKkp+UDk9qi8aW0OmaUWtWkeZ25fOAAOp/z61z2r/2jaR+F9WuLiVdN8lUmwSVySc7l9+Oa0hG8UovS/4jhyq1i6fDb/8ACBjTNMuDHNJfI9wxOC4x39hxxXqKWaRWEFrNllki2MOhYe59xXlOs319Pqen6DpcQ8+8iNyZFfa2MnaFPuFJ/EV64I54LHTkvXzdJGqu/Xcfr61jVc+WLk97vzFiHHn5Y+Zxug+Dm8O6rM0DzS2sgKszY2leo/EcCunkgH2dNsuXBzjpVu5nUkoMqig4A6Vi6vpbapJCY5pIY0cM4R9pIH8/pUObqSvNmcG7XZT8Z6TdanoDR6VePZ3gcSRyIxX5h2JHY1nyeI9W8N+H9Oa+jFxePG0ckkeWUSY43YHQ/wCNdfNbhYDHk+W4HPcVxOkeIby6a+025gW31iBX2kLlJMHG4A9++PQ5q6d5Rs1dIpWka3g/VLTxbo13FIv2eZ1McsZH+ql/H8xXP+FfDWo2EerW2p3pVAmzkEnOchs9CMD9aq+GfEWpx6rJbanbxI78b44wu7HGTjqfrXprTi4sQzjcQNr9waqblSbitmKcZRd+559p/h61iMkjhJWIw2VGCKqweJNHtLl7KO3dIkJRnQcKe+B1NdRexogdYBtjb+7xiuWh0GyS6eW6MW5yer7N5z9ea0jJSu5nQlpc7PQYbKazFxaHzGkzsbH3vpUUtrIshLoVJHzZ71z+u68PCekRybdzt8kUSj5V7/hXIQfEyUDdcR/un67M5z75qY0Zz96OxFmm3c1tV8JI9xK8DIVk4IP3l+ntV/wx4Ws9Ou7csS1xk/K+FX61H4bKeI52mgnjRUI3Et69P5V2x1vTNF2wTlZb3IUsyg/lmqqTmvcWrKqSsrR1ZoxGG3gIkJjkGc56H8a4nxH4ls7O9EJkDyAc/NzitK/u2uJ3dHOxz6/yrzS58Pz3fie6PzOhlz5jJ90euf0qaNOLbcmFKny6s6PxzdyDwXd3NsWw6KMgcgEjOfwrlPhpJdS3WBE6w/8ALR9p24I9fWuo8O376teahaSQCXSIwYGjI4x0Bz65Ga6iz0+3sdPWHTodiRqdq7iSx9yea0cvZwdNrVlczUr9Co8jWUrXKffQZ2/3sf41meHrHQb4tf6XCVvM7nhc7ghPcCqXhK+vdY1VrW4YEupJGMBMGnXVlpOheIwNM1uBLlyC9u6kI2ewbsfrU8vLeN9Qm43Xc7Z0iktU80oD35xXA6r4GimvjPayhCzbuR6mqF7qd7Hq8tjcO5AdjEGPqehrt9LEklh+8bdg/L+VFpUldMFHl6kuk2Rs7WOGRy7r3NQ6pcparvkOFA6YqO9vbq1hBitzOo6ruwR9K5ufWINbuvsk1tMjdAuCPwNRGm5O72KvZnY/D/Un1uG/3kG3if5F24I9j7V11nJGdLuLRol+ygGLnoQevNYHgyxt9PsbuOB0hPDOQeeB6muM8TeINb1LWoNA8NJ5abw1xP3/APrDHesnD2s2o6I45w55NHVR6QkWiz6docDW9rEH8sBjhpD33Hr9TWcdMsfDugx6d5p82aQTXMgblyD0JPr0rU1/UrrS9PFhZGM3IUDfJ91fcjvj0rjbuKe90yeCa5aW5A8zzXxyc+3QURnfST3Z1UaEn77+FF/TIBNqTybMbj8mRkDP+Aqv4z8Sa1prWS6BZrcQyPgsF3gYIAxj1pun3sFx8Mbu/maeJGLWRlQAEAgAuPXrVDW/D+oaT4KsbLwvNMzRxiUSFsNIGOSR2B56VdOmoytLvbUdev7aWmyIlhk0nXoZdTvpJ5L+BpjZybm684Yk447YxRpy+d4lkniMj3UpHyk8KvcD2rWsLCNZfDw8SXCLq0kLKIyuSc8c1oaq1noeq2MNld21nfXDbFaSEuWXpj257053k7J9Py/QqlVjTja130KMWl67deM7r7QFh02BFa3uUCkhuMg9yCc5BruLqaGS0KzkbyfyNI6xy74ZAqiVSrjOMn61k3KWmg2ZQb3gLFsHLuvHb1FZOXPY51rpI7lj5UzRhuMcH1FYsXhu0069e+02KSNp+WRW+Qe4XtV27jke3MSknHKMPvL/AI15xdT+PNM8TwypcSXWntKF2ADy9h4+Zeo+tOlByulK36nMovdM9ShdmYxtHy4ztJ4P0qrIyLcKgZ1Y8jcOnNTxuLiISqrK+edvb3FQ6rqjadZC5uLQ3EaH55IxnA9cdjWSTbshJ26HG6trviTw1qEkuqaObnSnbcL3TskbfVl7fpXT6ZqtnrUMd9YTI4cY3Yxn2I9afo3ijTbpVGm6lDKjZBt5GAdSfbrWk1pBLKSIVtyfmzHhQa0m1s42f9dBKTXxIy9M+yz3EoghW3eB/LkWNSq59cdPxFPh0bTrW9nvYLaJLiT78qDBbvz/AI0zVtUg0m08y6VmXOC23JA/CodK1KO/sXuLWTKdA7D5foaT5rcy2NFF7mjKhGZIWwJBtz2z2zUHgXxrp/iq81Owt1kjuLB/LdZBjcM43D2yK5i28daPHdSQ3UklqVYqxZS8eRxkMM4q54X0zSLPxBfa/os3mSXq4lSFgyHnJYY6EkU3TtF86d+hNWk5Kx3l1Yrdh4LiPbCchXUjIPrXjfjvwlqnhNLrUvDT+XvdZHkRMllHUY/pXsUl19piUCQx8gkjqagmZUDK87mEj5lYBgB+Paoo1ZU35djGlKcNH9x4foF4b+/W7t7Z7S6cgXESn5Cx/iUda6i4s7WG+uL4mS2uZVxKuDtc/wB4j1rqNY8KWUts0tiEVwdw2/Lt9wRXCJF4w0C7WMiTUtLGcMyiV0HY8811qaqu8dPI741YySsaVxo9tdgxz8xN1Ibge4NXdG0LR7EKbeGJfJ/5aYycema4S68Saxf6qbOK28xFcbliTGD9OlJ8RNUubbTbSwtHmWdiGlEfQDHAyOvOc/hTVKo2oX3NJpOOr1Ot1nS4E1BtQtI1jldTEZFGD0/wrG8E6HqUusziZXEBYEu3QD1z3rqNCW8u9K0+OKzE8AgQyzy8c7cEgfnWx4Z1jTL4X1rp6MZbRtsj7cBvpUe0nCLS1/QznWSilFanE/ESS6OpaZZ22nXNzA0jQTkISoOQBj8CSCa7m/hs4dFGl3sKNbhNhD8DHbntUPiLxLbeHrfz7sErI2E9N2O/5U/Rb+3163juyqSW06kc8g461Dk5Qi7WS6mOvUPD+gW/9pW+oxou+C1FvGzdNmcg/wA66zVRGXhyNxLA/lTYJIbeCKJIxHGBgDtjtVW/k82VPJYBl9a5pScndnO25zvsUNRkt40d2YDahLDPI4zXF+G/ECatY6hBZR3HnWuSiyD5mUgkHjtxU7eHdTi8e/2nps+7TLtcXlu8n3HA+8AfXiuittMsdDeT+zLaOFpyGkKZxnPAHoK39yEbbt2/pnTGVvdRieDvES61DcW83y3MIywxglT3/Pj8q1m02zkvrW8u4ys8R2rcR8E/7LeopF0iFdTN9p8IiuLg4m9AOpI9jiqz3aa3BLFpc7KySrnnGMHHfqDzzSdnK8NEN6lLUPB2mtrTa7cTTL5CGWWKIZEm0ZyMcj6d65e38e3d1Yz6rpelTfYIZNkqydWj7OMd+OeuMivSEvbWLUDpv2qP7YiZaPI3bfcd6z/EGnzDTHt9Jkjs7hEJiZVAUNnPbseauFTZVFft6BGTvqZ9tdQ6rpyXtiSUcfOpPKmuE8ZRNFfQM7q/mgbIxztAPP61taJc6oILvRtW02XSr24/1N7bRfJv7E44we5HrVWy09tXeWDxDbsmoQx+WtyGIDqc4PHBwTn3reC9nJvoaRm3ojpTDZa1ZKshiZZRtdXIG6sSfwJpNyPL+z7vcEg/hisSbw7qnh61a4trpZWVCybRkEZ67T3rMtfF+tLcoEklZt+D8mcH39KqNOWrpy0L0O+i0S08O6HJDp6K0h5AP3s1zuhaTeX2qNfahFshgG5pJDwf/rV1cMMt7aR3nPmsm6RT0Hqa5zxZpV7rFuLfT5yBt4hzgFs9T61EJO7Te/UaWmjOhtZNNvD5Gn38N1MGO9g3y/Sr9xZ2luTElyGm25PI59cVwFj8P9Ys7cuNStLScgYYtuH5CtHw34KutAkl1C91Y6lKy+WFUECMHknntUyjDpInn1SudjoGkWcOk3CIQrOS7IvUn1NYup6hNp+mzywKDIgJUntzjmuhtb42mlyKrbjJyf8AZ/GsS3jW4WVZlV0K4Kt0OTWcXq3IIRb5myn4SmSWc6t5Ecd1IrRytH0J7NjtXkGtWd1DrV9HMR54lJd2GfNBPr2r2SzgXT7kxaaqrDI25xncB7D0qrrnhq21G/8AOlYrhgxA/iFdNOqoSbezHy6mX/Y/9saBp9ycJfxxL8zfxAetdXpkM8VhFFKF83bzt5B981WlkFna+bEg8qDau3OOCcUtlqcbMsYZVVicbjwOfWsZSbXkXyt7GpHC0rLuAAJ2gnuazZ7CFNQCCMC4U5OOgrQnu2itZp4ozKIscRHcSScAAD3o061Y2xknt2iu5SSxeQEgY/Q/yrO/KrmKlZ6mRounXcuvHUdcnCopZLPTYWyqDoJJCOCxGcDtmuvsLG3tZTKsSiVuWOACfxqnpdjHZW8k0kuepMsh6nvXOP4/toPGf9gx2VxOVKiS4DABSwB4HfqKlqVVvl6GbV3ZDPGNrevqrSRwvJHJjBUbsEdqk8NaRLcXZgvYGjjKZkyvb0Ppmu7vb+PS4GeZYYwq5MjHJrC0jxZBrbzx2LSDy/vEwlcjPYmskpP30joWMqSo+yUVbuQ6rpdnH4Yu9FsbKH7NFExghfld/JGSevNcX4C1LV1sp01ZjfagHGyBnVDGg44xxtr0hrfcjBcksp61kaboukaDcPbwTKbmdgXlkb5m9Bn0rWE1yuL1OaFouyJv7DXU7+01XU0WOW3/ANWivnB98VPe6dZ3d9DdzW0Utxaq3lyFMlc+npWhATDIV+UDGM/4Vzepa5B4elMeqJMVuThJokLDGeh9DUx5pu0RpNsv3Nm13ChQlWx86rxz7GuNHhnXLF2aHU47mIsQYrpWBb8RkV1es+JI7fSUXThH5sq5STt9cVy1v43utPltYb4CUTSeUZcDIP8Ak1dOUl7q+46I06rg52sj1VlPvj2pGBIUP8w6c9amjGVprRlwwH3wDtz644rE4blOApFdyeWAOCGAP9KtNIsQODmKRPrXlLeEPGbai0Z1spAJN8c6vhvxGMn6ZxXp1skkUflXL7z2bbjNa1Kaja0rlSUXszH1T4deHNblS8jSS0vQP9dA2MnrkjpmtfT47nTIo7S9ZbqPAVZ26sQO/oanYmGJxDnceRj1p63EskGJY029WyKlzlJWk7ozSa80OuLRLhSvlrIQPusODWdOsT2z2BtTHCyc7BjHapJNSjiZNu7rwfSrkN7FIWkLYkZeXPPToB6VKuiuWS1aPMZ/h5axamJra6meIt88ci8n/gVQah4CuIrxbrw5qL28oPzBTsPt0616stxFKf36MGA4cYPHoaYYrdJGeIEu2MHsB71t9Zqdx88lpYx9Ei1eGyhXUJElnCfvMJ39QfSo9WTUZJozaBUGdro/Qj1Fb5ZSwIGGA/h6Gnh4m+WTzE9ehxWXPrewe0a1sZEaXNoEZ2cx+3KgVNHc/OHg2EoezDitCWylUBradXjPNcv4i0KO/AN3alWU/LLCxDD8aI2luXGUZl6f7Ibl51tEF2+AWEYDEemfSuY1eTTPtRXXLW3ikTPlHzsZGe47Vt6PbS2lskJkluY1Jx53JA9M0ut+B9M1u9iubk3MTqAuEbg4OefzrSDjGXvPQrmjS0NHRXeQRw2QRbUINiqeAMdjUtxYLZiaSC2iieU7iU/iPvVyx0y20yGJbeQQW9uoTLt1A96ydY8caHYTrDcSGY/9MucVmk5S9xXOdzcpXgjjdAuY/HelXWma1bNDcRsHDxdhyARn64P1rsvCvh618LWL28PmS/NlFPHHrjNaWgwaHFD9u0iJAtyN5YHqDzj2Ge1WZpRc3its+VAV4HINVUq3bjHSPYUpub2siOe5EgKSRBCgGAetRpGrfOeMjPWrMyLOxKAAgZO6qyFvK3dMnaPesio2toKF2I7KRg8Y9qhPkbBukCv/AHSKl3gLt2nn/OabI0Yjzk+hLc9fSgtaDQAUkTqhUhgOpBGODXF+DvA48LajdXiarcXqT5QLKCNq5z83PJr0G6jj42LggYIxiq5k/cGEgFGyeexqo1JRTitmKMm9UcZfeFp38ZWuvrKCikrsGc7sdD7Vr6YbjUNMuGuItsiyskYP93sa01uBBKIzIAz84OcmptOdW1F7dl2iTGT0z64q5VHJa9C23FXPPdf1bxbpElq2hRJcwxAia1lUEsM9R+HpUvjLRr/XtKtZrC7utGvNvnNCvTcV+63pg1ueN/CF9Nphew1o2ssTtIDISF2noCR6Vy/g7xJrrSyWF2bDVTCpKywy4cgexA3D6VtHWKnC11/XoCnGfvRNPw80zadHaau264hiAeQ8At3IP1qT7LELhjGi7vXGCf8AGrmmar4e8W200IiVbiMlJY3G1kPtVaSwm0SXCSy3Fk4+Vjhnj/H6VDdm76M6YTUnZKzKHiTU7mw0yK0tIXa4mbbnbyme5/DtSaJY3ENtvuWIlYZI6mr8CKjNJG28HqTyfxrQupSQXZDHkdeuatytGyHs7I838V+M20W+e00u386aM4lkZiFXPUACuj8C+If+El06a48oxTRFkmQ8jpnINVdc8I6brd2ZWSVJpCCxhONx9xW/p+h23hbR5LS2XbLN94ZyefU+tXOVPkSiveFJtuzMvxa6R6BJPZNmeLBdBxkDrVLwq11qHhosWJmJIyOMjNaFwHaaGJY98bna4xxjvSS3iadrVrbwDZavHswBgBs0J+7Zb7lP3dCDRbG4trlpJAQgyACeTV3XblrXSrmeMASRJkY6k9quPIgk2iVd7DgZ+b8qmOmNe6bcRXjpDBKQC79SPaocrvmkKUrK5yOkX02u6HJb3ey2eQDfKD1GeOvTpWheeEI2sRG05ltXGAYpAC3OevpTtX8J3sMcaaLDI8JGP3rbMn+8T2FdLomnpp2j2trcSCaaNT5kgz949hmpnU1vHa43VUY+5LV7lOLU7LQNMhs7SJLcgchQSXb2HU1padFJeQqWhljDcksRkj046CrlvpFvHMl0YY45Dx5kgy34Zq8uTH8pAUnAB71jKS6bnI6i+yUr/Rk1OCK2Eojt43DSKP4wO3506HRPD9nqj6qIYm1AgfvD6gYGB61cEUzKQMiNupGBVGe1txMGd3Zl9DjFQpPa5lbm0b+4z9YijvrhhchGIUtHG5OGbtux05rE8Hr4kGm351nTrOyZZP3CQHcCuOckHk+9WdZ8L6vqut2d5Y64dP06MDzIADlznOeOGyOOa62UJa24gQlht5kPVq0clGKS1/Qvn1Sicx4X1ibWo3ZLZ40XjzM9fb6/Sq2s+G21TUlKXRgaB1LHGe3+TXU20nlKpjVc5zhRUU6GVnkKkbmyxXufehTtK8dDTnd3bQc8ikJGmWRFA3HjdjvUJCOpSeMOh5+cZ/SqmparZae4tZZrdL50JgilO0O2OBn3NZ3hO71bUrKZ9ZtfLuUlKhQuzA9KSg+XmBJWKPiTw/LqN5FJbSiIxHOMcMvpWfaeCWutRtJdQmjFvbSeb5SsSWbt+FdM+t6MWnRtRhM8IJZFcZXHWp/DPibQdUMyWF5DNJH98qc1V5LW2xs69SNNwWx01uwacRdGqe5jEZUqG3d++aqSK0bggE/MCexFR6tNdLaeZZrulGAMjOPfHes0rs4WrtWIb2G9AMlnFFOo5Ks21sA9vfFXYiEVck7zydwyQfSktGupNPR7mKNbkjlQePb6VyOv+M10Fguo2cxLNwY+cDPB/wA+laKMp+7EcU5XR2MsDTQlon+cHkE4FMRQgwUwR33ZrP0PVk1ixt9QsGVoXPJI5+mK1JWBdsEE9OOlQ046MNVoyCZopots0YcEHOR0qWCysyi8bDjt0rkvCnhrU9O8Uazf6jrD3On3PzW9vknyznvnpgcYFdWPLYHczFuwxwKclZ2TuK99roivrFreQmEmRD1QckVmy6pp1nGzXl15AXqJCVxVxI/IvGnSVnQgAx8kdeo96sz29rqCGO8t4pk/uuufpQmluWpNLXUwh4s0OYgWuo27lRyEbcT+FbqyGa3yucEbgw688/lWHrWh2lvpVzc6XottLexIWiRUAJbtVD4e6nr2qWlzPr1iLIRMEiXGCeOfyq3GLjzQ6dxNxaOqieGMq5KCTuFyM1O1/GMCZGxn+6atNebki+zxxvJ0YntWR4k1BdNsnutUdEXnZGOrnGdoHesV7zsZr3nZovR3lkrArCobr0qSTUEYbI0JB9uBXnfw+8Rnxfb3cktgLVrZwvDEhs/1rt4Ytm0lgMjPAPAqp03CXLLcp0oodduswYSwRzZ/hK8VjzaHaXgbdptjECMFvLGf0rRuraKR/MV2WRT1BJB/Cp7aNpIsSDb+PJoUuXZlq0VdFXSdPhs7VYkPKHbjPyj6e1cOZtZ1H4npNbpdWdjaRtG4mBVJQCcn0OSRj6V6FMsluAUw0XrjJH41Umt1vB+9lKr6AHn8auFTlbb6jTv7zHWYmSL/AEpgbjqSnA57VNIdzEM5A6gU2IRxqY2ldiF4AXoKHKqqv0VueepFZvcfUcEOMoR9Sf0qdTHGnmuQfRDjAI7mqK6rZ7iN+Qv6mlhkS6kyUbaOmRxRZ9ROMnuQ6fr1pqZmNpPFc7Dhyh4Bqlc67ZxawmnGQNfONwiXkqPf0qxBotlYyzPp8C27THc+zpn1A7VxXhfwtqEHja51TUdzIjOyyuB85JwMfhW0YU3zO+iLjyo9DRfMw0iqXHIyOlJCjqxd2UFfmyeNo9SaVHMm5kJyPUdfxoniWaNo5RlXVkbb1AIxWJNyPxCtv4h8JXiJcbkKEGSA5II7YryS3tV0yMw6bOFnZcpdsOjdsjsOnFd18OvB954Uub5jqMV5Y3C4xyGyDxlfxOTV3W9H8PWztc3syWRb7xY4UmtuZQvCDuv66F4apClNpq6MHwejahM11e2Ntb3uwpdJGmxpG6iRXHBB96s+G9P8WR65NJq1xa/2a2fLtxGCT6c+3rXQ+HbOxuLcPpV5Bcxr3U5H0rRju10+7S1uAjPjKqrfMB7ClKq9VYipNczVP7ite28eFWaOFC3cfKDXmF9DrWr64mnQ217p81uzjzU3eUwxnO4cEccfWvXJn+0F9yttUcxbMMPxrlov7Kh1QPa6zfWt1zi3YlkJ/HrToz5b6EwnJKxFpMGp6TYqt7cJcTrn97t5+gxzVfWNRtfsz3V9cgeV99nHbtiuzs7lTbE3ESzKTy6jGfrVOfR9PuS5kgtlR/vKybgan2mt5I1jVSbclqedW3iewurtY7Ft5I4AyM+tb7+GbjUtThu3gcQKQyjGCMd66DSfDXh3Rro3VjaW6zZ+8OcfTNaGq6zbxW8hfzZCqlliVSC2Kbqvm/djqYjnsqcSmmkQiXdbWcJuguGmbHA9M96tIIrRvNuP3kiD5S44z/srWZ4M1HUtYtri51KzfS4VYrGvdx6gntW/GlsJC8rqf9pvvH/Csp3TtI5nPo9Sj5t9qjkIiRxHpuODVtNLhgj3OfNn9egH/wBap5b+2hiIiQkD+LHH51Qs9Sh1FnEbq0a9SOAfap16bCvNrRWRYWziMTT3Eh2cnJPb29qguJIYowyW7sD0LHAH4VDdXimQNcuqW8RzjoOKknu/7TIECsIgASxGQ30osylGSactiGNWupwGfZCByq/4065jhjmRLbpj5vaqniGe5stNlk0iwa+u41H7kNtY88/XrnFYvhfXNW1UzQ3eitYzRYLlyVXB+oBzVqDceZbFLXVM3iLlG+UxOnfdnP4U5IZJOTJHj+6P/wBdcFri6d4z8S2NppGq3VvfaTJ/pJt2ZVkGfmAx3zjmu60rRpNOvLm7u7s3LzncqEYCgU5w5Vq9ewOXLvuWFtJBJHh/lc44HNT3VsIGVvNYqeBkZxXMar4yS0klt7QLJKpwWH3Qap6X4mkv7kRX0mXP3NnA+lZ2ZusLXa52tDF8a6pA/izT7S+8MC/gTH+nEkNGc9RjqPrXbXNysbxAthCBtfdjPHXmq2kanpWtaldaZFcj7bacyQ7SGHY5z1FV/HN1aaHoN1c3rs8RUoPLXLg46Ct37zjC2pnHlT5ThtI8A2ep+KbjVbTVLWQF282FWyMNkHgdiM10uleANL8KXrahYyOYQdxVj90Y5ye4rhvg5bW8uuNqmnNMlqu5HRuucZA/GvS9P1dta1q7026t3SMIQRt4b6mtq0pqTjfTqVJOMrp6HXOZnO5iinHOOaQI0eDL8yfyqTkjJDAds0xuvIOD6VyHOuwBmzhTgZqvd21rewyQX9vHOjrtO5c4+h7VU1/W4tCsTfXVvcSWq/6xolz5Y9SPSr9rPb6haQ3dpIstvMgdHXuDTs0uYfqM0+ytdPto7ewh8mFRjaOnWnyuGOY+H6Y9KkB8o46r2PpTZSAoKISzdMCi7buw2IArnCvI5HU4q1AUHymViAMjPA/KrNpCyRhivJ9axPE17b6PYy3t67rCpGRGMkk8YFCvJ2QuZTdjYhuWGQ0Qki/iwOcetI1xbnLx/fz0K4qPQdRs7nTop7WQMjqDk9fxqBwJZJiiBm38EngVNrOzJUU5O6sWnn2oEjIyDk98moheTA7Zo1RT6DDVVeJcFCwJPt/nFRSypErvK7eYF6u/AFNJGigi5LOCRn5R2xwKyvEdla6vZJHqcrRwoxMcgYKyt7Z4qS01Oyvjttp4pc9djg1wvxmS+ubTR7LT0nke4nbKRqWyMDGcfjWtGDdRR2Lso2vodvodhZ6JYmDTUDCRgzSA5Mh9TjitMytEgDxOM9Dg1l+GNA1DS/D9rbSFRdOBuIPKj0rcSyeBI/tV0iKg6bsk1nNq71uQ5wvo7lBMPyqSdfvAEip4yGyPnB9xjFWPOgLjbcz8f3fu1U1G5WFXKLNKwG7gZJpb7DTcnawoRDkNP5f+yzYB96dmNY3ZJImT1Vs81haddavd5e7slghboshyT9a07e1t7aUvAio7DBVfu/lTceXRlNeZJ58roPssJJ4G5+K5TX/Duua9f+XNqP2TSyACkIPmue+f6YrtIwF+d/m7DHQVHJdNE6uFJZcY9qcJuDvEE39k5Ofw1e6JbWcPhq3gmCEmRryQ7j9B65rp7Frp7SNryJIpwMFVOVBpDcT3LNO0axIOWklbAWrccRmt/NS5WRcbgRyrD2PeiU3Je994pSeikyuHDcN8jD+dKzhSods54+apF+eFUkCnDZ47VJLG/wBldFhBR+M45qQchYBGc7+AVIG3pTfKkYAQhnHXOOPxpLW2aO3VZSSFHODyBUkEsiSxm3kQg5zk8EdaTIbtflIHkmtb0NOAgI+bb0I9aTxJodjrtgYb2JZw4+TPB/AisL4h+N7PQ7QNcwo8YwSGXPJOOB+tY2j+KNZhvIrlPstxpUgDCP7jqh7qT1rSNOdlNaFqjUnFTSszAnjfwbcRWFpasba5chna4wyYI4GcV2NhpsU9zbXpu52bAO4Hj8TXQX9n4d8aWYS/t4bjj5Sww6fQ9RWLoHwyt9EvzNp2t6iLds5gcgjB9/8A61aOvGUfedpfmL6xy+7NWZqvcxtcZ8xVJ+UMzYyasi3tHYtPEDL2YKAD7isXX/CupSapZTWN+hihJLCRMn/OKyfG+keJruSwfwtfx2scchMyynl/TqDwOeKzUYytaQOUWrxZ2aQwQDzZ5NkXRVHUn6VQvL5Cf3NncSIecKOT+ZApkuoWNvcW9pcXAfVHAG1Rk/XHYVy3imw8VahdmPRr6CytRhvNYZZvUdOlEIXfvO3qOK6s6yCdETzI7K8jc9eAcVKuoTXLKDCyOowHdOcfWsDwtDrVmPL1a6S8ZjhZEXbwPWrniPxNb+HrRbmW2MwLbQEG4k+/YUODcuWOrHKPlc0vIviTtjlkUnPzHj9akS0uUBklREX/AH8msvw94sl8Q2zutpcWqqOC4IB+hrRMk0oAkZm9MnNRKMou0he/s7IdcGJoJIpNoVlwRzk1n6dZQWUBihVlTOc9yauqWbAwfehmVHGUYZ/ixmhN2sUtNDI8S6K2taHNZRSlJWwVJbGcHOM+9chB4d8baHFFDo2pxvGv/LKSTcEHpyOfwr0fcdpZ3CjnnI6UQNalyizLNMBuKIwzirjWlFcu6E5O1ihI02naBd6vrEqpcwWblpI8kAheoHrmuV+DV1quq+E7qfUtRn1ESzFIXmXBCjqPpzXZ6pdxrGIbiBWRsgRuMgr3+tcZqniU6UfKsI4LCxgJGxFCg+vSiPvRcUtWFOjUqu6Ox0TR7TTZLq8ijiEzPhigALfUiuZ8Z+I5njktbSZQ/IfaeB6Cl1TV/s/hCbV7CUsbpR5SA5CE9T71wNnbh7I21zexJdXSbjuP7wMe+fQ1pCm5Xmzow1OPtOaZj6Ubuz1OazuT5qyN5iS5zwfUVu+HlvJ/FiosqpCoBWMEHzB/e9Rg0+z0XVliZYLWS7JISPYuSW9z6etd34F8DL4XM+q6tcrc6nKoBOBtjH91aTaV5ytd/wBfI7sVi4U4KnF3ZuR6JY2GpTanBCiahcIFkmUYJHHH6Uy/htNQt2stSt2lhdtxK9cimTaglxeCGSXy53GUXcAQPYHr9adcXS2sEk8kgKRqS54HGOax97Rvc8pQaWu5htrmi+H7MW2nactvk7vLjxyPVj6mnWfjGG41CBINPkxM4V3QjC/WvKhqM2oanqeoTx4tJpcwgn+AcAfkM16T8Obcxae+pXS7TM+2FO4A7mm7qbT1R6VTDUaeHU2nzM9KNuhcbJgOMgGqs6PJG6CYxsDw6AH8xWX4burnVNMN1qVottMXK+V3GD1qzc6aLm6jkt53hdc8A/KT7iny8rs2ePFW3ZYa3eeGSC723EDrtZXUAOD2IqKztY7G1SCxtTDbxDaiRc7R9KvR6dciFZFmUuOSCeCKasinI+66nle4qb9AUk9hBl16bgPSkDHy8AjOehpzMpdfvcjO4Hn86jaORn+RxIGHBPBoGvMuCRzBkEgAc+1Yfiaxj1nTZNPum2hxw4/nUrXdxbFklVmhOd2BzT7vbdW/7t9pPAK84pxvF3RShyu5T0HTIdK05beGXzQMYbvxxVzTiyRP52cljnPeo9PtvssSoTuweSepqLV9Zs9Fs5Jr6VI4geCTyT6Ad6bvKWmtynrpuWbqd4CGRWdT2XtXO2NrqOqT6jDrdvBJpsnyRKpILA+uPatHQNZttZhJtWzxk5GD1rXjyTgcEe1O7hdW1H8OhR0jw9pWmQeTZ2sVuo7RKTirepy3cWmyReH5IIb1hjz7lMge+B3q1Z+VJIwmwq49cc1HdQxrMzRO0qD17VHM27vUxdm+WRx2neFrptVXUtc1zUNSvVHy/MYol+irW40lo7PFBcr5i8squCwAq5cpBNbtHKSqMMH5tv61WsdO021YtbwI7n+Inca0cnLWRtHRaFmOeMY2jpxwM81IHkZsqFB6ZxzUkVs00gSFDjucYAFeaXuv69rvjYaN4ct7i3sYJdktxLDtVgp+ZiT0HUCinTdRu3QlyjfU9JQhiASCw4rkfif4g1LwxpljLplg9yk0+25cAnYvYDHQn1rqI4ktW2LuyP4uv51et7rerIUMgbr8vUVMWoyUmroU77xMrRJftGmRSldgPOGPJ+vpVp2UKeePbqT6VZsdLRImJZkhDEqpqaUW8EYJz5p+7g4xUtpvQTqK+hyvizRLXXtLjivnubS3B+ZGcDePSsrR/FmjDX4dG0621KR4E+zowXEQVRznPQcda1vFPiDTtDtmurvN9ddI7aMb3Y/U9B71g/8ACer5kAuILDSZLqIFVkG6Uv2Xjj05NdEIylDVXXT+upooSlokd8Z1WPzZGhjU9AmT+pqu/iO1Enk+fDuGBjufyrzSbxJDq2uHSHmle4TiQ8ABuoABp3hLwZY23jca9JrQKSOWitSrZ3kdGPTAPNQ6UYp87tpoaSw0Yw5nr6HeXPiWCzgkniCySscAEYGBXDL8Q7m41J4/s1miRTFX8pySw/oa5u9tPFT6jrFl4vV001w4FyuAE5ypRh26cVkXGhaT4es43TU3X7XnE0gJ3HHt0rohQprR6tmtGnTa50tO56RNp8HiebUY7yOCUuqywiblMr1A9OK47xAdc/4Su0s1tR/YixJFuRQFC4wxB9qv/C5J7TT5pPPhmCqzROsm4Memc1BFaeL5Tq0KOtw8kAe0liGFDbsbVJ6NinFck2rqy7mjVtehe8LalJocipFdfa0R2UluDtJ4XjpjtW/PZa+dRttb0jVmXT4I2b7GzFiz4PykdMHPXtXnlho0nh2wXU9UaS5vFk2XNosoG0nJLMx6Yr0v4eXbazowvHiFuXkKBEbeACOOR14GazmnBuad0GJcJwTSs+pufCjWNX1rwnv8RwFL5ZHRhjaSueOO3p+FVLPxELvxze+H10+6VLUCQXDL8jHjp+db2laVb6NJPND5xeUhsF8hvXirc1w0seVVUkPBI6iueUo80mlv+B5UdJNx2Znf8I7p9lqNxqFnbk3k/Mkkjkn8PSncj5SMVy/g/Rtc0rW9Tvda1Y30Vw5EMAztQZ4PPQ44wK6uR/Mm+ZOO+KJq0rXubRTWj1Fd8QhFUFiOTmqWzdExZ1CemO341sC0jMaygYX+7naT+dZq63p899JZS20vnRgtsZfl4FSrvYSn/KrnI33jjRbW4FuDcTMG25QEqD9ScVo+IvEFzpujwXljYm7WQbg2eFGO4HNX4rPwtdSzXD6fYiWH5peQRH3yRnH6Vor5ckKTW7Ry2zruUpgjHbFaNwTVov5j5r6NWMLwf4k1HWdOlkvtPjtAuNjKrAOO+M9a2hLGBhyxA4wW61x2p+Ktag1R7XTPDF7fFGx5khKqR6gY6V2lpdXl1pkbSaXHaXDD95FNIG2H6jrSqQad7WT8xNpbfmS+cssZ+9uztVNuCPp61zeueEk1a5S6ilbTtQRcrcwHBVh0yvQj6V0MVrceS3mTbS55ZBkj6elDSW1uES4kKSNwvmyDc3v1qIycHeLFe2kTMaKSS/t3uWVyigOVGFYjr+tcP4l8C3GvMSX8mETGRWJ6j3HevQnnijcKnz71I+TmpU3ORCij5zgZ5H0NVGo4O8TZVJRVjnrbRLe20KHTGHmQxKAC/wDFjqfzrkbzRtEsfEURvr2Rbm5kDBdpKjnjJHQdvwr1G6s1tpESRlbdySeAv0qKawsZHQmzjnZcMJGQHBHQinCs43u9yVW00JIlnso1RUQf3do4qtJHNNIZ5pSwTomeKbJBNNKT5sjEnAHQD2oOnBFHnF33H7pYnn3rNCVlq3qZuv6tpuntHqepG3haMBIpWHzN32qO/euf8U675lp5KbR56BpOBhVI6VQ8VQaT4q1G2spvta/ZpQVwmEB4GGH4VJBoSazqkyX8pitoyDIV7gcACtZQUYrv+R3YaEIPnqLRGT4V0WbVrkzGBk0yIbto/wCWn/1q9gsLaJNOgEkKJtHChcYHaqNrdafptnHZ6UojjjAHTk/4mnfbJLzETFQvcnuazeuxz4mrUxDvLRGmVSJiowADT4fm+8uMc5rgdS8eWNp4ri0iS2kz5qw+ax43N0OOuM16DmQLh2yeq7eCa0nTlBJy6nLJcqRj6/4otvDMDT3jt5QwOB6nA/Wrun3kOpWUd0igrIN6n60mo6dbXcLJewrIr/fWQA5p6xR28CrBhI0G1UA4Hoan3babj91rTcsAbFbgbcZJxUNwgmiIDmMY+8h6Vm+Iob290m4g068NndYUxyjjJHY+xrP8Gxa7Z6e8fiSWOaYSEJIHDEpjgnHvTUfd5r69gsbM1yts8S3UsJEnyqZGAL+2Ko3c8cFz+5lVXPLrnjPaofFHh7TvEsEa3hZXgcNFLC210b29qWDR445N0qi4I43OcEU0o2vfU2pcq+IsWkstwFZZNyD72B/KsLxh4Oh8UtEt3c3EXkZMflMADn1Broplmt7dDZJGEBwyk9fxqQT+VC084MaKCWOc0RlKL5ojk77Gd4R8M23hqxCQyvLJnJdup9q3D97d055zXL6d4z0671ZtMldftLYKIAQyg+vvXQSxsL6Bt5MZXBxyM+9E4z5rz3Zm1Z6ljYG4zhvUUBGRcZYjuTUV8rwtG6/dzyAeoqxFdJOpCgsi8MPSsxO9rorTRw3Vu8MyrJE4wTWPN4TVBv026mhOd20HGfauiaOMjEfp0psZaMcHJHY1UZuOwX6oraImqacjefi7Rj8qr94VpXNy88Y8yNon7qetKNSighORlhzjGMGs5Wa4PBIDc5PWpfvO7RmouT5pIsKASOO/Jq8J1NvtjOGHTI5rGkN3CP3aRuMcHPUVf02JmBaX75HI7ChrqOcVa7MzxNqdzp+lM8Q82fb8kRPU1wh1G8vtPca5ejT5WO4tA+GUDseoUfrWj4/1WS11G2tyv7wkgHHUV5brl5qGqC4tbm1XTtLUsJrqR+SoP3vce3vXXRpNpbep30acYwu9/I2rl7PwF4fTUrGZNdm1CbCO0hZVPv3z1q5qfh+01qPRte1NZ7WZ0+a2Cgh8HPU8jnisoXVj4Y8O21hp80dz9oxMjSJuU5PXngV0zajKvha5u/EcfkxLJHFbugyRnrx6f41dRyXvR3fX/gF06cdOd6XRivfaZJqd7qekWnm39sjK2VwQ4/maTw5rN1eWMkl/aPauj/IzDG8euMUuoW2laVYvqUlylrHc/wDLTB3SN9BVoll8I319ZyQyzPBi0ZjksSeSB64z1rOXvRtbd7vod0HGm7p7dF1Na+vZNW0i4sdUa7urefaF2NyuDVHxHE+i61pWg2OiLe6QYxl5ULMc8EhugIBp3hm41uf4dakFijg1NlzblyMsf7y1p/DfUtXsdDNt4gMl3du52rjcYx2yegpxi6cX1t0/U86vLnm3CNl+Zzqax4Ut7G90Xw4s8U8BJLyEncQ3Iyfeuh8C+KJZGWGERtMoPHY49felg8DW1pdPPClrbWs8jPPJNy2Sc4XJ6V1+laPYWkRjsLaOPPVwAN341NWdK2ibbJ9olDkbuiG802z1OO6LaYVuboguS3yE4xkD3zyKfFc2HhSwjsba1kllUcpbR5wf5CtB5pLWSOOWFgGbBIPAFaUYEqlreNZWxnJGADXPfTXY5aknaz2MjQLy41MG9u7drZY2KpFJ1+tX3DbSxG0sDggflmoZmnWeNGtmjxyXznA9hXKXzeJr7xnAY5P7P0GBvnyAWlGPz9B+dUo8zb2RK1dza1DUX0yxubq7jcRQIXZwudwHoBVfRdetbrw5HqsKytC25z5ylT19PTPSt2V7lrKd4DFuXBHm8kjvxWP4R0HU7SzvrjxHqQ1g3LbkhePCIuegB/DjpxSXLy3e4Sqaao5JvHaalrEcCWMsm+QRKznk884HqPSk1H4cMNQk1LRNRvBfRzCYJI2UI3ZKnvgjNd01tpsiCGwsYbdgdxdEC7T/AI+9YHiDVp7XV7W3glcFSAQnC+nNbRqO9qSsbQvPSKsZPhDwZLomqX95NM91Hc7kMRTHysc856121nAsFslrAiW8MS4VEH3R/Ss/XtbbS7Nr+Z2ENurPKka5LY7CsLQPF9v4msJp9OaWBiSgMqA7Wx3FTL2lX32JqUtzrDFaKSJjO24YbExXPtgVat5kUKscZUJ0zkj8688i8D3E12LjVNTuJ2zv3FiD6+vFd5DFHFAiNIzvjrms6kYrRO5Eki0SXA3SHGeMccVw2v8Aw8tdU1ptSm1e6Vw4cKCG6dl/Ku5jQMxWTHA456UxCFUkNsbOBgZNKFSUHeLITcdik9nfywstvC0C8bWPBYfzFSWthdRRiNpSHJyTnJFSC6ukb57h3TqQq8/SrlvNMY2n8oLH1y55xUajlOaXQbHZFH33JMjerc8f57VkXvibQv7QFk+qxLdoSDFH8zZ9OM0+4MurrLD9reOKQYPlnace3eotA0fR9At5ZbWGGFEOCcYOfUnqTTSjb3tyeVp3luXhqtqkW5AWIGc7SOfxrNTXYrm5ljjzu6898VzfiTxG15dlbbC2/Tkcmszw2i2l7M5d5Z7luPRBVqmrXZ3wwdoc0lqO0XwncQ/EjU9XmndrOaJpIF3feYgAqR7f4V0trIFt5SYxGzt830FZ2ka3bXmtzwWkoaSDcCEHC4OMH8a07r7O4KXEu6QdUBxg1c5Sk/e8iVDldtypaXiXe88x7GxymKuJBvxvcFByS3GKfHbRxxJ5Sjk9AOtcv4h8PeKNSllR9Qs7Kxz8iQltxHbccc/QUJKT3sEqiWiO9eLSb2ZJZNPtpbgEHzGwSCO9bkdxCAfMQ5A5x0HpXMC6sJo9xUJOCfnQ7R+NEWowbj5k4lA7gEUnG5zyw3NsmdBLciUHy/LMZyDgDrUNjieRhKpCpxg8/rVOO+gMJRfmI6Y7elSTTyJBKNm4uC+V4/CpsR7NpWSsS3rwRlDbsXVvvYO7Fcd498Sro8cNvDE1xcFd/lp1b0B9BWFHP4ku/FojjAg0eN8klOWUe55Oa6O/jhkuXlZFLYxuI5x9a3VONNpy1OmlTs/Q5vwvqmsa1qPnm2FnZ553HH8+tehLqFrDEsETic4yzEVy0l2jjZEdqgYIFRQyusq+ShLk/Lxn8aKlpu9rHT9X517zO9mltpLbd8zOcfKR+npViezgvbZYZQPLKfNtHANUdPhaCyBuD8z/AM6txrmCQbtg2nP+z71zvTY8yats9jmdP8EWNtrs2rqTLcdAGPC+/wCVQ+JtX8V23iDSbPRLKB9NmOLiUxk7eeQf7vHSmfDjw5qHhiLVRq2rrfLdTebGqlm2erZPc8cCuvUBxGypu5Jxg1rKdp6+8kF7u7JQD5iRuDKE4we/vTZ5EFrK7sIyjYEQ4A7fjWV4z07VL3SBDot9HaXjyDzZCxBSPuBjv0/KrWnWq2tpFBiW4dUVTI5yz+5JrLlVk7ijZq5YBG3kdM9KTY5Xd0PQClMhQKojEeOQXH+c0sFuLgfPfASnjATj6c0h81tWRjbKpWVVYfyqpNbqwVYo3R1ORsPWr72FwoG1dw6FlNQF3t5jHPE+4ngoM59Oaa8i1JPZgjMYiWUr2INOS5lgZSuHBPI9qItQjjhcSqzEkkAoarwkyqkxUjnuMZ/Ci3cdu6Of8e+Fz4jtkns5ngvI33wv1APoR3Brl7X/AIRDVpJ9D1uK4t9SjXy5omYosxHdAfccV6wNxXgqxXtisLX9C0HVbu2XVbVJ7pjiJiOVPpkc/nWsKmnLK+m1ugRqNLlPNvFvgS9vdDsbTwxYm1azkyombG5T/tH3rA8QaJ4hm0e302YTxOGHnMyna+O4PQ4Ne1y6K9siolyY4xhQN2fpQ+kK0BEt8hRvfNUq7VvI6qdeMU10fqeXp4DXWtD0+31a6eMWg+W4fA3DuMHk1Q8RwJpK2uhaSqiGUiIXN7MkYGf4tuc45716zpfhmzsXZ0kWWM8k7+R9M1z/AI5tP7Ali1bwp4QttR1S4lHmyzRmR1P97GeOgqoVeaXK9V0v3M6mJ5Zc1LT8DLt/AEs9/YSX+rT3NjbwqjQWwMa7x1O7jjvXo2labFDGFjjQQAYDnOTjp9altJ9Qura3OoxoLkortEDlVbHP1xT7h13BZbhcjtjp+Vc86kp6N7HPzylo2cD8RdCsPFyrHHrE9hLbZjTeh8onPf8Axqx8PPB2s+HZi2qa39utnAMcaSMVHv8AN/Kt7WNO069s3S5clTzx1pnhbVrLUbBotHikkjtj5QaUYBI9Ca19pL2fKtv66g1b4Td1BI7gi3tYiZH4L9cVpWiNZWaRyMu4DG5u/vVON7i3UBI4oyewGSfxqrey/aUeK5nVZRyIweSPpXNa+hk05JR6Fm5uUknCxzK7KPmwOBVZY4zMqFdyjln3VXtoEgjcxBiD1JNS7wB/qzgc4NO1tjRRsrImRomupY1YiM5UsDmm3nmeW0UT/uyQBk+tVy21TJIDEhOMDnn1rO8Q6tb6Zbu25kDYLF+30NNK70KhTcpJI0Npt3CFOMYD1wPxBe70/VrW50yPzEuWBkJXd82QNvse9a+g+JBrUxS2kWZQOq84/Gte/QrZvIyZ28/Q1rBunPVGyi6ctWQazZxXmlTwT8CRcHPQmk0CzsNNsYobK1ghES8iNRkn1PvXFeJNQ1nVfEqaDo0MuImV2dTgcgE5PYc16RDbrZ24i2A3BAPPr9aJxcIpN76ik42tfUiuJrq4J8i1eVcdu/1qgtpq+0jymj3sSdxJPPvVfxPNNLpps7PUxbX5HEiH5hjrgU2z1+WI28U8zOxKxM+ep9fzqVF2uioKVvdSLg0TUfNWSaXaoOc7iSK3ksmGwrlwerE1z9344s4PEp8OCVm1T5V8sRkjkZxnp0rr7RGQkvI23bwD29aifMrcysc1WrNpNjYrdEjYyYVRySf8aoz3cDQCG2ljlMmQFV/1yK5zxlpA8RnyrjULpbZQQsMT+Wr89TjrWQwsfA/h/dY2zu6ksEDZJ7FiTVRpqSVndvoEKTerOzlh8oDBJf0XuawPEt19ks2VFGWySc8mp/CV3c6vpZv7hBFNJkIgYnA9a5bx9f2+kgS3TmQ9dqjqT2pxg+fl6nTQivaWk9jB05ZTG0l4R9olO4J/dXsPrXQ2Kixh3y4+0P8AdUc7B6n39q5dbnV72w+0WVvBau/KmU87fXFaemWN3Y2DXWpXDTXMmAST6+g7Ctpx6tnpt390u+F9KtNKikt7Ji0kzmSWaU/PK56fQCpLvS76S+yJfk3ZYe9WLDTneVJrh1iteG85jjPsK6nT4la7UITIv97tis5Sd2zmnUVH4B1nH9is905C+UgLN6AdTWbZ3kmoPI9uSwJxgnnGetYPjnxFcRzXkKgC2MyW0C/3yPvMfbJx+FZ3gzVLm419lREW0/1QcnmRu+PbtQqT5eZmEIc0HUe7NPXcwW/lxEqCw5HWmSMVYAEjAGKKK2eyO+nsbnhpPtEoWVmww5wat6vfTw3KwxkKhB4xRRWcviOSSTrWZkWU7/anbOT71dux+5Vu7nBooo6mlT4kY5VRdbFAAJwcV3GiWUKwKwHI+lFFKexni21TRsW8KSXEsjjPl8Kp6Dj0rG1GaSXVIrZmxD5e9lXjcfeiiso7nnUdZ/L9DoUtYQkMgjXcCADVG5nkd5ecbemOKKKlGVLWWpArE8HpjP1qYZSAMpIJbbx2FFFUbyKaTSGVlLkgYxnmtAwoVIPOBnNFFD2FPR6HOeLtZvtI0VprSY79wHz89ateAtSub/T2e5cM26iitLL2Vy5xXs3obdtcu99JA4VkC7uRzVm5iQyFAoAxk46miisOpzPSasUyPJjOzPA7/U00MRtYYzzg46UUUzVEMzGN8LjaWAIIzWjDo1ouWIkcscne5IooobsiaraSsI8McMJWFQgz2FcvZa3d3uvXtrceW0ML7UG3B6UUVUFdNsukrptm0QzMTvZT0ypxxViS0gRQ3lgt6nmiipZMna1ieyijkhG6NPmHPyisPUWNvqUdrbYhhTLAIMelFFFP4iaWtRl+V2js7q4zukhhLru5GcV5R8JJJNQutQ1C9lee7lOWdznqc8UUV00v4U36GtPdnqJY+WOnIqMuwxzRRXMUjB1O8n84KJCFz09a828URnW9btra+llNsW5iRtqnmiiuygrO67HfRSsz1nwxpFjpliIrK3SJNvRRj0rVlgjSIuBz3z3oorjk23dnnTb5yO2UCc7QBxk4GM/WsKeeRPEl3bbi0Yt4nG7k5OSTRRVR6+hUNzxzV9Ru7bUNangmZZkkwH6nG7GOav8AwrubjVbqe6v55JpC+MMflGPQdqKK9Sql7Js609T2u38PaWmvNrf2SM6n5WwzkZbGMfyqbVJWDW6ggB927A68UUV5CbctTzYazKE8agLIRktjg9K5/wAUqsmoWsDqDG/ysPUUUVtT+I66T95G1ZSfZLFUgVVwpGe9cH4nRLjUUFwqygAEbh0ooog9bnTg177HaYSpeXqyg4B6V0Om6bBe3T/ad75AbGfbOPpRRTkdFd2TaNrTrSG/5uUDLGdip0UAe1P1q6ktWW3tgkSMOWRcN+dFFYr4rHlPWok9jhfFttGbqwUjhFJX2JPWs7QtPgi1yB13fuxlBnhT7Ciiuq75PkepTX7s/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urothelial carcinoma in situ (CIS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_1_39962=[""].join("\n");
var outline_f39_1_39962=null;
var title_f39_1_39963="Juvenile fibromyalgia criteria";
var content_f39_1_39963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Yunis and Masi criteria for juvenile primary fibromyalgia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       The diagnosis for juvenile primary fibromyalgia is based upon all four major criteria plus 3 of the 10 minor criteria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Major criteria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1. Generalized musculoskeletal aching at &ge;3 sites for at least 3 months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2. Absence of an underlying condition or cause (eg, arthritis or trauma)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       3. Normal test results",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       4. Five tender points",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Minor criteria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1. Chronic anxiety or tension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2. Fatigue",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       3. Poor sleep",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       4. Chronic headaches",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       5. Irritable bowel syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       6. Subjective soft tissue swelling",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       7. Numbness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       8. Pain modulation of physical activity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9. Pain modulation by weather factors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       10. Pain modulation by anxiety and/or stress",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Yunis, MB, Masi, AT. Juvenile primary fibromyalgia syndrome. A clinical study of thirty-three patients and matched normal controls. Arthritis Rheum 1985; 28:138.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_1_39963=[""].join("\n");
var outline_f39_1_39963=null;
var title_f39_1_39964="Instruments spiritual history";
var content_f39_1_39964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F63804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F63804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Instruments for obtaining a spiritual history",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Tool",
"       </td>",
"       <td class=\"subtitle1\">",
"        Domains",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples of content",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        HOPE*",
"       </td>",
"       <td>",
"        H: Sources of hope",
"       </td>",
"       <td>",
"        H: What gives you hope (or strength or comfort or peace) in the time of illness?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        O: Organized religion",
"       </td>",
"       <td>",
"        O: Are you a part/member of religious or spiritual community? Does it help you? How?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        P: Personal spirituality and practices",
"       </td>",
"       <td>",
"        P: What aspects of your spiritual beliefs do you find most helpful and meaningful personally?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        E: Effect on medical care and end-of-life issues",
"       </td>",
"       <td>",
"        E: How do your beliefs affect the kind of medical care you would like me to provide over the next few days/weeks/months?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        FICA: spiritual history&bull;",
"       </td>",
"       <td>",
"        F: Faith",
"       </td>",
"       <td>",
"        F: What is your faith?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I: Importance/influence",
"       </td>",
"       <td>",
"        I: How important is it?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C: Community",
"       </td>",
"       <td>",
"        C: Are you a part of a religious community?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A: Address/apply",
"       </td>",
"       <td>",
"        A: How would you like me as your provider to address these issues in your care?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"6\">",
"        SPIRIT&Delta;",
"       </td>",
"       <td>",
"        S: Spiritual belief system",
"       </td>",
"       <td>",
"        S: Do you have a formal religious affiliation? Do you have a spiritual life that is important to you?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        P: Personal spirituality",
"       </td>",
"       <td>",
"        P: In what ways is your spirituality important to you?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I: Integration with a spiritual community",
"       </td>",
"       <td>",
"        I: Do you belong to any religious or spiritual groups or communities?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        R: Ritualized practices and restriction",
"       </td>",
"       <td>",
"        R: What specific practices do you carry out as part of religious or spiritual life?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I: Implications for medical care",
"       </td>",
"       <td>",
"        I: Would you like to discuss religious or spiritual implications of health care?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T: Terminal events",
"       </td>",
"       <td>",
"        T: Are there particular aspects of medical care that you wish to forgo or have witheld because of your religion/spirituality?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Anadaraja G, Hight E, Spirituality and medical practice: using the HOPE questions as a practical tool for spiritual assessment. Am Fam Physician 2001; 63:81-89.",
"     <br>",
"      &bull; Puchalski CM, Romer AL. Taking a spiritual history allows clinicians to understand patients more fully. J Palliat Med 2000; 3:129-137.",
"      <br>",
"       &Delta; Maugans TA. The SPIRITual history. Arch Fam Med 1996; 5:11-16. (Reprinted with permission from: J Palliat Med 8:402, 2005.)",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Okron, T. Spiritual, religious, and existential aspects of palliative care. J Palliat Med 2005; 8:392.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_1_39964=[""].join("\n");
var outline_f39_1_39964=null;
var title_f39_1_39965="5As of smoking prevention counseling children and adolescents";
var content_f39_1_39965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    5As of counseling to prevent smoking initiation in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Child's age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ask",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advise",
"       </td>",
"       <td class=\"subtitle1\">",
"        Assess",
"       </td>",
"       <td class=\"subtitle1\">",
"        Assist",
"       </td>",
"       <td class=\"subtitle1\">",
"        Arrange",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Early childhood",
"        </p>",
"        <p>",
"         (0 to 4 years)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Ask",
"         </strong>",
"         parents",
"        </p>",
"        <p>",
"         -- about their smoking habits and those of other household members",
"        </p>",
"        <p>",
"         (Forms to assist in screening available from CEASE website)*",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Advise",
"         </strong>",
"         parents to maintain a smoke-free environment. Message should include health risks to parent and child, and importance of parents as role models for child.",
"        </p>",
"        <p>",
"         (Educational and motivational materials available from CEASE website)*",
"        </p>",
"       </td>",
"       <td>",
"        <strong>",
"         Assess",
"        </strong>",
"        readiness to quit among parents or other household smokers.",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Assist",
"         </strong>",
"         parents in quit attempt, by referral to self-help materials and/or to their own clinician.",
"        </p>",
"        <p>",
"         Quit support:",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         -- smokefree.gov",
"         <br/>",
"         (800-QUIT-NOW)",
"        </p>",
"        <p>",
"         -- National Cancer Institute",
"         <br/>",
"         (877-44U-QUIT)",
"        </p>",
"       </td>",
"       <td>",
"        <strong>",
"         Arrange",
"        </strong>",
"        follow up visit within 3 months if a parent smokes; check on parents' progress at each pediatric follow-up visit.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         School age",
"        </p>",
"        <p>",
"         (5 to 12 years)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Ask",
"         </strong>",
"         child",
"        </p>",
"        <p>",
"         -- how do you feel when someone is smoking near you, and what you do about it?",
"        </p>",
"        <p>",
"         -- do you think that it is harmful to try smoking and do you think that you will smoke when you are older?",
"        </p>",
"        <p>",
"         -- have you tried smoking, and do you have friends who smoke?",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Advise",
"         </strong>",
"         child to stop experimenting, or give praise for remaining a non-smoker and/or making an effort to avoid smoke exposure. Remind child of the negative short-term effects of tobacco use, including smell and decreased athletic performance, and personalized health risks (eg, exacerbation of asthma).",
"        </p>",
"        <p>",
"         <strong>",
"          Advise",
"         </strong>",
"         parents to quit if they are smokers, and to give clear anti-smoking messages to their children.",
"        </p>",
"        <p>",
"         (Educational and motivational materials available from CEASE website)*",
"        </p>",
"       </td>",
"       <td>",
"        <strong>",
"         Assess",
"        </strong>",
"        risk factors for initiating smoking or progressing to regular smoking, including level of experimentation, smoking among peers, depressive symptoms, school performance and attendance, and adverse experiences.",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Assist",
"         </strong>",
"         parents in quit attempt if needed.",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          Assist",
"         </strong>",
"         child in developing refusal skills and avoiding exposure.",
"        </p>",
"        <p>",
"         <strong>",
"          Assist",
"         </strong>",
"         parents in efforts to prevent smoking in their children, through modeling, firm anti-smoking messages, and smoking bans.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Arrange",
"         </strong>",
"         follow up visit within 1 to 2 months for any child who is experimenting with smoking or has concerning risk factors for smoking.",
"        </p>",
"        <p>",
"         Refer as needed for any identified risk factors such as social or learning difficulties, or mental health issues.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Adolescents and young adults",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Ask",
"         </strong>",
"         adolescent",
"        </p>",
"        <p>",
"         -- about smoking behavior in a confidential setting",
"        </p>",
"        <p>",
"         -- about smoking among peers",
"        </p>",
"        <p>",
"         -- about use of smokeless tobacco",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Advise",
"         </strong>",
"         teens who are smoking to quit, reinforcing personalized health risks and danger of addiction.",
"        </p>",
"        <p>",
"         Praise teens who are not smoking and remind them of health risks.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Assess",
"         </strong>",
"         motivation and symptoms of tobacco dependence in teens who are smoking.",
"        </p>",
"        <p>",
"         <strong>",
"          Assess",
"         </strong>",
"         risk factors for smoking initiation among those who are not smoking.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Assist",
"         </strong>",
"         teens who are smoking in quit attempt; include nicotine replacement and referrals as needed.",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          Assist",
"         </strong>",
"         parents in efforts to prevent smoking in their children, through modeling, firm anti-smoking messages, and smoking bans.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Arrange",
"         </strong>",
"         follow up visit within 1 month for any teen who is smoking, to support quit attempt or assess motivation and barriers to quitting.",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"        <p>",
"         Refer as needed for any identified risk factors such as social or learning difficulties, or mental health issues.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * CEASE (clinical effort against secondhand smoke exposure). Available at: www2.massgeneral.org/ceasetobacco/index.htm.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      See topic review, \"Management of smoking cessation in adults\".",
"      <br>",
"       &Delta; See topic review, \"Management of smoking cessation in adolescents\".",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Guidance based on Klein JD, Camenga DR. Pediatrics in review 2004; 25:17.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_1_39965=[""].join("\n");
var outline_f39_1_39965=null;
var title_f39_1_39966="Correction of hyperopia";
var content_f39_1_39966=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/51690/hypr_ref_conv.mp4?title=Correction+of+hyperopia\" style=\"width:336px;height:226px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hyperopia corrected with refractive convergent lens",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 208px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperopia is corrected with convergent (convex) lenses which move the focus onto the retina from a point of focus behind the retina.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the University of Michigan Kellogg Eye Center, file://www.kellogg.umich.edu.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_1_39966=[""].join("\n");
var outline_f39_1_39966=null;
var title_f39_1_39967="SCFE progression";
var content_f39_1_39967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Progression from minimal stable/chronic to unstable/acute slipped capital femoral epiphysis (SCFE)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 238px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anteroposterior (Panel A) and \"frog\" lateral (Panel B) views demonstrating minimal stable/chronic SCFE on the left. Widening, lucency, and irregularity of the physis and blurring of the junction between the physis and the metaphysis are present in Panel A. The posterior displacement and step-off are better demonstrated on the lateral view (Panel B). The child was sent home after these radiographs. Four days later, the patient returned with an unstable/acute SCFE (Panel C), highlighting the importance of urgent management and avoidance of weight bearing until orthopedic evaluation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Phillips, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_1_39967=[""].join("\n");
var outline_f39_1_39967=null;
